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ABSTRACT 
Obstetric haemorrhage is still a leading cause of mortality and morbidity in what is 
essentially a young healthy population. Treatment for haemorrhage, outside surgical 
techniques, was replacement of blood loss with allogeneic (donor) blood. Although 
blood transfusion is a life-saving treatment, it is a limited resource with shortages, is 
increasingly expensive and is not without risk. Blood from the UK is one of the safest 
in the world, but there is still a risk of bacterial and viral transmission, as well as 
concerns with the quality. As such, alternatives need to be identified. 
 
One such alternative is the process of intra-operative cell salvage. For many years, 
and still ongoing to some degree, obstetric cell salvage has been contraindicated, 
essentially based on two concerns: amniotic fluid embolus and red cell 
alloimmunisation. 
 
The focus of my research has been the implementation of an intra-operative cell 
salvage service into our hospital, addressing the concerns and risks with it, and 
investigating the quality of the cell salvaged blood. 
 
Following the research work undertaken, intra-operative cell salvage is now 
established in all caesarean sections 24 hours a day, seven days a week within our 
hospital; very few centres offer this. It is an essential component of our obstetric patient 
management strategy. 
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PREFACE 
There are significant concerns with the safety and supply of allogeneic blood, and 
there is a requirement for alternatives to be sought. This thesis is divided into sections 
that explore these concerns with transfusion, the alternatives, the role of intra-
operative cell salvage in obstetrics and the impact on our hospital transfusion rates, 
the quality of cell salvage blood and the future aspects. 
 
The thesis provides a narrative that combines nine published peer reviewed articles 
that I have authored or co-authored over a ten-year period. In the appendices, these 
articles are included in their full text format, alongside my contribution within each 
article and the number of citations. 
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CHAPTER 1 – INTRODUCTION 
Obstetric haemorrhage is still a leading cause of mortality and morbidity in what is 
essentially a young healthy population. The most recent report (published 15th June 
2018) on maternal health ‘Saving Lives, Improving Mothers’ Care’ MBRRACE-UK 
(Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across 
the UK) covering the period 2013-2015 showed that 22 women died from 
haemorrhage, equating to a mortality rate of 0.88 (Knight et al., 2017). Despite 
advances in medicine, there has not be an improvement in the number of deaths from 
haemorrhage. In fact, there has been no improvement since 1994, with this period 
2013-15 seeing the highest mortality rate. The World Health Organisation reported 
that 25% of maternal deaths worldwide are due to severe haemorrhage (World Health 
Organization, The World Health Report, 2005). 
 
Treatment for haemorrhage, outside surgical techniques, was replacement of blood 
loss with allogeneic (donor) blood. Although blood transfusion is a life-saving 
treatment, it is a limited resource with shortages, is increasingly expensive and is not 
without risk. Alternatives are now being sourced. 
 
In the UK, the demand for donor blood is decreasing, however, the supply rate is also 
decreasing, but at a quicker rate. There is also an increased demand for certain blood 
groups which is outstripping supply, putting significant pressures on the National 
Health Service Blood and Transplant (NHSBT) (NHS Blood and Transplant Annual 
Review of Key Risks, 2017). For example, there is an increased demand for “universal” 
group O RhD negative blood. Approximately 7% of the population are O RhD negative, 
yet the demand from hospitals is approximately 13% (NHS Blood and Transplant 
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Annual Reports and Accounts, 2018). Only 4% of the eligible population donate, and 
there is a continuous need to replace donors who can no longer donate (Joint UK 
Blood Transfusion and Tissue Transplantation Services, 2014). The impact on the 
supply chain is continuously assessed by NHSBT and is flagged at their annual board 
meetings of risk review (NHS Blood and Transplant Annual Review of Key Risks, 
2017). The demand-supply issue is being addressed. 
 
Blood in the UK is one of the safest in the world, but there is still a risk of bacterial and 
viral transmission such as human immunodeficiency disease, hepatitis A, B and C 
virus, human T-cell leukaemia virus, cytomegalovirus, Epstein-Barr virus, human 
parvovirus B19, West Nile virus, dengue virus and malaria, to name some (Mollison et 
al., 1997). The risk increases in countries with a low human development index 
(Marcucci et al., 2004). 
 
Prion disease (variant Creutzfeldt-Jakob disease) is another concern with a confirmed 
risk of transmission from blood transfusion. To date there have been four reported 
cases of infection post transfusion in the UK. The UK blood services implemented 
changes to reduce this risk, however, there is still no screening test available.  The 
initial outbreak of variant Creutzfeldt-Jakob disease seems to be over, but a further 
outbreak has not been entirely ruled out (Seed et al., 2018). In 2015 it was identified 
that hepatitis E virus can be transmitted through an allogeneic blood transfusion and 
hepatitis E virus negative components should be provided for certain populations. In 
2017 it was recommended that NHSBT undertake universal screening of all units for 
hepatitis E virus (SaBTO, 2017). This additional screening of all blood added a 
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significant financial cost to the National Health Service (NHS), which is reflected in the 
increasing cost of a unit of blood. 
 
There are also concerns with the quality of allogeneic blood, such as reduced oxygen 
carrying capacity (low 2,3-diphosphoglycerate (2,3-DPG) concentrations), reduced 
adenosine-triphosphate concentrations, increased leakage of potassium, increased 
red cell rigidity (which will affect the ability of the cells to pass through the circulation) 
and blood becoming increasing acidotic with storage. My unpublished work has shown 
potassium concentrations increase over time with storage, with concentrations of 24.8 
mmol L-1 to 51 mmol L-1 after day 35. There is also a strong correlation between the 
age of allogeneic blood and the pH (Pearson’s r correlation -0.727), with the pH falling 
from 7.15 in five-day old blood to 6.65 at 35 days age.  
 
2,3-diphosphoclycerate concentrations have been shown to fall as early as the third 
to fifth day of storage and by day 14 levels are almost at zero (Mollison et al., 1997). 
Low concentrations are associated with poor survival, however, once transfused, 2,3-
DPG concentrations return to 50 percent after seven hours and normal levels within 
two to three days (Tinmouth et al., 2006; Yoshida & Shevkoplyas, 2010).  The pH of 
the allogeneic red cell product also plays a critical role with 2,3-DPG, with 
concentrations rapidly decreasing when the pH falls below 7.2 (Beutler et al., 1969; 
Mollison et al., 1997; Zimrin & Hess, 2009).  
 
Alongside the concerns with the quality and risks of blood, having an allogeneic blood 
transfusion alone can increase length of stay rates within the hospital, by 1.3% per 
unit transfused (Baker et al., 2014), and the rate of post-operative infections 
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(allogeneic blood suppresses the recipients immune system), which all increases 
demand and costs for hospitals.  There are also increased risks of morbidity and five-
year mortality with allogeneic blood (Duffy & Neal, 1996; Vamvakas, 2002; Davis et 
al., 2003; Karkouti et al., 2004; Innerhofer et al., 2005; Koch et al., 2006). Women who 
delivered at the Royal Cornwall Hospital (RCH) who have had an allogeneic 
transfusion are more likely to have a higher estimated blood loss and infections treated 
post-operatively, when compared to those who have had no transfusions (Baker et al., 
2014). 
 
Other effects of allogeneic transfusion include febrile reactions, haemolytic reactions, 
transfusion-related acute lung injury, graft-versus-host disease and citrate toxicity 
(Mollison et al., 1997). There are also reports of transfusion circulatory overload, which 
is now a leading cause of mortality or morbidity. Exposing patients to many allogeneic 
units increases the risks of sensitisation and producing antibodies which may 
complicate further crossmatching, or in our population of interest, haemolytic disease 
of the fetus and newborn (HDFN).  
 
In the UK, there is an independent haemovigilance reporting scheme (Serious 
Hazards of Transfusion (SHOT)) which collects and assesses reported adverse events 
and reactions from blood transfusions and/or those involved in blood transfusions such 
as the NHSBT, hospital laboratories and clinical areas. Each year a report covering 
the previous year is published, which makes startling reading. The most recently 
published report (12th July 2018) covering the year 2017, identified 21 deaths where a 
blood transfusion was implicated, of which 14 were classed as preventable. There 
were a further 112 cases of major morbidity where a blood transfusion was involved 
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(Bolton-Maggs et al., 2018). ABO incompatible red cell transfusions are on the NHS 
“never event” list, and despite there being a reduction over time (three in 2016 and 
one in 2017) they still re-occur. There were a further 606 ABO-incompatible red cell 
near miss events in 2016 and 2017. In 2017, there were also four ABO incompatible 
transfusion involving fresh frozen plasma and two involving platelets. Alongside ABO 
incompatible transfusions, there were 326 reported cases of reactions to a blood 
transfusion, febrile or haemolytic, all of which are not preventable (i.e. is a risk of a 
transfusion). There were also 789 cases of wrong blood in tube incidences (i.e. blood 
in a sample to be tested is not from that patient recorded) which resulted in a near 
miss wrong component transfusion. Where an incorrect blood component was 
transfused, 51.5% were due to laboratory error with the remaining 48.5% due to 
clinical errors, of which the majority were due to collection of blood. 
 
What this summary has shown are that there are serious complications with allogeneic 
blood transfusions, and regarding variant Creutzfeldt-Jakob disease and hepatitis E 
virus, it has shown that we do not know what is ‘around the corner’ with regard to 
emerging pathogens and the impact on the blood supply. We should therefore be 
reducing these risks as much as possible, and there is now a drive to review 
alternatives to allogeneic transfusion. 
 
In 2012 a Patient Blood Management initiative was created by the NHSBT and 
National Blood Transfusion Committee along with the Department of Health to look at 
alternatives and support hospitals to manage their blood use effectively, reduce 
allogeneic transfusion rates, and ensure that patients receive the best treatment and 
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that avoidable, inappropriate use of blood and blood components is reduced (Joint UK 
Blood Transfusion and Tissue Transplantation Services, 2014).  
 
One such alternative is the process of cell salvage which will be the focus of this 
commentary. 
 
 
  
 
7 
 
CHAPTER 2 – CELL SALVAGE 
Cell salvage, simply put, is a method where lost patient blood is collected, washed, 
filtered and then re-infused to the patient. This is known as an autologous blood 
transfusion. 
 
Autologous transfusion was first postulated in 1874, when a doctor who attended a 
woman bleeding post-delivery noted that even though blood loss was stopped, the 
woman died with “several pounds of blood in a vessel and in the bed”. He speculated 
that if the blood had somehow been collected and re-infused, it could have saved the 
woman’s life (Highmore, 1874). There is documented evidence of its use in 1874 
(Halstead, 1883), with a successful case report published in 1886 which showed its 
potential. Higher than expected blood loss was experienced post leg amputation. 
Blood was collected and injected back into the femoral vein. The patient made a good 
recovery with no shock or change in temperature. The patient was very weak and 
anaemic pre-operatively and due to the haemorrhage experienced, it was concluded 
that if the blood was not given back, the patient was very unlikely to have survived and 
that the patient ultimately gained from having the re-infusion (Miller, 1886). 
 
Since the late 1800’s to 1940’s there are documented cases of its use in ruptured 
ectopic, splenectomy, haemothorax, perforating abdominal injuries and neurosurgical 
procedures (Thies, 1914; Lockwood, 1917; Watson & Watson, 1936). Interest in 
autologous transfusion increased up to the Second World War when blood supply was 
not an issue due to increased donor numbers (Konig & Waters, 2012; Sikorski et al., 
2017). Interest increased again post Korean and Vietnam wars, with the first 
commercially available autotransfusion device being introduced in 1968 (Klebanoff, 
 
8 
 
1970). In 1974, Haemonetics® Corporation launched the ‘Cell Saver’ which is still 
going strongly today, albeit with many major improvements over the years. 
 
There are two forms of cell salvage: post-operative cell salvage (used mainly in 
orthopaedics) and intraoperative cell salvage (ICS), with the latter being the focus 
here. 
 
There are different models of cell salvage machines available, but specifically to our 
hospital is the model that uses the “Latham” style bowl and process. Blood lost is 
collected via a dual lumen suction tube which mixes with an anticoagulant (either 
heparin or acid citrate-dextrose anticoagulant) into a collection reservoir through a filter 
to remove large clots and debris. Filters are usually of the size 40-150 µm. Once a 
sufficient volume has been collected, blood is pumped into the Latham centrifugal bowl 
where it undergoes centrifugal forces. Denser red cells move to the outside of the 
bowl, whilst the less dense plasma, contaminants, free haemoglobin, platelets and 
clotting factors move towards the centre of the bowl and exit to waste. Once sufficient 
red cells remain in the bowl, a washing stage is initiated with intravenous saline to a 
specific volume dependant on the bowl size. Washed red cells are then resuspended 
in a re-infusion pack ready for re-infusion (Figure 1). Reported red cell concentrations 
are approximately 50-80% (Allam et al., 2008; Kuppurao & Wee, 2010; Liumbruno et 
al., 2011). Internal RCH data which I have collected from vascular, obstetrics and 
orthopaedics have a concentration of approximately 50%, with a range 38 to 79% 
(Sullivan, RCH data). 
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Figure 1: Schematic diagram showing the cell salvage process (reprinted with 
permission of the UK Cell Salvage Action Group). 
 
Cell salvage is now routinely employed in vascular, orthopaedics, neurology and 
cardiac surgery to name a few (Allam et al., 2008; McDonnell et al., 2010). Multiple 
studies have found autologous blood to be a safer alternative to allogeneic blood; one 
such example is a five-year retrospective study by The Cleveland Clinic which found 
the incidence of adverse effects with autologous transfusion to be 0.027% compared 
to 0.14% with allogeneic blood (Domen, 1998). Table 1 summarises the benefits of 
cell salvage autologous blood. 
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Table one: Advantages of autologous cell salvaged blood 
No risk of ABO incompatibility 
Acceptability by Jehovah’s Witnesses (dependant on their exact beliefs) 
Blood is at room temperature 
Less acidotic (allogeneic blood pH 6.8, autologous blood pH 7.6)* 
Normal 2,3-DPG concentrations* 
Normal potassium concentrations (0.3 mmol L-1) * 
Normal adenosine-triphosphate concentrations (Buys et al., 2017) 
Available in cases where no allogeneic blood is routinely available due to antibodies, 
or insufficient time for full laboratory investigations 
(*Unpublished data, Sullivan, RCH) 
 
Intra-operative cell salvage can be of great benefit where there are issues supplying 
crossmatched allogeneic blood due to antibodies. It may be the only available source 
of blood in emergencies, as we have experienced (RCH unpublished work). 
 
A key disadvantage of ICS is often thought to be that clotting factors and platelets, 
essential for maintaining haemostasis, are removed in the cell salvage washing 
process, and in cases of massive blood loss, ongoing coagulation testing must be 
undertaken to monitor plasma and platelet transfusion support. However, we have 
identified that autologous blood behaves differently to allogeneic, where it behaves 
more like whole blood. We have noted that patients who receive large volumes of 
autologous blood maintain haemostasis and require little to no additional clotting 
factors, suggesting that 1 mL of autologous blood is not similar in-vivo to 1 mL of 
allogeneic blood. Our ICS users have lower blood component support than those who 
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receive allogeneic only. Research into this in-vivo observation is currently in progress 
at RCH (IRAS: 225799; REC ref 17/NW/0586). 
 
Autologous transfusion does have issues though. All adverse events or reactions 
should be reported to SHOT for ongoing investigations, monitoring and trending. There 
has been an increase in reports to SHOT with the use of cell salvage (Figure 2), but 
this could partly be due to its increased use and awareness to report to SHOT, 
although underreporting is still a SHOT concern (Haynes & Ralph, 2018). 
 
 
 
Figure 2: Cell salvage cases reported to SHOT 
 
In the most recent SHOT report for the year 2017 there were 17 cases reported. There 
were no deaths or major morbidity reported due to cell salvage. Eight cases were from 
obstetrics, one from orthopaedics, two from trauma, one from urology, one from 
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vascular and four from spinal surgeries and emergency laparotomy. From these 17 
cases, 14 were adverse events and three were reactions. Of the 14 adverse events, 
12 were machine or operator failure/errors. These numbers should improve if cell 
salvage becomes employed more routinely and user experience and confidence is, 
therefore, increased. Of the other two cases, one was an administration error and the 
second was due to hyperlipidaemia. Cell salvaged blood was discarded. These last 
two were not directly caused by cell salvage but were identified whilst cell salvage was 
in use. Of the three clinical reactions, all three were in obstetrics. The first was an 
allergic reaction, but unlikely due to cell salvage as the patient stated that the reaction 
started before re-infusion. The other two were due to the use of a leucodepletion filter 
(LDF) resulting in hypotension. This will be discussed later. 
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CHAPTER 3 – OBSTETRIC CELL SALVAGE 
For many years, and still ongoing to some degree, obstetric ICS has been 
contraindicated. This has resulted in these patients having to receive allogeneic blood 
as a treatment. The Royal College of Obstetrics and Gynaecologists (RCOG) ‘Green-
Top’ guidance estimate that each year in the UK there are greater than 4000 cases of 
severe obstetric haemorrhage, with the majority receiving an allogeneic transfusion 
(Green et al., 2015). The most common cause of post-partum haemorrhage is uterine 
atony. At term, 600 mL min-1 of blood, equivalent to 20% of cardiac output, perfuse the 
uterus (Greenawalt & Zernell, 2017), so blood lost can be very significant at placenta 
separation. 
 
A caesarean section (C/S) itself is a risk factor of needing a transfusion with reported 
rates varying from 1.4% (Sullivan et al., 2011) to 5% (Geoghegan et al., 2009). 
Caesarean section is the most common risk factor of abnormal placentation, with C/S 
rates in England increasing with 27.8% of deliveries in 2016-17 by C/S (NHS Digital, 
2017). There is also an increase in the age of women delivering, by all methods, with 
a 9.5% increase in the 40 and over age group. Caesarean section rates increase with 
age and accounts for 44.1% of these women 40 and over. Of this, 23.5% were elective 
and 20.1% were emergencies. The 40 and over age group also have the highest body 
mass index at booking (NHS Digital, 2017). These are all risk factors for bleeding and 
can result in increased allogeneic transfusion.  
 
With the endorsement of the Association of Anaesthetists of Great Britain and Ireland 
(AAGBI), the Obstetric Anaesthetists Association and The National Institute of Health 
and Clinical Excellence (NICE), obstetric cell salvage availability has been steadily 
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increasing and is now available in 84% of obstetric units, although only 50% of units 
have 24-hour access and use it routinely (Nelissen et al., 2018). The RCOG ‘Green-
Top’ guidelines 47 and 52 (Green et al., 2015; Mavrides et al., 2016) recommend the 
use of ICS, although only for where the anticipated blood loss is great enough to 
induce anaemia or expected to exceed 20% of estimated blood volume. The most 
recently published AAGBI guidelines on cell salvage for perioperative blood 
conservation (published July 2018) did not recommend the routine use of cell salvage 
in obstetrics (Klein et al., 2018), however, their recommendations contradict each 
other. Intra-operative cell salvage is not recommended in routine C/S, however, it is 
when blood loss may exceed 500 mL (which is not uncommon in C/S) or if the patient 
is anaemic. It has been estimated that approximately 25% of pregnant women in 
Europe are anaemic, with this figure increasing in parts of Asia and Africa (Muñoz et 
al., 2017). 
 
Despite these endorsements, cell salvage is still not routinely employed by most 
obstetric hospital units, essentially based on two concerns: amniotic fluid embolus and 
red cell alloimmunisation. 
 
Amniotic fluid embolus (AFE) occurs in 1:8000 to 1:30,000 deliveries (Esper & Waters, 
2011). It results in acute pulmonary hypertension, decreased ventricular output, 
cardiac and pulmonary collapse, altered mental state and disseminated intravascular 
coagulation (DIC) (Rogers et al., 2013). Precise elements in amniotic fluid (AF) that 
may cause the AFE, and the pathophysiology of the changes, are still not fully 
understood, although complement activation and mast cell activation may be involved 
(Benson, 2012). In the MBRRACE report (Knight et al., 2017), nine women died due 
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to AFE, equivalent to a mortality rate of 0.36. These were not linked to ICS. The clinical 
diagnosis of AFE is usually one of elimination and is now considered to be a type of 
anaphylactic reaction rather than an embolic disease, and perhaps would be better 
described as sudden obstetric collapse (Yentis, 1999). 
 
The washing and filtering processes used in cell salvage have now been shown to 
effectively remove AF contaminants, fetal squames and other debris (Catling et al., 
1999; Waters et al., 2000; Sullivan et al., 2008). It had been postulated that tissue 
factor, which is known to be present in amniotic fluid (Lockwood et al., 1991), may be 
the cause of the cardiovascular collapse and associated DIC that is seen in AFE. 
Tissue factor concentrations have been shown to increase in AFE (Conde-Agudelo & 
Romero, 2009). A 1997 cell salvage study showed no tissue factor present post 
washing stage (Bernstein et al., 1997). This study involved collecting all blood and AF 
into an older style cell salvage machine and then washed with no filtering. Since then, 
machine efficiency has significantly increased with improved washout rates. Squames 
cells were once thought to be a marker of AFE, but these have been found in healthy 
maternal circulation (Clark et al., 1986). 
 
As for the second main concern of alloimmunisation, it is known that in obstetric ICS 
fetal red cells are collected during the cell salvage process. Due to the similarities 
between fetal and adult red blood cells in size and density, the cell salvage machines 
cannot differentiate between them, and, therefore, any fetal red cells aspirated will be 
washed, filtered and returned to the woman together with her own red cells. The 
significance of this contamination is not known and has not been systematically 
investigated. Does it increase the risk of alloimmunisation where the women produces 
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an antibody which could potentially have significant impact in future pregnancies due 
to HDFN? There is a need to be aware of the risk of formation of antibodies other than 
anti-D. Anti-D rates in pregnant women, although clinically significant, have been 
reduced by the use of routine prophylactic anti-D treatment throughout pregnancy. 
However, fetal hyperbilirubinaemia and anaemia in future pregnancies can still occur 
when antibodies have been formed to other mismatched red cell antigens, e.g. 
following the formation of anti-K, anti-c, anti-Fy(a) and anti-Jk(a) (Murphy & 
Pamphilon, 2008). This fact is not widely appreciated, and many investigators involved 
in obstetric ICS are still only concerned with the risk of anti-D. 
 
It is unclear what follows if we re-infuse a larger volume of fetal cells into the maternal 
circulation than the amount that occurs secondary to transplacental haemorrhages in 
normal pregnancy. It is also unclear, at least in this setting, if there is a critical volume 
of fetal red cells required to cause alloimmunisation or if progressively larger volumes 
of fetal red cells increase the risk of alloimmunisation. Furthermore, there is no 
evidence to show how these rates of alloimmunisation compare to those following an 
allogeneic blood transfusion. As such, alloimmunisation is a significant concern. 
 
These two areas of AFE and alloimmunisation have been the focus of research. The 
number of cases of ICS usage in obstetrics up to 1999 is sporadic with key larger 
reports being published between 1998 and 2000. Rebarber and colleagues (1998) 
published a multicentre cohort study involving 139 patients who had ICS compared to 
87 similar control patients who had no ICS. They noted no significant difference 
between the two groups in length of stay, DIC rates, infectious morbidity or time on 
ventilatory support. However, there are many variables in this retrospective review in 
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that it was performed over three sites with different post-operative care and differences 
between the two groups. 
 
In 1999, a report based on 10 patients examined for markers of AFE and 
alloimmunisation. Fetal red cells were found in all 10 samples, with up to 5 mL 
detected. Alpha-fetoprotein (AFP) was reduced to below detection limits in all 10 
samples post wash. Squames cells were present in four cases pre-wash, with one still 
present post wash. Lanugo and vernix were not detected (Fong et al., 1999). 
 
Also in 1999, Catling et al. published, which at that time, was a leading case series on 
27 elective C/S cases where for the first time a leucodepletion filter (LDF) was included 
to investigate further reduction in the AFE risk. Patients were split into two groups, the 
first using one suction where all AF and blood was collected into the cell salvage 
machine, and the second using a separate suction initially to remove as much AF as 
possible to waste prior to blood collection. Samples were taken pre-wash, post-wash 
and post-filter and tested for AFP, fetal squames, trophoblastic cells and lanugo hair 
as markers of AF, and fetal red cells for alloimmunisation risk. Alpha-fetoprotein was 
reduced post-washing with no further reduction by the LDF. Fetal red cells were 
detectable but results were inconclusive and lacking reliability. Cellular elements 
(squames, white cells, trophoblastic cells) were not completely removed by the LDF. 
The authors concluded that “the risk of AFE is probably remote and should be carefully 
weighed against the life-saving potential of this technique” (Catling et al., 1999). 
 
Following on from this, Waters et al. (2000) published a further report on 14 patients, 
including an additional step by taking a maternal sample from a femoral venous 
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catheter above the level of the uterine veins as they flow into the common iliac vein, 
in order to collect blood that may be contaminated with AF post-delivery. Only one 
suction apparatus was used, along with a LDF. They found that the use of a LDF (a 
newer advanced model compared to that used by Catling et al. (1999)) reduced levels 
of markers similar to those found in the maternal circulation.  
 
From 2000 to 2005 there were no further published reports on investigating the risks, 
although there may have been further usage of ICS not reported. What these studies 
have shown is that there is limited information available before 2005. 
 
In 2005 the National Institute for Health and Care Excellence (NICE) considered the 
evidence for the use of obstetric ICS and published guidance on its use (NICE 
Guideline, 2005). Their recommendations were based on review of three studies 
(Rainaldi et al., 1998, Rebarber et al., 1998, Catling et al., 1999), along with a further 
six case reports. In March 2007, the Health Service Circular “Better Blood Transfusion: 
Safe and appropriate use of blood” 2007/001 was published which required hospital 
trusts to implement a new programme of actions, which included to develop a blood 
conservation plan, reduce the need of blood and blood components, and of relevant 
to this area, progress further the use of cell salvage and avoid unnecessary blood 
transfusions in obstetrics (Health Service Circular, 2007). 
 
Based on the recommendations, and the already active ICS use in other disciplines, 
our hospital wished to explore its use and suitability in obstetrics. Up to this time, ICS 
had only been used in orthopaedics and vascular, with much success, and obstetrics 
seemed the next logical progression. This led me in 2007 to undertake an exploratory 
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study (initially as part of my Master’s Degree) into implementing ICS into obstetrics, 
and to investigate the concerns/contraindications previously mentioned with obstetric 
ICS. Despite having a low observed power, this study was one of the largest studies 
to date in the obstetric setting, and was published in 2008 (Sullivan et al., 2008). It 
had been recommended to use two suction devices to minimise the risk of re-infusing 
AF resulting in AFE (Rebarber et al., 1998; Fong et al., 1999, Potter et al., 1999) where 
the AF is initially collected by a separate suction to waste prior to collecting blood. 
There was no evidence to support this recommendation but based solely on a 
theoretical suggestion. To assess this theory, along with the AFE and alloimmunisation 
risks, 34 consented patients undergoing elective C/S were split randomly into two 
groups; the first group only used one suction apparatus to collect both AF and lost 
blood into the cell salvage collection reservoir, and the second group involved a 
second suction to remove AF to waste first prior to blood collection. Samples were 
taken pre-wash, post-wash and post-LDF, and tested for markers of AFE and 
alloimmunisation and heparin contamination. Seven cases were excluded as 
insufficient blood was lost/collected to process (two from group one and five from 
group two). Alpha-fetoprotein concentrations were significantly reduced post-wash (p 
< 0.001) with no further reduction seen post filtration (p = 0.996). Fetal squames were 
present in all post-wash samples, but only present in two cases post filter (both group 
one). Heparin was washed out in all cases. We identified that the final re-infusion 
volume was higher in those in group one (i.e. one suction), as was the 
haemoglobin/haematocrit concentration, however, both were not statistically 
significant. Based on this, we therefore suggested that only the one suction device 
should be used. Apart from the financial savings of using one less instrument, 
practically it is easier to collect everything into one and not having to swap halfway 
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through surgery. The other advantage is that there is no clear point where it is only AF 
and then blood, so by using two suction devices the volume of salvaged red cells will 
be reduced, resulting in reduced return to the woman. We showed that the washing 
and filtering process significantly reduced concentrations of AF contaminants and that 
whether the squames cells are of maternal or fetal origin is irrelevant as the filters 
remove both. We concluded that one suction may be used, a LDF should be included 
and partial bowls should not be re-infused. It was hoped that these results could be 
used to change the guidelines and allow routine use of ICS as opposed to overriding 
guidance in extreme emergency. It was not the intention in this study to re-infuse any 
ICS blood, however, approximately 500 mL was re-infused to two cases, which shows 
that even in elective C/S, significant and unexpected blood loss can occur. 
 
Since our leading report, the number of hospitals now only employing one suction 
device has increased. A correspondence reply in 2010 confirmed our recommendation 
that there is no evidence to support two suction devices (Catling et al., 2010). An audit 
from 2014 reported that 12% used one suction only (UK Cell Salvage Action Group, 
2014), but in 2017 this increased to 58.1% (Khan et al., 2017), showing there is a clear 
indication that more users are moving to one suction.  
 
There have now been over 2000 reported cases of re-infusion in obstetrics with no 
reported adverse events or AFE linked directly to ICS (Rebarber et al., 1998; 
McDonnell et al., 2010; Sullivan et al., 2011; Khan et al., 2017; Akindele et al., 2018; 
Kenyon et al., 2018; Orr & Wrench, 2018; Yan et al., 2018; Zeng et al., 2018; Sullivan 
& Ralph, 2019). Reports have shown a shorter length of stay, lower hysterectomy 
rates and reduced allogeneic transfusion rates when ICS has been employed (Zeng 
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et al., 2018). This number will carry on increasing as further studies are published. It 
is now widely agreed that AFE is no longer a valid contraindicative reason, and this 
risk remains entirely theoretical. It has been reported that all recently delivered women 
must have AF in their blood and, therefore, if there was AF in the returned ICS blood, 
it would not represent an increased risk (Catling & Joels, 2005). 
 
In 2019, I published a key report on the last ten years of our experience (Sullivan & 
Ralph, 2019) where we have re-infused to 1170 women, all without any clinically 
significant adverse events and no cases of maternal collapse or hypotensive episodes, 
with and without LDFs. This is now the largest published report to date. I presented an 
update on the use of ICS, data on alloimmunisation rates, quality of cell salvaged blood 
and the role of partial bowls. To my knowledge, there is no other such comprehensive 
report and it is hoped it will be used to lead further research, be of assistance to other 
users, and be used to rewrite guidelines. Intra-operative cell salvage methodology was 
included, alongside quality control processes, and following up women post re-
infusion. I concluded that the risk of amniotic fluid embolus should not be a barrier to 
implementing an ICS service. In contrast to our initial 2008 report, we now recommend 
that LDFs are no longer used in obstetric ICS, based on observational data. 
 
Alloimmunisation is still however an ongoing concern though but there has been 
limited investigations on this, with case numbers varying from 3 to 27 (Rainaldi et al., 
1998; Catling et al., 1999; Fong et al., 1999; Waters et al., 2000; McDonnell et al., 
2010). Fetal red cell contamination is one of my big interests within my profession, and 
as such, I therefore keenly investigate this area. The only way to confirm if there is an 
increased risk/rate of alloimmunisation due to cell salvage is to know what 
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concentration of fetal cells are in the final product, and to follow-up all women post re-
infusion. These have both been addressed. Of the 1170 women re-infused in our 
hospital, 509 (44%) have provided a sample three to four months post-delivery, and 
on further checking of the women who did not provide a sample, a further 138 had a 
sample taken at a later date for other reasons (such as subsequent pregnancy, other 
surgery/procedures) taking the total to 647 (55%). Of these, two cases (0.3%) had 
returned a positive antibody screen post ICS. Both were anti-E. The first case was an 
abruption with an estimated blood loss of 600 mL, receiving 237 mL ICS blood and 
one unit allogeneic transfusion (unit was E-antigen negative). The second case was a 
twin vaginal delivery requiring urgent surgical intervention due to complications and 
bleeding with the second baby being born by caesarean section an hour later. Four 
hundred mL ICS blood was re-infused. No allogeneic units were transfused. The 
techniques used within our laboratory have a similar detection profile to enzyme 
methods for Rh antibodies, and as such these antibodies may be ‘naturally occurring’ 
(i.e. not as a result of red cell stimulus), but this cannot be proven with confidence. 
 
But how do these rates compare to normal pregnancy/normal alloimmunisation rates? 
Answering these questions, will assist in answering the alloimmunisation concern. 
 
I investigated and published a report on “Obstetric intra-operative cell salvage and 
maternal fetal red cell contamination” (Sullivan & Ralph 2018), where fetal red cell 
levels in women immediately prior to delivery and post-delivery were quantified and 
compared to those found in cell salvaged blood, as well as investigating antibody 
formation rates following allogeneic transfusions. I identified that with our results and 
that of others, up to 78% of women are exposed to fetal red cells ante-natally with 
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levels up to 5.15 mL, and more than half of all mothers are exposed to fetal rbcs post-
delivery with levels up to 26.6 mL. These volumes are comparable to those found in 
ICS. We have not noted an increase in antibody formation within our population when 
compared to normal pregnancy or those having an allogeneic transfusion, although 
these numbers (647) are still too small to answer this risk with confidence. 
 
From data I have collected within our hospital at RCH, I have calculated the current 
risk of producing an antibody due to allogeneic blood transfusion is 0·35%. To rule out 
an increased rate of producing an antibody from receiving ICS blood with 95% 
certainty, that the upper 95% confidence interval is less than 0·45%, would require a 
total study size of 15,236 patients; the total sample is split randomly, 7618 patients to 
receive allogeneic blood compared to 7618 receiving ICS blood, making this study not 
feasible. We are the only hospital who follow up women, and we are strongly 
recommending that other institutions follow-up women three to four months post-re-
infusion in order to collect data on alloimmunisation rates. We recommended to a large 
proposed randomised controlled trial in 2013 to follow-up women, which would have 
significantly increased the numbers, however, it was decided by the research team to 
not assess alloimmunisation at that time (personal communication). Other hospitals 
are now following our practice and starting to follow-up women for antibody formation. 
In one UK hospital, referencing our work and using it as a foundation, 225 women had 
an ICS re-infusion. Of these, 52 (23%) had an antibody screen. No antibodies were 
detected, concluding that ICS is not associated with alloimmunisation (Akindele et al., 
2018). Another hospital, who I assisted in their report based on our work, followed up 
80 women, for which none had produced an antibody (Davies et al., 2018). I am now 
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working with this hospital on setting up a formalised follow-up system. I am also 
working with another hospital to follow up their women who have had a re-infusion. 
 
It is hoped that other centres will adopt this approach, and I would work with others to 
set up a central database to capture all follow-ups. I am in consultation with several 
hospitals to repeat the fetal red cell levels in maternal circulation pre- and post-
delivery, using more sensitive methodologies and a significantly higher sample size 
population. 
 
However, despite the evidence listed, a recent large randomised controlled trial on cell 
salvage during caesarean section ‘SALVO’ has somewhat negatively impacted on the 
use of ICS in obstetrics based on alloimmunisation concerns (Khan et al., 2017). Their 
results have been adopted into the recently published AAGBI guidelines where they 
have recommended to not use ICS routinely (Klein et al., 2018). We have responded 
to SALVO with our concerns (Ralph & Sullivan, 2018), and the AABGI guidelines, as 
have others. 
 
In the SALVO trial, it was reported that fetal-maternal haemorrhage (FMH) was 
significantly increased by the use of cell salvage, however, the SALVO authors do 
state that results should be treated with caution due to such small numbers and data 
available. Data are only available on those cases where the FMH was greater or equal 
to 2 mL, and a RhD positive baby was born to a RhD negative mother. From 761 re-
infused cases, this FMH risk was based on 30 cases: 21 in the ICS group and 9 in the 
non-ICS group. Of the 21 cases investigated for alloimmunisation in the ICS group, six 
(29%) did not have a re-infusion but the data compared included these six, and so 
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raises concerns with the validity of the data. Of interest, the non-ICS group had the 
highest fetal contamination (37 mL) compared to 26 mL in the ICS group. It cannot be 
postulated that collecting ICS blood only increases the number of fetal cells entering 
the maternal circulation. It is concerning that such important decisions have been 
made on such a small sample size, where there are more significant sample sizes 
studied, including our data from over 180 cases, the largest to date by far. I am in 
correspondence with the trial authors to discuss this finding. 
 
The use of ICS in obstetrics had been increasing. In 2014 the UKCSAG repeated a 
survey of UK hospitals using ICS and compared results to the 2010 survey (UK Cell 
Salvage Action Group, 2014). Most specialities have seen similar levels of use 
between the two dates, however, there has been an increase in its use in obstetrics 
and gynaecology. In 2014, obstetrics and gynaecology accounted for 25% of ICS use, 
the largest of all specialities (Figure 3). It was postulated that this obstetric increase 
may be due to the SALVO trial recruitment. However, as more information is becoming 
readily available and support is available, this could also have contributed to its 
increase. Unfortunately, one hospital has commented that their use of ICS and 
enthusiasm has reduced post-negative SALVO findings (Orr & Wrench, 2018). 
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Figure 3: Cell salvage use across the UK (taken from the UK Cell Salvage Action 
Group survey, 2014) 
 
Since 2008, I have carried on investigating and improving our ICS service offered. 
Apart from concerns with AFE and fetal red cell alloimmunisation, concerns have been 
raised about staffing and finances to run an ICS service in general. The 2014 UKCSAG 
survey (UK Cell Salvage Action Group, 2014) identified that 21% of hospitals were 
unable to use ICS out of hours, compared to 23% in 2010, so no significant 
improvement. Reasons why not used included lack of trained users and insufficient 
staff available. In 2011 we published a report on staffing, finance and implementation 
of the service (Ralph et al., 2011). 
 
In this study, blood was collected and re-infused to 70 women. We assessed the 
quality of the returned blood by taking a sample and testing the haemoglobin and 
haematocrit and assessing fetal red cell contamination. Mean haemoglobin 
concentration was 142 g L-1, and mean haematocrit was 0.418 L L-1. All samples had 
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detectable fetal red cells with a range 0.2–12.9 mL. Throughout this period, we 
investigated allogeneic transfusion rates and noted a reduced allogeneic transfusion 
rate over a three-year period.  
 
To overcome staffing and training barriers, ICS is included into routine preparation of 
our obstetric theatre and is entirely run by the normal quota of theatre staff. We also 
introduced a competency training programme for operating department practitioners. 
The operating department practitioner operates the cell salvage machine as well as 
assisting the anaesthetist. No additional staffing has been required, and at the time of 
reporting (2011) ICS was being used for more than 40% of C/S. This figure is now 
greater than 99% in 2018 (Sullivan & Ralph, 2019). This showed that it is possible to 
implement an ICS service with no additional staffing requirements, which is often seen 
as a limiting factor. We have since been contacted by other hospitals to ask our advice 
on how to implement ICS.  
 
In our initial 2008 report we recommended the use of a LDF, partly based on historical 
concerns and comments, our lack of experience in obstetric ICS, and the NICE 2005 
guidance which recommended that they could be considered (NICE Guideline, 2005). 
Before current LDF introduction, several hundred patients received ICS blood with no 
filter or less effective models, with no evidence of AFE (Catling et al., 2010). The 
washing process alone has now been shown to completely remove AF and reduce 
fetal squames cell levels (Thornhill et al., 1991; Sullivan et al., 2008). In the SALVO 
trial (Khan et al., 2017) only 54.1% of 26 UK obstetric units in the trial used LDFs, 
demonstrating a move away from its use in obstetrics, partly due to concerns with 
hypotensive reactions and slow re-infusion rates (Khan et al., 2017; Haynes & Ralph, 
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2018). Since SHOT started recording cell salvage events in 2010 there have been 20 
hypotensive events due to the use of the LDF (Haynes et al., 2017). Due to concerns 
and comments with the filters, we wrote a correspondence (Ralph & Sullivan, 2010) 
discussing their use and confirming that the manufacturers had not validated their use 
for its ability to remove fetal squames cells, but rather that they only remove white 
cells, fat and microaggregates. Within our hospital we stopped using the filters in 2015, 
and since then we have not had any adverse events due to not using these filters, 
which led us to recommend to not use LDFs in our recent 2018 paper. The recent 
published AAGBI guidelines only recommend that LDFs should be considered for 
cancer surgery (Klein et al., 2018). 
 
Also, in our initial 2008 report we recommended to not re-infuse partial first bowls. The 
role of partial bowls is now a debated subject, although evidence for this concern is 
limited and could just be theoretical based on the hypothesis that “partially filled bowls 
are inadequately washed based on the physics of centrifugal cell separation” 
(Szpisjak, 2001).  
 
Since then I have assessed the quality of the blood obtained from partial bowls 
(defined as a first bowl that does not fill after processing in the automatic setting on 
the machine) (Sullivan & Ralph, 2019). The haemoglobin and haematocrit are lower 
in partial bowls, as would be expected, but the plasma free haemoglobin, lactate 
dehydrogenase (LDH) and potassium concentrations from full bowls were found to be 
higher (p < 0.001), with albumin levels similar with no significant difference between 
full and partial bowls (p = 0.861). Plasma free haemoglobin and LDH concentrations 
from partial bowls were found to be similar to that of allogeneic blood, however, levels 
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from full bowls were higher than allogeneic (p < 0.001), consistent with our previous 
finding that there is more haemolysis in ICS compared to allogeneic blood (Sullivan 
& Faulds, 2014). I concluded that the quality of blood processed from partial first bowls 
is no worse than that of full bowls, apart from haemoglobin/haematocrit, and that 
partial first bowls should be considered in obstetrics for re-infusion. Haemonetics® 
product literature now states US Food and Drug Administration (FDA) clearance to 
wash and re-infuse a partially-filled bowl to maximise red cell re-infusion 
(Haemonetics® product brochure, 2012), although information available to support 
this is limited. 
 
One consideration is how partial a bowl will be cost effective? For example, does 115 
mL blood (from a 125 mL bowl) with median haemoglobin of 98 g L-1, haematocrit 
0.286 L L-1 reduce the allogeneic transfusion risk? The re-infusion of even these small 
quantities of blood could be of benefit to women who refuse blood products, such as 
Jehovah’s Witnesses, where all salvaged red cells could be potentially returned to the 
patient. At the RCH, some women had ICS blood collected but were not re-infused as 
the processed volumes were only partial first bowls. A minority of these cases went on 
to receive an allogeneic transfusion, although it is unclear whether it was due to a low 
starting haemoglobin, poor tolerance of the small blood loss during delivery or 
continued bleeding post-natally that resulted in the further drop in haemoglobin. If 
partial bowls were re-infused, potentially the allogeneic transfusion rate could be 
reduced further, something that could be audited if we introduced partial bowl re-
infusions. 
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Another debated point, which authors often contradict themselves frequently, is 
whether cell salvage should be employed for all cases, or just for those with expected 
high risk/high blood loss cases. Within our hospital we collect on all cases, setting up 
a ‘stand-by’ system, also known as ‘collection only’, where all blood lost is collected 
into the cell salvage reservoir. If blood volume collected is significant to process fully, 
the more expensive processing kits are opened at this point. This method has been 
shown to be cost effect (Waters et al., 2007; Sikorski et al., 2017; Zeng et al., 2018), 
and we have not noted a significant increase in costs associated with this practice. 
 
Since 2012, the number of cases where ICS has been used to collect blood within our 
hospital has raised from 95.4% to 99.1% in 2017. Not all cases lose sufficient blood to 
be processed, but the percentage of blood re-infused of those processed cases has 
raised from 53.1% in 2012 to 70% in 2017. Many women who receive cell salvaged 
blood are women who have no pre-operative predictors for blood loss. By trying to 
predict, and only collect for those women at risk of bleeding, many women who bleed 
will be missed, and limiting the use of ICS to high-risk cases may result in reduced 
opportunities for training and maintenance of skills (King et al., 2009). I have shown 
there is no correlation between C/S category and ICS volume, C/S category and 
estimated blood loss, nor para gravida and estimated blood loss (Spearman’s rank 
correlation 0.253, -0.228 and -0.050, respectively) which confirms the perception that 
those women at risk of bleeding cannot be predicted. There was weak correlation 
between estimated blood loss and length of stay (0.334), and moderate correlation 
between estimated blood loss and ICS re-infused volume (0.535), which would be 
expected. 
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Although each year the percentage we process to re-infuse increases, it is unlikely 
more than 80% of processed collections will be re-infused as some will always be 
wasted due to training, partial first bowls and rarely, women who decline the re-
infusion. 
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CHAPTER 4 – ALLOGENEIC TRANSFUSION RATES POST CELL SALVAGE 
INTRODUCTION 
As well as recording data on ICS use, we have also been auditing allogeneic 
transfusion rates. All obstetric women who receive an allogeneic transfusion are 
audited to assess reason why transfusion given and whether it was appropriate or 
could have been avoided. The use of ICS has been critical in reducing these rates, 
although it is not the sole cause. We have an active patient blood management 
programme in place, which includes treatment of ante-natal and post-natal anaemia 
with total dose intravenous iron (implemented 2012), tranexamic acid for major 
obstetric haemorrhage, and education and training of medical staff in using blood 
wisely. As can be seen in Figure 4, the number of cell salvage re-infusions has 
increased, and the number of allogeneic transfusions has reduced. 
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Figure 4: Number of women transfused allogeneic blood or cell salvaged blood 
 
The rate of allogeneic transfusions in our obstetric population has fallen to 0.6%, which 
includes ante-natal and post-natal women who have both vaginal and C/S delivery, 
one of the lowest in the UK. The allogeneic transfusion rate for those women who 
delivered by C/S is 0.4%, far lower than the suggested 5% standard in the UK 
(Geoghegan et al., 2009). Not only has the percentage of women needing a blood 
transfusion dropped to below 1%, but as important, is the reduction of the number of 
units of blood transfused, which has reduced from average 3.3 units pre-2008 to less 
than two units after 2012 when the service was fully established. Obstetric patients 
(C/S and vaginal deliveries) now account for 0.3% of allogeneic red cells units 
transfused within our hospital. I have a responsibility to manage and improve 
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transfusion services within our Trust and the NHSBT, where I sit on several working 
groups.  
 
Since 2016 the allogeneic transfusion rate has plateaued, mainly being due to women 
requiring blood following vaginal deliveries. As can be seen in Figure 5, the majority 
of our allogeneic blood transfused goes to those women who deliver vaginally. The 
rate in this group is increasing, with the rate in the C/S group falling.  
 
 
Figure 5: Percentage of allogeneic transfusions – vaginal or caesarean deliveries over 
time 
 
In 2017, 71% of allogeneic blood use in obstetrics went to women post vaginal 
delivery. As part of our patient blood management programme, this is something that 
needs to be targeted. 
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CHAPTER 5 – VAGINAL CELL SALVAGE 
As has just been shown, the biggest users of allogeneic red cells within our obstetric 
department are now those who deliver vaginally. Could ICS be used within vaginal 
deliveries? 
 
The use of ICS in vaginal deliveries has been contraindicated mainly because of 
bacterial contamination concerns, although there is no evidence to support or reject 
its use. Concerns also lie with the collection and the quality of returned blood. This led 
us in 2014 (Teare et al., 2015) to undertake a feasibility study into whether blood lost 
vaginally can be safely collected, processed and re-infused after vaginal delivery. This 
was the first study to attempt to collect vaginal blood loss. A project grant was awarded 
from the National Institute of Academic Anaesthesia to support this. Fifty women were 
consented and enrolled. No women were re-infused. 
 
One of the first challenges was how to collect lost blood and stop it from clotting. An 
under-buttock drape with pouch was used and 200 mL heparinised saline was run 
rapidly into the pouch, and then adjusted to a slow drip. Blood collected could then be 
aspirated into the cell salvage machine. Samples were taken pre- and post-wash, and 
post LDF filter and tested for quality, fetal red cell contamination and bacterial 
contamination. To assess the risk of bacterial contamination, blood cultures were 
collected from 20 post-wash samples from emergency C/S cases. 
 
Of the 50 cases, results were available from 34 cases. The remaining 16 were not 
included as were taken from a partial bowl, and at that time, the quality of partial bowls 
was not known. Alpha-fetoprotein as a marker of AF was significantly reduced post-
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wash, as was heparin, albumin, LDH and plasma free haemoglobin. Fetal red cells 
were present in all cases. The results obtained were consistent with our and other’s 
experiences with ICS and C/S. The main additional concern still remaining was 
bacterial contamination.  
 
From all 50 cases enrolled, bacteria were detected in all cases post-wash and post-
filter, with a significant reduction in concentration by the washing process. The 
predominant bacteria identified were Escherichia Coli, Enterococcus species. and 
coagulase-negative Staphylococci which were likely to be part of the genital or skin 
flora. From the comparison group of 20 C/S cases, all had detectable bacteria, with 
contamination levels from vaginal similar to those from C/S. We calculated that the 
median dose that could potentially be re-infused was similar to dental procedures and 
is likely to be clinically insignificant. We concluded that salvaged vaginally collected 
blood was unlikely to increase the risk of infection, but this has not been established.  
 
We have since collected on a further three cases but none have been re-infused. The 
34 cases reported is still the largest report to date. In an editorial in the International 
Journal of Obstetric Anesthesia (Wilson & Wrench, 2015), reference was made to our 
vaginal study and how the findings add “to the existing evidence challenging this 
concept”. 
 
Our work and input was used in a later report by Lim and colleagues (2018a) who in 
2017 assessed the use of ICS after vaginal delivery. Re-reviewing their cases they 
identified ten women had had a cell salvage re-infusion post vaginal delivery. A further 
28 had blood collected but insufficient volumes for processing. A second group of 
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vaginal deliveries with no cell salvage re-infused were compared. Results showed no 
difference in length of stay between the two groups, and there were no cases of wound 
infection, sepsis, thromboembolic events, AFE or increased rates of allogeneic 
transfusion, however, the numbers (10) are very low to make conclusive decisions. 
Since then, there have been a handful of other reports involving cell salvage of vaginal 
blood lost following vaginal deliveries, but numbers still limited. In one case 380 mL of 
vaginal lost blood was collected and re-infused to a Jehovah’s Witness experiencing 
a significant PPH. The woman showed no signs of post-natal sepsis, and blood 
cultures were negative after 48 hours (Weingarten et al., 2017). I have received other 
personnel communications, for which I am encouraging these users to publish. 
 
Further large-scale trials are required to confirm the safety and effectiveness, 
compared to allogeneic blood, which we recommended in our 2015 study. A survey 
was undertaken by Nelissen and colleagues (2018) to assess the use of ICS in 
obstetrics including after vaginal delivery, and perceived thoughts on its use. There 
were no hospitals in England, Scotland or Wales who use ICS routinely after vaginal 
birth, although there was support for its use.  
 
Based on our results and experiences, within our Trust policy on cell salvage, we state 
that if surgical intervention is attempted vaginally, ICS may be considered in life 
threatening circumstances (when there are no alternatives, such as with Jehovah’s 
Witnesses). We are currently re-reviewing our use of ICS and hope to work in 
collaboration with others to advance this area. 
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CHAPTER 6 – QUALITY OF CELL SALVAGE BLOOD 
Another key area that I am focusing on, which currently has not been investigated in 
much depth, is the quality of blood being returned to the patient. Is it acceptable to 
return blood without even knowing exactly what is in it? How do we know that what we 
are routinely returning is of safe and consistent quality? This area I feel needs to be 
investigated. 
 
Quality control (QC) is seen as integral in laboratories but not so in theatres. In the 
2017 SHOT report, the authors commented that “an awareness of cell-salvaged blood 
quality is important for both operators and clinicians”. They recommended that cell 
salvage operators should be trained and competency assessed with ongoing 
retraining and updating, standard protocols should be in place and the quality of the 
re-infused product known (Haynes & Ralph, 2018). The UKCSAG 2014 survey 
identified that 55% do not control the machine and 61% do not QC the users, with no 
improvement since the 2010 survey when 58% do not QC the machine and 68% do 
not check the user (UK Cell Salvage Action Group, 2014). 
 
I have an active interest in ICS quality control/assurance and have undertaken various 
studies to investigate the implementation of a readily available, cheap, quick and 
reliable testing system for hospitals to assess the quality. 
 
Heparin is the anticoagulant used in all cell salvage specialities within our Trust. There 
was no cheap quick screening test readily available to detect heparin contamination 
in ICS. There had been concerns from the surgeons that heparin may still be present 
in the final end product which could compromise the patient’s recovery. Previous 
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studies have shown that heparin is still present in the final product (Umlas & O’Neill, 
1981; Kling et al., 1988; Burman et al., 2002), but in our 2008 study we showed it is 
possible to completely remove heparin. To ensure that the cell salvage machines wash 
out the heparin to a safe level, I devised a suitable test. Current screening test is the 
anti-Xa assay, but this is expensive and not readily available in all laboratories. It 
requires specialised reagents and time to make these reagents, calibrate and QC the 
analyser. 
 
The standard laboratory thrombin clotting time test was modified and shown to be a 
reliable and sensitive marker in measurement of heparin up to 0.14 iu mL-1. This 
modified test was only designed to exclude gross heparin contamination. Anything 
above 0.15 iu mL-1 are flagged as high heparin concentration and require further 
testing. Heparin concentrations greater than 0.5 iu mL-1 affect in-vivo coagulation, so 
at concentrations up to 0.14 iu mL-1, this equates to a clinically insignificant amount 
that could be re-infused safely. This was published in 2012 (Sullivan et al., 2012). 
 
This QC test has been successfully incorporated into our hospital QC scheme for 
obstetrics, vascular and gynaecology, but not for orthopaedics. This being due to high 
levels of haemolysed blood in orthopaedic cases post wash, and the coagulation 
analysers unable to test grossly haemolysed samples. The haemolysed samples 
obtained were of concern, especially with the effect of re-infusing haemolysed blood 
to patients. This is still a reoccurring theme in ICS with further haemolysis caused by 
the suction pressure, washing/centrifuging process and/or the aspiration method, but 
the significance has not been fully addressed, and so I investigated the role of 
haemolysis in ICS. 
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Blood lost from orthopaedic surgery tends to be of a gradual loss, with blood suctioned 
from bone and tissue in a ‘skimming’ fashion, resulting in mechanical trauma, whereas 
in obstetrics and vascular surgery there is more of a ‘pooling’ of lost blood. When these 
cells are collected they are not exposed to the same trauma as that in orthopaedics. 
Free haemoglobin as a result of haemolysis released into the circulation is bound by 
haptoglobin which is then removed by the reticuloendothelial system. When in excess, 
or insufficient haptoglobin to bind to the free haemoglobin, free haemoglobin becomes 
nephrotoxic resulting in circulatory free haemoglobin in the plasma. When levels 
exceed reabsorption rates in the kidneys it presents in urine as haemoglobinuria 
(Dacie & Lewis, 1991; Rother et al., 2005). Acute renal failure could theoretically occur 
in severe episodes of haemoglobinuria caused by re-infusions of haemolysed ICS 
blood. This, however, does not seem to occur in the clinical setting possibly due to the 
low volumes returned in most surgical collections.  
 
In addition, the haem part of haemoglobin breakdown can increase procoagulant 
effects resulting in increased platelet activation and increased release of inflammatory 
substances (Rother et al., 2005; Sloan et al., 2009). Damaged cells also cause 
coagulation abnormalities and other inflammatory morbidities including acute lung 
injury (Kelleher et al., 2011). 
 
Free haemoglobin is also a scavenger of nitric oxide irreversibly binding to and 
reducing levels. Nitric oxide is a regulator of smooth muscle tone and platelet 
activation and acts as a vasodilator in the microcirculation (Rother et al., 2005; Ley et 
al., 2012). Reduced levels result in vasoconstriction, systolic and diastolic blood 
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pressure increases, reduced tissue oxygenation, smooth muscle dystrophy, 
gastrointestinal contractions, endotheliac dysfunction and platelet aggregation with 
increased thrombotic events (Rother et al., 2005; Sloan et al., 2009; Kelleher et al., 
2011; Vermeulen Windsant et al., 2012). Haemolysis also results in the release of 
enzymes that can affect nitric oxide synthesis (Rother et al., 2005).  
 
With all these potential consequences, I undertook a project to quantify the amount of 
haemolysis in orthopaedics (skimmed) and obstetrics (pooled) and to compare that to 
allogeneic blood. This was published in 2014 (Sullivan & Faulds, 2014). I confirmed 
the hypothesis that haemolysis (as measured by free haemoglobin levels) was 
significantly higher in orthopaedics compared to obstetrics and allogeneic blood. This 
does not, however, address the clinical significance of re-infusing haemolysed blood. 
In-vivo effects, dilutional effect and haptoglobin levels for example need to be 
considered, although I feel there is no significance due to the thousands of re-infused 
cases reported with no complications due to haemolysis. I did review the notes from 
the 50 patients enrolled into this study and noted no new cases of renal dysfunction 
or other complications. This study needs to be repeated, including assessing the 
patient’s free haemoglobin levels pre and post ICS re-infusion, as well as testing 
haptoglobins and monitoring renal function. 
 
Following on from implementing a heparin screening test into our QC package, I also 
wanted to ensure there was no gross haemolysed blood being returned, and so next 
investigation was for a cheap reliable and sensitive test for haemolysis. The gold 
standard test would be plasma free haemoglobin levels, but this requires expensive 
devices and consumables that are not available to many hospitals. Therefore, I 
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explored the possibility of using the LDH test as an alternative. Lactate dehydrogenase 
is an enzyme widely distributed in almost all body cells and when cells are damaged, 
it is released into the circulation and can therefore be quantified. In 2013 I published 
results showing the sensitivity and reliability of this test (Sullivan & Faulds, 2013). 
The LDH test strongly correlated (Spearman’s rank correlation 0.960) with plasma free 
Haemoglobin levels measured by a specialised HemoCue® Plasma/Low Haemoglobin 
System (HemoCue®, Ängelholm, Sweden). Other hospitals have used potassium as a 
haemolysis marker, so I also compared potassium to plasma free haemoglobin levels 
and concluded the correlation was not acceptable (Spearman’s rank correlation -0.16) 
and recommended that potassium should not be used. This LDH test has since been 
incorporated into our QC package alongside heparin test, haemoglobin/haematocrit 
and albumin (microalbumin). Other hospitals have been in contact with myself 
enquiring about our findings/experiences. 
 
Although we have suitable tests available, acceptable ranges for quality markers have 
not been established. In 2010-11 on behalf of the UKCSAG we asked hospitals to 
participate and provide data on results from QC sample testing. Uptake was poor with 
insufficient data collected to answer this question. I presented this at British Blood 
Transfusion Society annual conferences to gain interest (Faulds & Sullivan, 2011; 
Faulds & Sullivan, 2013). It is hoped that the recently reformed UKCSAG will repeat 
this, for which I am currently working in collaboration with to undertake a survey on 
what QC hospitals currently do, how often, and if they would be interested in setting 
up a national database in order to establish reference ranges. In the meantime, I am 
currently setting up a local database.  
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Several users still report quality as a percentage, for which I disagree with and I am 
promoting an alternative method of reporting quality. Reporting the washout rates of 
the machines as a percentage does not provide useful clinical information for the 
clinical team. Rather than knowing that the average washout rate is 98% for proteins, 
would it not be more beneficial to know exactly what concentration is in the final 
product (e.g. 1 mmol L-1). Again, it is hoped that in collaboration with the recently 
reformed UKCSAG group this can be taken forward. 
 
Another challenge for the future is to make QC testing point of care so results are 
immediately available, rather than waiting for laboratories to process and report. This 
I will be exploring further. 
 
Quality control is now part (ad-hoc) of our Trust protocol but I am currently drafting a 
Trust policy on quality assurance to formalise and standardise QC along with 
servicing, down-time reports, training, documentation and competency assessment. 
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CHAPTER 7 – FUTURE 
Now that ICS has become established within our hospital for caesarean sections, the 
focus has been moved to the quality and consistency of blood returned, and general 
quality control including machine downtime logs, staff training and competency. 
Collection and cell salvage of vaginal blood following vaginal delivery is another 
specific area for development. 
 
Outside these two topics, other general issues need to be reviewed. 
 
In an ever-demanding NHS setting, hospital budgets are tightly controlled, and 
expenditure must be justified. Is ICS cost effective to use in all surgical cases or limit 
to high risk cases where massive blood loss is expected? It had been previously 
reported that once the capital of the cell salvage machine had been paid for, ICS was 
cost neutral so long as the equivalent of two units of blood had been transfused, and 
any more than this is a cost saving (Waters et al., 2011). However, more recent reports 
have suggested that ICS is no longer cost effective in routine C/S (Khan et al., 2017; 
Lim et al., 2018b). 
 
Recommendations to not use ICS routinely based on cost alone is worrying and could 
be a backwards step in implementing this critical service. Assessing costs must 
accurately reflect clinical practice in which collection costs are considered separately 
to costs of processing and providing a re-infusion. We have previously shown it is 
possible to run a service with no additional staffing needed, and in a recent report, 
significant cost savings were made by the use of ICS. From 543 C/S cases in a one-
year period, cell-salvaged blood was re-infused to 182. Based on a theory that one 
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unit allogeneic blood is the same as one unit cell-salvaged blood, a cost saving of 
£9776.20 was calculated (Kenyon et al., 2018). Based on their calculations, I believe 
the costs savings could be greater than that, as one unit of cell-salvaged blood is not 
equivalent to one unit of allogeneic, but possibly two to three units, thus representing 
an even bigger financial saving. Micro-costing of ICS in obstetrics in the UK has not 
been undertaken yet (to my knowledge) and would, therefore, be the obvious next 
step. Micro-costing analysis has been undertaken for allogeneic transfusion, 
estimating that it costs £57 for a unit of allogeneic red cell transfusion, and a further 
£36 per subsequent unit. This includes reagents, nursing time and consumables 
(Stokes et al., 2018). The cost of the unit (currently £128) has not been included, and 
so would take it to a total of approximately £185 per unit. Patient recovery and 
avoidance to potentially dangerous blood components also needs to be considered. I 
will shortly be undertaking a thorough UK-based cost-effective study of ICS compared 
to allogeneic transfusion. 
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CHAPTER 8 – NATIONAL AND INTERNATIONAL IMPACT 
Locally, the work I have been involved in has been implemented into our Trust policy 
on intra-operative blood cell salvage for obstetrics (V1.3, Dec 2017). Our work has 
been presented at numerous national and European conferences – see page 70 for 
list. 
 
One UK hospital referred to our work at a UK annual conference (Davies et al., 2018) 
and are now using our work as a baseline on how to set up a follow-up service. I will 
be working with them on undertaking a new project looking at fetal cell levels in 
maternal circulation, similar to what I have done previously, but on a much larger scale. 
 
Our work was used to assist in writing the Cell Salvage Chapter in the latest SHOT 
annual report (Haynes & Ralph, 2018), although not directly referencing my work. And 
the UKCSAG guidelines/technical factsheets refer to our work. These are currently 
being reviewed and updated. 
 
As our work is becoming more recognised, I have been asked by the Association for 
Perioperative Practice to write an updated article on obstetric cell salvage. This follows 
on from myself raising concerns about a report from 2011 republished in 2018 which 
contained outdated information. 
 
With regards to my QC work, I am often asked for advice on ICS QC and have recently 
advised a large UK hospital on setting up a QC programme. Internationally I have had 
communication from as far as China regarding our QC work (Dong et al., 2014). 
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CHAPTER 9 – CONCLUSION 
We were the authors to the first study to state that only one suction device is required 
in theatre, and also the first study to show it is possible to collect and potentially re-
infuse blood lost from vaginal deliveries. We have shown it is possible to safely employ 
ICS routinely within an obstetric unit for caesarean sections with no additional staffing 
costs and a notable reduction in the rate of allogeneic blood transfusion. Intra-
operative cell salvage is now established in all caesarean sections 24 hours a day, 
seven days a week with a dedicated machine within our obstetric theatre. Very few 
centres offer this.  Intra-operative cell salvage is an economical and essential 
component of an obstetric patient management strategy. 
 
Despite the limited follow-up data of test for antibody formation, data so far suggests 
that receiving a re-infusion of ICS processed blood does not put women at any more 
risk of antibody formation compared to women who receive an allogeneic transfusion. 
However, without more complete follow-up, rates may be deceptive, and as I have 
previously recommended, all Institutions using ICS in obstetrics should adopt this 
method of following up women three to four months post re-infusion in order to collect 
alloimmunisation rates and record this data on a central database.  
 
Our work, and along with that of others, may be of great assistance in justifying the 
use of cell salvage in low-resource countries, where the allogeneic blood supply may 
not be as sufficient or as safe as of that in the UK. 
 
 
  
 
48 
 
REFERENCES 
References in bold contribute to body of published work submitted in evidence for the 
awards of PhD by publication. 
 
 
Akindele, O., Davy, B., Sharafudeen, S., & Skelton, V. (2018). Red blood cell antibody 
formation post re-infusion of cell salvaged blood during caesarean section. 
International Journal of Obstetric Anesthesia, 35(S1), 19. 
 
Allam, J., Cox, M., & Yentis, S.M. (2008). Cell salvage in obstetrics. International 
Journal of Obstetric Anesthesia, 17(1), 37-45. 
 
Baker, D., Teare, K.M., & Ralph, C.J.  (2014). Does re infusion of blood salvaged at 
emergency caesarean section increase the risk of infection? International Journal of 
Obstetric Anesthesia, 23 (S1), 56. 
 
Benson, M.D. (2012). Current concepts of immunology and diagnosis in amniotic fluid 
embolism. Clinical and Developmental Immunology, Article ID 946576, 1-7. 
 
Bernstein, H.H., Rosenblatt, M.A., Gettes, M., & Lockwood, C. (1997). The ability of 
the Haemonetics 4 Cell Saver System to remove tissue factor from blood 
contaminated with amniotic fluid. Anesthesia and Analgesia, 85(4), 831-833. 
 
Beutler, E., Meul, A., & Wood, L.A. (1969). Depletion and regeneration of 2,3-
diphosphoglyceric acid in stored red blood cells. Transfusion, 9(3), 109-114. 
 
49 
 
Bolton-Maggs, P.H.B., Poles, D., et al. on behalf of the Serious Hazards of Transfusion 
(SHOT) Steering Group (Eds. P Bolton-Maggs). (2018). The 2017 Annual SHOT 
Report. Retrieved from: https://www.shotuk.org/shot-reports. 
 
Burman, J.F., Westlake, A.S., Davidson, S.J., Rutherford, L.C., Rayner, A.S., Wright, 
A.M., ... Pepper, J. (2002). Study of five cell salvage machines in coronary artery 
surgery. Transfusion Medicine, 12(3), 173–179. 
 
Buys, W.F., Buys, M., & Levin, A.I. (2017). Reinfusate heparin concentrations 
produced by two autotransfusion systems. Journal of Cardiothoracic and Vascular 
Anesthesia, 31(1), 90-98. 
 
Catling, S.J., Williams, S., & Fielding, A.M. (1999). Cell salvage in obstetrics: an 
evaluation of the ability of cell salvage combined with leucocyte depletion filter to 
remove amniotic fluid from operative blood loss at caesarean section. International 
Journal of Obstetric Anesthesia, 8(2), 79-84. 
 
Catling, S., & Joels, L. (2005). Cell salvage in obstetrics: the time has come. An 
International Journal of Obstetrics and Gynaecology, 112(2), 131-132. 
 
Catling, S., Wee, M., & Thomas, D. (2010). A reply. Anaesthesia, 65(2), 207-208. 
 
Clark, S.L., Paylova, Z., Greenspoon, J., Horenstein, J., & Phelan, J.P. (1986). 
Squamous cells in the maternal pulmonary circulation. American Journal of Obstetrics 
and Gynecology, 154(1), 104-106. 
 
50 
 
Conde-Agudelo, A., & Romero, R. (2009). Amniotic fluid embolism: an evidence-based 
review. American Journal of Obstetrics and Gynecology, 201(5), 445.e1–e13. 
 
Dacie, J.V., & Lewis, S.M. (1991). Practical Haematology (7th ed.). Edinburgh, UK: 
Churchill Livingston Publishers. 
 
Davies, J., Johnston, D., Galvin, I., & Kerr, P. (2018). Cell salvage in obstetrics – 
increasing the risk of alloimmunisation? Transfusion Medicine, 28(S1), 22. 
 
Davis, M., Sofer, M., Gomez-Martin, O., Bruck, D., & Soloway MS. (2003). The use of 
cell salvage during radical retropubic prostatectomy: does it influence cancer 
recurrence. British Journal of Urology International, 91(6), 474–476. 
 
Domen, R.E. (1998). Adverse reactions associated with autologous blood transfusion: 
evaluation and incidence at a large academic hospital. Transfusion, 38(3), 296-300. 
 
Dong, P., Che, J., Li, X., Tian, M., & Gao, F. (2014). Quick biochemical markers for 
assessment of quality control of intraoperative cell salvage: a prospective 
observational study. Journal of Cardiothoracic Surgery, 9(86), 1-7. 
 
Duffy, G., & Neal, K.R. (1996). Differences in post-operative infection rates between 
patients receiving autologous and allogenic blood transfusion: a meta-analysis of 
published randomized and nonrandomized studies. Transfusion Medicine, 6(4), 325–
328. 
 
 
51 
 
Esper, S.A., & Waters, J.H. (2011). Intra-operative cell salvage: a fresh look at the 
indications and contraindications. Blood Transfusion, 9(2), 139-47.  
 
Faulds, J., & Sullivan, I. (2011). Intra-operative cell salvage – national quality control 
update. Transfusion Medicine, 21(S1), 40. 
 
Faulds, J.N., & Sullivan, I.J. (2013). Implementation of a national intra-operative cell 
salvage quality control programme, in association with the UK Cell Salvage Action 
Group. Transfusion Medicine, 23(S2), 50. 
 
Fong, J., Gurewitsch, E.D., Kump, L., & Klein, R. (1999). Clearance of fetal products 
and subsequent immunoreactivity of blood salvaged at cesarean delivery. Obstetrics 
and Gynecology, 93(6), 968-972. 
 
Geoghegan, J., Daniels, J.P., Moore, P.A.S., Thompson, P.J., Khan, K.S., & 
Gülmezoglu, A.M. (2009). Cell salvage at caesarean section: the need for an 
evidence–based approach. British Journal of Obstetrics and Gynaecology: An 
International Journal of Obstetrics and Gynaecology, 116: 743-747. 
 
Green, L., Connolly, C., Cooper, T.K., Cho, G., & Allard, S. (2015). Blood transfusion 
in obstetrics (Green-top guideline 47). Retrieved from the Royal College of 
Obstetricians and Gynaecologists website: 
https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-47.pdf. 
 
 
52 
 
Greenawalt, J.A., & Zernell, D. (2017). Autologous blood transfusion for postpartum 
hemorrhage. The American Journal of Maternal/Child Nursing, 42(5), 269-275. 
 
Haemonetics® product brochure. Cell saver 5+ standard of care in intraoperative 
autotransfusion. (2012). Retrieved from: 
http://www.haemonetics.com/~/media/sharepoint/devices/cell_saver_5+/marketing/br
ochures/colpp000009usbrochurecs5pdf.ashx. 
 
Halstead, W.S. (1883). Reinfusion in carbonic-oxide poisoning. New York Medical 
Journal, 38, 625-629. 
 
Haynes, S.L., Ralph, C., & Thomas, D. (2017). Cell salvage incident reporting – the 
UK experience. Vox Sanguinis, 112(S1), 278. 
 
Haynes, S., & Ralph, C. (2018). Chapter 21: Cell salvage. In P.H.B Bolton-Maggs (Ed), 
D. Poles et al., on behalf of the Serious Hazards of Transfusion (SHOT) steering 
group. Annual SHOT Report 2017, 166-169.  
 
Health Service Circular 2007/001: Better blood transfusion. Safe and appropriate use 
of blood. (2007). Retrieved from: 
http://webarchive.nationalarchives.gov.uk/+/http://www.dh.gov.uk/en/Publicationsand
statistics/Lettersandcirculars/Healthservicecirculars/DH_080613. 
 
Highmore, W. (1874). Practical remarks on an overlooked source of blood-supply for 
transfusion in post-partum haemorrhage. The Lancet, 103(2629), 89-90. 
 
53 
 
Innerhofer, P., Klingler, A., Klimmer, C., Fries, D., & Nussbaumer, W. (2005). Risk of 
postoperative infection after transfusion of white blood cell-filtered allogeneic or 
autologous blood components in orthopedic patients undergoing primary 
arthroplasty. Transfusion, 45(1), 103–10. 
 
Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services 
Professional Advisory Committee (n.d). Patient Blood Management. Retrieved from:  
https://www.transfusionguidelines.org/uk-transfusion-committees/national-blood-
transfusion-committee/patient-blood-management. 
 
Karkouti, K., Wijeysundera, D.N., Yau, T.M., Beattie, W.S, Abdelnaem, E., McCluskey, 
S.A., … Karski, J. (2004). The independent association of massive blood loss with 
mortality in cardiac surgery. Transfusion, 44(10), 1453-1462.  
 
Kelleher, A., Davidson, S., Gohil, M., Machin, M., Kimberley, P., Hall, J. & Banya, W. 
(2011). A quality assurance programme for cell salvage in cardiac surgery. 
Anaesthesia, 66(10), 901-906. 
 
Kenyon, C., Mallaiah, S., & McNamara, H. (2018). Cell salvage can we really save 
blood (and money)? International Journal of Obstetric Anesthesia, 35(S1), 12. 
 
Khan, K.S., Moore, P.A.S., Wilson, M.J., Hooper, R., Allard, S., Wrench, I., … Dodds, 
J. (2017). Cell salvage and donor blood transfusion during cesarean section: A 
pragmatic, multicentre randomised controlled trial (SALVO). PLoS Medicine, 14(12), 
e1002471, 1-19. 
 
54 
 
King, M., Wrench, I., Galimberti, A., & Spray, R. (2009). Introduction of cell salvage to 
a large obstetric unit: the first six months. International Journal of Obstetric Anesthesia, 
18(2), 111-117. 
 
Klebanoff, G. (1970). Early clinical experience with a disposable unit for the 
intraoperative salvage and reinfusion of blood loss (intraoperative autotransfusion). 
The American Journal of Surgery, 20(6), 718-722. 
 
Klein, A.A., Bailey, C.R., Charlton, A.J., Evans, E., Guckian-Fisher, M., McCrossan, 
R., … Torella, F. (2018). Association of Anaesthetists guidelines: cell salvage for peri‐
operative blood conservation. Anaesthesia, 73(9), 1141-1150. 
 
Kling, D., Börner, U., Von Bormann, B. & Hempelmann, G. (1988). Heparin elimination 
and free hemoglobin following cell separation and washing of autologous blood with 
Cell Saver 4. Anasthesie Intensivtherapie Notfallmedizin, 23(2), 88–90. 
 
Knight, M., Nair, M., Tuffnell, D., Shakespeare, J., Kenyon, S., & Kurinczuk, J.J. 
(2017). Saving lives, improving mothers’ care. Lessons learned to inform maternity 
care from the UK and Ireland Confidential Enquiries into Maternal Deaths and 
Morbidity 2013–15. Maternal, Newborn and Infant Clinical Outcome Review 
Programme (MBRRACE-UK). Retrieved from: 
https://www.npeu.ox.ac.uk/downloads/files/mbrrace-uk/reports/MBRRACE-
UK%20Maternal%20Report%202017%20-%20Web.pdf. 
 
 
55 
 
Koch, C.G., Li, L., Duncan, A.I., Mihaljevic, T., Cosgrove, D.M., Loop, F.D., … 
Blackstone, E.H. (2006). Morbidity and mortality risk is associated with red blood cell 
and blood-component transfusion in isolated coronary artery bypass grafting. Critical 
Care Medicine, 34(6), 1608–1616. 
 
Konig, G., & Waters, J. (2012). Washing and filtering of cell-salvaged blood – does it 
make autotransfusion safe? Transfusion Alternatives in Transfusion Medicine, 12(3-
4), 78-87. 
 
Kuppurao, L., & Wee, M. (2010). Perioperative cell salvage. Continuing Education in 
Anaesthesia, Critical Care and Pain, 10(4), 104-108. 
 
Ley, J.T., Yazer, M.H., & Waters, J.H. (2012). Hemolysis and red blood cell 
mechanical fragility in shed blood after total knee arthroplasty. Transfusion, 52(1), 34-
38. 
 
Lim, G., Kotsis, E., Zorn, J.M., Dalby, P.L., Ralph, C.J., & Waters, J.H. (2018a). Cell 
salvage for postpartum haemorrhage during vaginal delivery: a case series. Blood 
Transfusion, 16(6), 48-501. 
 
Lim, G., Melnyk, V., Facco, F.L., Waters, J.H., & Smith, K.J. (2018b). Cost-
effectiveness analysis of intraoperative cell salvage for obstetric hemorrhage. 
Anesthesiology, 128(2), 328-337. 
 
 
56 
 
Liumbruno, G.M., Meschini, A., Liumbruno, C., & Rafanelli, D. (2011). The introduction 
of intra-operative cell salvage in obstetric clinical practice: a review of the available 
evidence. European Journal of Obstetrics and Gynecology and Reproductive Biology, 
159(1), 19-25.  
 
Lockwood, C.D. (1917). Surgical treatment of Banti’s Disease. Surgery, Gynecology 
and Obstetrics, 25, 188-191. 
 
Lockwood, C.J., Bach, R., Guha, A., Zhou, X., Miller, W.A., & Nemerson, Y.  (1991). 
Amniotic fluid contains tissue factor, a potent initiator of coagulation. American Journal 
of Obstetrics and Gynecology, 165(5), 1335-1341. 
 
Marcucci, C.,  Madjdpour, C., & Spahn, D.R. (2004). Allogeneic blood transfusions: 
benefit, risks and clinical indications in countries with a low or high human 
development index. British Medical Bulletin, 70 (1), 15-28. 
 
Mavrides, E., Allard, S., Chandraharan, E., Collins, P., Green, L., Hunt, B.J., … 
Thomson, A.J. on behalf of the Royal College of Obstetricians and Gynaecologists. 
(2016). Prevention and management of postpartum haemorrhage (Green-top 
guideline 52). British Journal of Obstetrics and Gynaecology: An International Journal 
of Obstetrics and Gynaecology, 124(5), e106-e149. 
 
McDonnell, N.J., Kennedy, D., Long, L.J., Gallagher-Swann, M.C., & Paech, M.J. 
(2010). The development and implementation of an obstetric cell salvage service. 
Anaesthesia and Intensive Care, 38(3), 492-499.  
 
57 
 
Miller, A.G. (1886). Case of amputation at hip-joint, in which re-injection of blood was 
performed, and rapid recovery took place. Edinburgh Medical Journal, 31(8), 721-722. 
 
Mollison, P.L., Engelfriet, C.P. & Contreras, M. (1997) Blood transfusion in clinical 
medicine (10th ed.). Oxford UK: Blackwell Science. 
 
Muñoz, M., Peña-Rosas, J.P., Robinson, S., Milman, N., Holzgreve, W., Breymann, 
C.,  … Hardy, J.F. (2018). Patient blood management in obstetrics: management of 
anaemia and haematinic deficiencies in pregnancy and in the post-partum period: 
NATA consensus statement. Transfusion Medicine, 28(1), 22-39. 
 
Murphy, M.F., & Pamphilon, D.H. (2008). Prenatal and childhood transfusions. In M.F. 
Murphy, & D.H. Pamphilon D (Eds.), Practical Transfusion Medicine (2nd ed., 97-118). 
Oxford, UK: Blackwell Publishing. 
 
National Institute for Health and Clinical Excellence (2005). Guideline IPG144: 
Intraoperative blood cell salvage in obstetrics—guidance. Retrieved from: 
http://guidance.nice.org.uk/IPG144/Guidance/pdf/English. 
 
Nelissen, E., Vaughan-Williams, S., Birchall, J., Cairns, E., Darley, T., Draycott, C., … 
Laxton, C. (2018). Exploring the availability and acceptability of cell salvage after 
vaginal birth in the UK: the SalVage Study. 19th Annual Symposium on patient blood 
management, haemostasis and thrombosis (NATA). Retrieved from: 
http://www.nataonline.com/sites/default/files/imagesC/19th_Annual_NATA_Symposi
um_Abstract_Book.pdf. 
 
58 
 
NHS Digital. (2017). NHS Maternity Statistics 2016-17. Retrieved from: 
https://digital.nhs.uk/data-and-information/publications/statistical/nhs-maternity-
statistics/2016-17. 
 
NHS Blood and Transplant. (2017). Annual Review of Key Risks. Retrieved from: 
https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/5919/annual-review-of-
risk-sept-2017.pdf. 
 
NHS Blood and Transplant. (2018). Annual report and accounts 2017-18. Retrieved 
from: 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach
ment_data/file/729719/nhs-blood-and-transplant-annual-report-and-accounts-2017-
2018.pdf. 
 
Orr, T., & Wrench, I. (2018). Trends in the use of intraoperative cell salvage in a tertiary 
obstetric centre over eight years. International Journal of Obstetric Anesthesia, 35(S1), 
15. 
 
Potter, P.S., Waters, J.H., Burger, G.A., & Mraović, B. (1999). Application of cell-
salvage during cesarean section. Anesthesiology, 90(2), 619-621. 
 
Rainaldi, M.P., Tazz ari, P.L., Scagliarini, G., Borghi, B., & Conte, R. (1998). Blood 
salvage during caesarean section. British Journal of Anaesthesia, 80(2), 195-198. 
 
 
59 
 
Ralph, C., Faulds, F., & Sullivan, I. (2010). Cell salvage and leucocyte depletion 
filters. Anaesthesia, 65(12), 1228-1229. 
 
Ralph, C.J., Sullivan, I., & Faulds, J. (2011). Intraoperative cell salvaged blood as 
part of a blood conservation strategy in caesarean section: is fetal red cell 
contamination important? British Journal of Anaesthesia, 107(3), 404-408. 
 
Ralph, C., & Sullivan, I.  (2018). A reply to: Cell salvage and donor blood transfusion 
during caesarean section: A pragmatic, multicentre randomised controlled trial 
(SALVO). Retrieved from: 
http://journals.plos.org/plosmedicine/article/comments?id=10.1371/journal.pmed.100
2471. 
Rebarber, A., Lonser, R., Jackson, S., Copel, J.A., & Sipes, S. (1998). The safety of 
intraoperative autologous blood collection and autotransfusion during cesarean 
section. American Journal of Obstetrics and Gynecology, 179(3), 715-720. 
 
Rogers, W.K., Wernimont, S., Kumar, G.C., Bennett, E., & Chestnut, D. (2013). Acute 
hypotension associated with intraoperative cell salvage using a leukocyte depletion 
filter during management of obstetric hemorrhage due to amniotic fuid embolism. 
Anesthesia and Analgesia, 117(2), 449-452.  
 
 
 
 
60 
 
Rother, R.P., Bell, L., Hillmen, P., & Gladwin, M.T. (2005). The clinical sequelae of 
intravascular hemolysis and extracellular plasma haemoglobin: A novel mechanism of 
human disease. The Journal of the American Medical Association, 293(13), 1653-
1662. 
 
SaBTO: Advisory Committee on the Safety of Blood, Tissues and Organs. (2017). 
Guidelines from the expert advisory committee on the Safety of Blood, Tissues and 
Organs (SaBTO) on measures to protect patients from acquiring hepatitis E virus via 
transfusion or transplantation. Retrieved from:  
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach
ment_data/file/680297/Hepatitis_E_Guidelines.pdf. 
 
Seed, C.R., Hewitt, P.E., Dodd, R.Y., Houston, F., & Cervenakova, L. (2018). 
Creutzfeldt-Jakob disease and blood transfusion safety. Vox Sanguinis, 113(3), 220-
231.  
 
Sikorski, R.A., Rizkalla, N.A., Yang, W.W., Frank, S.M. (2017). Autologous blood 
salvage in the era of patient blood management. Vox Sanguinis, 112(6), 499-510. 
 
Sloan, T.B., Myers, G., Janik, D.J., Burger, E.M., Patel, V.V., & Jameson, L.C. (2009). 
Intraoperative autologous transfusion of hemolyzed blood. Anesthesia and Analgesia, 
109(1), 38-42. 
 
 
 
61 
 
Stokes, E.A., Wordsworth, S., Staves, J., Mundy, N., Skelly, J., Radford, K., & 
Stanworth, S.J. (2018). Accurate costs of blood transfusion: a microcosting of 
administering blood products in the United Kingdom National Health Service. 
Transfusion, 58(4), 846-853.  
 
Sullivan, I., Faulds, J., & Ralph, C. (2008). Contamination of salvaged maternal 
blood by amniotic fluid and fetal red cells during elective caesarean section. 
British Journal of Anaesthesia, 101(2), 225-229. 
 
Sullivan, J.V., Crouch, M.E., Stocken, G., & Lindow, S.W. (2011). Blood cell salvage 
during cesarean delivery. International Journal of Gynecology and Obstetrics, 115(2), 
161-163.  
 
Sullivan, I.J., Hicks, M.K., Faulds, J.N., Carson, P.J., & Noble, R.S. (2012). A 
modified thrombin clotting time test as a quality control marker for heparin 
contamination in obstetric intraoperative cell salvage. Transfusion Medicine, 
22(1), 68-70. 
 
Sullivan, I.J., & Faulds, J.N. (2013). Lactate dehydrogenase and haemolysis 
index as quality control markers of haemolysis in intra-operative cell salvage. 
Transfusion Medicine, 23(5):326-329. 
 
Sullivan, I.J., & Faulds, J.N. (2014). Assessment of intra-operative cell salvage 
haemolysis in the obstetric and orthopaedic clinical setting, in comparison with 
allogeneic blood. Transfusion Medicine, 24(5), 280-285. 
 
62 
 
Sullivan, I.J., & Ralph, C.J. (2018). Obstetric intra-operative cell salvage and 
maternal fetal red cell contamination. Transfusion Medicine, 28(4), 298-303. 
 
Sullivan, I.J., & Ralph, C.J. (2019). Obstetric intra-operative cell salvage: a review 
of an established cell salvage service with greater than 1000 re-infused cases. 
Anaesthesia, accepted for publication. 
 
Szpisjak, D.F. (2001). Debris elimination from partially-filled cell salvage bowls. 
Anesthesia and Analgesia, 92(5), 1137-1138. 
 
Teare, K.M., Sullivan, I.J., & Ralph, C.J. (2015). Is cell salvaged vaginal blood 
loss suitable for re-infusion? International Journal of Obstetric Anesthesia, 
24(2), 103-110. 
 
Thies, H.J. (1914). Zur Behandlung der Extraueringraviditat. Zentralbl Gynakol, 38, 
1191-1193. 
 
Thornhill, M.L., O’Leary, A.J., Lussos, S.A., Rutherford, C., & Johnson, M.D. (1991). 
An invitro assessment of amniotic fluid removal from human blood through cell saver 
processing. Anesthesiology, 75(3), A830. 
 
Tinmouth, A., Fergusson, D., Chin Yee, I., & Hebert, P.C. (2006). Clinical 
consequences of red cell storage in the critically ill. Transfusion, 46(11), 2014-2027. 
 
 
63 
 
UK Cell Salvage Action Group (UKCSAG). (2014). Intra-operative cell salvage: 2014. 
A survey of equipment and practice across the UK. Retrieved from: 
https://www.transfusionguidelines.org/document-library/documents/ukcsag-updated-
survey-april-2014/download-file/2014%20UKCSAG%20survey%20-
%20April%202015.pdf. 
 
Umlas, J., & O’Neill, T.P. (1981). Heparin removal in an autotransfuser device. 
Transfusion, 21(1), 70-73. 
 
Vamvakas, E.C. (2002). Meta-analysis of randomized controlled trials investigating 
the risk of postoperative infection in association with white blood cell-containing 
allogenic blood transfusion: The effects of the type of transfused red blood cell product 
and surgical setting. Transfusion Medicine Reviews, 16(4), 304–314. 
 
Vermeulen Windsant, I.C., de Wit, N.C., Sertorio, J.T. Beckers, E.A., Tanus-Santos, 
J.E., Jacobs, M.J., & Buurman, W.A. (2012). Blood transfusions increase circulating 
plasma free hemoglobin levels and plasma nitric oxide consumption: a prospective 
observational pilot study. Critical Care, 16(3), R95, 1-11. 
 
Waters, J.H., Biscotti, C., Potter, P.S., & Phillipson, E. (2000). Amniotic fluid removal 
during cell salvage in the cesarean section patient. Anesthesiology, 92(6), 1531-1536. 
 
Waters, J.R., Meier, H.H., & Waters, J.H. (2007). An economic analysis of costs 
associated with development of a cell salvage program. Anesthesia and Analgesia, 
104(4), 869-75. 
 
64 
 
Waters, J.R., Dyga, R.M., Waters, J.H., & Yazer, M.H. (2011). The volume of returned 
red blood cells in a large blood salvage program: where does it all go? Transfusion, 
51(10), 2126–2132. 
 
Watson, C.M., & Watson, J.R. (1936). Autotransfusion: Review of American literature 
with report of two additional cases. The American Journal of Surgery, 33(2), 232-237. 
 
Weingarten, M., Rao, S., Toop, K., Simpson, H., & Winnard, J. (2017). Use of the cell 
salvage for re-infusion of autologous blood retrieved vaginally in a case of major 
postpartum haemorrhage. European Journal of Obstetrics and Gynecology and 
Reproductive Biology, 211, 215-216. 
 
Wilson, M.J.A., & Wrench, I.J. (2015). Cell salvage for vaginal delivery – is it time we 
considered it? International Journal of Obstetric Anesthesia, 24(2), 97-99. 
 
World Health Organization. (2005). The World Health Report 2005: Make every 
mother and child count. Retrieved from: 
https://www.who.int/whr/2005/whr2005_en.pdf?ua=1. 
 
Yan, H., Hu, L.Q., Wu, Y., Fan, Q., Wong, C.A., & McCarthy, R.J. (2018). The 
association of targeted cell salvage blood transfusion during cesarean delivery with 
allogeneic packed red blood cell transfusions in a maternity hospital in China. 
Anesthesia and Analgesia, 127(3), 706-713. 
 
 
65 
 
Yentis, S.M. (1999). Sudden obstetric collapse syndrome. International Journal of 
Obstetric Anesthesia, 8(4), 296. 
 
Yoshida, T., & Shevkoplyas, S.S. (2010). Anaerobic storage of red blood cells. Blood 
Transfusion, 8(4), 220-236. 
 
Zeng, K., Huang, W., Yu, C., & Wang, R. (2018). How about “The effect of 
intraoperative cell salvage on allogeneic blood transfusion for patients with placenta 
accrete”?: An observational study. Medicine, 97(22), e10942, 1-8. 
 
Zimrin, A.B., & Hess, J.R. (2009). Current issues relating to the transfusion of stored 
red blood cells. Vox Sanguinis, 96(2), 93-103. 
 
 
 
 
 
 
 
 
  
 
66 
 
PUBLISHED ABSTRACTS 
Sullivan, I., Faulds, J., & Ralph, C. (2008). Contamination of salvaged maternal blood 
by amniotic fluid and fetal red cells during elective caesarean section. Transfusion 
Alternatives in Transfusion Medicine, 10(S1), 37. 
 
Ralph, C., Faulds, J., & Sullivan, I. (2009). Implementing cell salvage for non-
emergency caesarean sections. International Journal of Obstetric Anaesthesia, 
18(S1), 46.  
 
Sullivan, I., Faulds, J., & Ralph, C. (2010). Is fetal red cell contamination in obstetric 
cell salvage an important consideration? Transfusion Alternatives in Transfusion 
Medicine, 11(S2), 27. 
  
Sullivan, I., Hick, M., Faulds, J., Carson, P., & Noble, R. (2011). A modified thrombin 
clotting time test as a quality control marker for heparin contamination in obstetric 
intraoperative cell salvage. Transfusion Medicine, 21(S1), 40. 
 
Faulds, J., & Sullivan, I. (2011). Intra-operative cell salvage quality control pilot 
scheme: Report 2011. Transfusion Medicine, 21(S1), 40. 
 
Ralph, C., Sullivan, I., Faulds, J., & McGovern, C. (2012). Intraoperative cell salvage 
in obstetrics: the present and the future. Transfusion Alternatives in Transfusion 
Medicine, 12, 22.  
 
 
67 
 
Faulds, J., & Sullivan, I. (2012). Intraoperative cell salvage quality control pilot scheme 
report. Transfusion Alternatives in Transfusion Medicine, 12, 23.  
 
Sullivan, I.J., & Faulds, J.N. (2013). Assessment of haemolysis from obstetric and 
orthopaedic intra-operative cell salvage. Transfusion Medicine, 23(S1), 30. 
 
Sullivan, I.J., & Faulds, J.N. (2013). Assessment of haemolysis from obstetric and 
orthopaedic intra-operative cell salvage. Transfusion Medicine, 23(S2), 50. 
 
Faulds, J.N., & Sullivan, I.J. (2013). Implementation of a national intra-operative cell 
salvage quality control programme, in association with the UK Cell Salvage Action 
Group. Transfusion Medicine, 23(S2), 50. 
  
Teare, K.M., Sullivan, I.J., & Ralph, C.J. (2014). Is salvaged vaginal blood loss suitable 
for re-infusion? Transfusion Medicine, 24(S1), 33. 
 
Ralph, C.J., & Sullivan, I.J. (2016). Blood conservation in obstetrics – anchoring 
change in clinical practice. Transfusion Medicine, 26(S1), 43.  
 
Sullivan, I.J., Faulds, J.N., & Ralph, C.J. (2016). Role of partial bowls obtained from 
intraoperative cell salvage in obstetric caesarean section. Transfusion Medicine, 
26(S1), 43.  
 
 
68 
 
Sullivan, I.J., & Ralph, C.J. (2016). Foetal red cell contamination in obstetric 
intraoperative cell salvage. Transfusion Medicine, 26(S1), 44.  
 
Endean, E., Pooley, S., Sullivan, I., & Ralph, C. (2017). Routine use of intra-operative 
cell salvage for caesarean section and its effect on donor blood transfusion rates and 
antibody formation. Transfusion Medicine, 27(S2), 51.  
 
Sullivan, I.J, & Ralph, CJ. (2018). Using intra-operative cell salvage for all obstetric 
caesarean sections. Data report of greater than 1000 women receiving re-infusions at 
the Royal Cornwall Hospital. Abstracts of the 19th Annual Symposium: 71. Retrieved 
from: 
https://nataonline.com/sites/default/files/imagesC/19th_Annual_NATA_Symposium_
Abstract_Book.pdf 
 
Sullivan, I.J., & Ralph, C.J. (2018). Obstetric intra-operative cell salvage and maternal 
fetal red cell contamination. Abstracts of the 19th Annual Symposium: 72. Retrieved 
from: 
https://nataonline.com/sites/default/files/imagesC/19th_Annual_NATA_Symposium_
Abstract_Book.pdf 
 
Sullivan, I. & Ralph, C. (2018). Obstetric intra-operative cell salvage: a review of an 
established cell salvage service with greater than 1000 re-infused cases. Transfusion 
Medicine, 28(S1), 53. 
 
 
69 
 
Tagell, T., Sullivan, I., Ralph, C., & Bassey, S. (2018). Does reinfusion of autologous 
blood collected during a caesarean section alter coagulation in vivo? Assessment 
using ACL TOP 550 coagulation analyser and Haemonetics® TEG6s. Transfusion 
Medicine, 28(S1), 70. 
  
 
70 
 
NATIONAL AND INTERNATIONAL PRESENTATIONS 
Poster presentation at the 9th Annual Network for Advancement of Transfusion 
Alternatives Annual Symposium 2008. Lisbon, Portugal.  
 
Poster presentation at the annual meeting of the Obstetric Anaesthetists' Association 
2009. Jersey, UK.  
 
Poster presentation at the 11th Network for Advancement of Transfusion Alternatives 
Annual Symposium 2010. Barcelona, Spain. 
 
Poster presentation at Annual Scientific Meeting of the British Blood Transfusion 
Society 2011. Glasgow, UK. 
 
Poster presentation at Annual Scientific Meeting of the British Blood Transfusion 
Society 2011. Glasgow, UK. 
 
Poster presentation at the 13th Annual Network for the Advancement of Transfusion 
Alternatives Annual Symposium 2012. Copenhagen, Denmark. 
 
Poster presentation at the 13th Annual Network for the Advancement of Transfusion 
Alternatives Annual Symposium 2012. Copenhagen, Denmark. 
 
Poster presentation at Annual Scientific Meeting of the British Blood Transfusion 
Society 2013. Birmingham, UK. 
 
71 
 
Poster presentation at Annual Scientific Meeting of the British Blood Transfusion 
Society 2013. Birmingham, UK. 
 
Poster presentation at the 14th Annual Network for the Advancement of Patient Blood 
Management, Hemostasis and Thrombosis Annual Symposium 2013. Vienna, Austria. 
 
Poster presentation at the 15th Annual Network for the Advancement of Patient Blood 
Management, Hemostasis and Thrombosis Annual Symposium 2014. Porto, Portugal. 
 
Poster presentation at the 17th Annual Network for the Advancement of Patient Blood 
Management, Hemostasis and Thrombosis Annual Symposium 2016. Dublin, Ireland. 
 
Poster presentation at the 17th Annual Network for the Advancement of Patient Blood 
Management, Hemostasis and Thrombosis Annual Symposium 2016. Dublin, Ireland. 
 
Poster presentation at the 17th Annual Network for the Advancement of Patient Blood 
Management, Hemostasis and Thrombosis Annual Symposium 2016. Dublin, Ireland. 
 
Poster presentation at the Annual Scientific Meeting of the British Blood Transfusion 
Society 2017. Glasgow, UK. 
 
Poster presentation at the 19th Annual Network for the Advancement of Patient Blood 
Management, Hemostasis and Thrombosis Annual Symposium 2018. Lisbon, 
Portugal. 
 
72 
 
Poster presentation at the 19th Annual Network for the Advancement of Patient Blood 
Management, Hemostasis and Thrombosis Annual Symposium 2018. Lisbon, 
Portugal. 
 
Poster presentation at Annual Scientific Meeting of the British Blood Transfusion 
Society 2018. Brighton, UK. 
 
Poster presentation at Annual Scientific Meeting of the British Blood Transfusion 
Society 2018. Brighton, UK. 
 
 
 
 
  
 
73 
 
OTHER PUBLISHED WORK 
Sullivan, I.J. (2018). Reply: Prevalence of maternal alloantibodies in a large teaching 
hospital and their impact on outcomes of fetuses/neonates. Transfusion Medicine, 
28(6), 460.  
  
 
74 
 
Appendix 1 
Sullivan, I., Faulds, J., & Ralph, C. (2008). Contamination of salvaged maternal blood 
by amniotic fluid and fetal red cells during elective caesarean section. British Journal 
of Anaesthesia, 101(2), 225-229. 
 
 
Contribution by I Sullivan: 
 Design including literature search 
 Data collection 
 Data analysis 
 Manuscript writing 
 
 
Number of citations:  
Google Scholar:  81 
Pubmed:    8 
Web of Science:  40 
Clarivate Analytics:  60 
 
 
 
 
 
 
 
OBSTETRICS
Contamination of salvaged maternal blood by amniotic fluid and
fetal red cells during elective Caesarean section
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Background. Cell salvage in obstetrics is still a controversial subject and has yet to be fully
embraced. The aim of this exploratory study was to measure amniotic fluid (AF), heparin,
and fetal red cell contamination of washed filtered salvaged maternal blood and to investigate
differences based on the number of suction devices used.
Methods. Patients undergoing elective Caesarean section were assigned alternately to one of
two groups. In Group 1, all blood and AF was collected with one suction. In Group 2, AF was
aspirated to waste with a second separate suction device before collection of any blood.
Results. In both groups, alpha-fetoprotein (AFP), squames cells, and heparin were significantly
reduced (P,0.001) by the washing and filtering process. Mean AFP levels post-filtration were
2.58 IU ml21 in Group 1 and 3.53 IU ml21 in Group 2. Squames cells were completely
removed in all but two cases. Fetal red blood cells were still present in the final product, range
0.13–4.35%. In Group 1, haemoglobin and haematocrit were higher than in Group 2, with
lower white blood cell, AFP, and fetal red cell counts.
Conclusions. This study adds to the growing body of evidence that there is little or no
possibility for AF contamination to enter the re-infusion system when used in conjunction with
a leucodepletion filter.
Br J Anaesth 2008; 101: 225–9
Keywords: blood, salvage; equipment, cell saver; transfusion, autotransfusion
Accepted for publication: March 31, 2008
The use of cell salvage in obstetrics remains controversial.
There is a concern of potential contamination of the
salvaged blood with amniotic fluid (AF), which may cause
AF embolus (anaphylactoid syndrome of pregnancy),1 and
the risk of alloimmunization of the mother with any fetal
red blood cells aspirated.
Previous studies investigated the use of cell salvage
in obstetrics and focused on the feasibility of the
washing process in removing potential contaminants.
After the use of a leucodepletion filter in cancer
surgery, these filters were introduced into obstetric prac-
tice.1 A later study using a newer advanced model
demonstrated complete removal or a further reduction in
contaminants by these filters.2 Along with these results
and later reports, the National Institute of Health and
Clinical Excellence (NICE) published guidelines in
2005 suggesting that these filters can be considered for
use in obstetrics.3
A common assumption was that two suction devices
should be used, with as much AF aspirated to waste before
any lost blood is collected.1 4
Although current evidence supports the use of cell
salvage in obstetrics, a recent review suggested that more
clinical data are required to add to this evidence and make
the use of cell salvage more commonplace in obstetrics.4
The aim of the study was to add results to the current
clinical evidence to support the use of cell salvage. We
measured AF and fetal red cell contamination, and residual
heparin levels of washed salvaged maternal blood when
using either one or two suction devices, filtering the
washed product through a leucodepletion filter for cell
salvage (RS1 VAE PALLw Medical).
# 2008 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/ /uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
British Journal of Anaesthesia 101 (2): 225–9 (2008)
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Methods
Information to perform power analysis and produce a well-
designed prospective study is lacking due to the limited data
available.4 This study was set up as an exploratory study to
investigate the safety and feasibility of cell salvage in obste-
trics. Ethics Committee opinion was sought, but approval
was not required. The sample size was dependent on the
number of patients accessible over a set time period.
Written informed consent was obtained from 34 patients
undergoing elective lower segment Caesarean section at the
Royal Cornwall Hospital over a 4 month period. Patients
were alternatively assigned to one of two groups before
surgery. Group 1 (n¼17) involved only one suction where all
AF and blood was collected into the cell salvage machine,
with Group 2 (n¼17) using a second suction to aspirate as
much AF to waste before any lost blood was collected.
All patients had a spinal anaesthetic apart from one who
had an epidural top up; all spinals were performed using a
Whitacre 25 gauge needle, with hyperbaric bupivacaine
0.5% and morphine 0.1 mg plus in some cases fentanyl
10–20 mg. In two cases, spinals had to be performed
twice due to incomplete blocks and one was converted to
a general anaesthetic.
During the surgical procedure, any blood lost was
salvaged into a Dideco Electa Autotransfusion Cell
Separator (Sorin Group, Milan, Italy). Aspirated blood was
mixed with heparin 30 000 IU litre21 of saline. Suction
was set at 100–150 mm Hg with a prime at 100 ml min21
and wash volumes of 900 ml on a continuing wash at
100 ml min21. The set was emptied at 150 ml min21.
A 55 ml Latham bowl was used in all cases. In addition,
any swabs from the surgical procedure were soaked in
1 litre of saline and ‘compressed’ at the end of case and
solution aspirated, maximizing red cell collection.
Processed washed blood was then gravity run through
a Pall RS1 VAE leucodepletion filter (Pall Medical,
Portsmouth, UK) into another re-infusion bag.
Pre-wash samples were taken from the collection reser-
voir, and post-wash and post-filtration samples were taken
from the re-infusion packs, which were inverted gently
several times to ensure even mixing before sampling.
The cell salvage machine use and sampling, in all
cases, was performed by the same member of staff.
Pre-wash, post-wash, and post-filtration samples from
both groups were tested for markers of AF contamination
and heparin levels. Post-filtration samples were also tested
to quantify any fetal red blood cells.
Six millilitres of blood were collected into a specimen
tube and processed for alpha-fetoprotein (AFP) on an
E170 Modular Analytics Analyser (Roche Diagnostics,
Basel, Switzerland).
Four millilitres of blood were collected and centrifuged
at 1600g for 5 min and processed for heparin levels on an
Instrumentation Laboratory Futura Advance Coagulometer
(Instrumentation Laboratory, MA, USA).
Six millilitres of blood were collected for fetal squames
cell levels. After centrifugation at 1200g for 5 min, one
part plasma was mixed with three parts Cytolyt Solution
(Cytyc Corporation, West Sussex, UK). Vials were then
centrifuged at 1200g for 5 min and supernatant discarded.
Two to three drops of the cell bullet were then transferred
to 20 ml PreservCyt Solution (Cytyc Corporation) and pro-
cessed on a ThinPrepw2000 Processor (Cytyc Corporation)
using blue-box non-gynae filters (Cytyc Corporation), gen-
erating one alcohol-fixed slide per sample. Slides were
stained using the Papanicolaou technique. To avoid any
potential carryover, pre-wash, post-wash, and post-
filtration slides were stained separately using fresh
reagents. Each slide was then examined under light
microscopy for presence of fetal squames cells, with the
whole slide being counted to exclude any variables, giving
a result of number of cells per slide.
Two millilitres of blood were collected into EDTA for a
full blood count to provide haemoglobin (Hb), haematocrit
(HCT), and white blood cell (WBC) levels on a Bayer
Advia 120 analyser (Bayer, Newbury, UK).
Post-filtration samples were also tested for fetal red
blood cell quantification. Five millilitres of blood were
collected into EDTA and processed with a monoclonal
antibody to fetal Hb (IQProducts, Groningen, The
Netherlands), with a Becton Dickinson FACSCalibur (NJ,
USA) flow cytometer at 540 nm. Note: it was planed to
perform all 34 cases for fetal red cells by flow cytometry,
but due to unforeseen circumstances, the first seven cases
were analysed using the Kleihauer–Betke technique.
Pre- and post-wash samples and post-wash and post-
filtration samples were compared. Parametric data were
analysed using a paired t-test, and non-parametric data
analysed using a one-sample Wilcoxon test. P,0.05 was
considered statistically significant. The observed power of
the study was calculated after the collection of the data.
Results
Mean (SD) (range) age of patients in Group 1 was 32.1
(19–46) yr, and weight 82.7 (16.2) kg. In Group 2, the
age was 32.1 (24–41) yr and body weight 82.4 (12.6) kg.
Table 1 gives the reason for Caesarean section along with
any coexisting diseases as shown in Table 2.
Table 1 Reasons for Caesarean section
Reason Number
Previous section 23
Twins IVF 2
Back injury/pain 2
Breech 2
Failure to progress/Category 3 1
IUGR 1
Polyartetitisnodosa 1
Raised BP/pregnancy-induced hypertension 1
Placenta praevia 1
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There were no surgical problems during the procedures.
Four cases did not lose enough blood to obtain post-
filtration samples (one from Group 1 and three from
Group 2), with three further cases having partially filled
bowls. A partial bowl was defined as a bowl that was not
completely filled in the automatic mode of the cell salvage
machine. These three bowls provided erroneous post-
filtration results and, therefore, were excluded from analy-
sis. The final blood product in these cases (one from
Group 1 and two from Group 2) had a reduced Hb level of
7.1–10.3 g dl21 and HCT of 21–31%, with a higher level
of fetal red blood cells: 10.5% compared with 1.51%.
Apart from fetal red blood cells in one case (Group 2),
the values for Hb, HCT, and fetal red blood cells all were
considerably above the upper 95% confidence limit for the
full bowls.
The collected blood volume from Group 1 [1782 (354)
ml] was slightly higher than that collected in Group 2
[1497 (562) ml], but the difference was not statistically
significant (P¼0.14). Similarly, on average, the red blood
cell volume was higher in Group 1 [168 (77) ml] than in
Group 2 [135 (94) ml], but again the difference was not
statistically significant (P¼0.30).
Table 3 shows the mean Hb, AFP, squames cells, and
fetal red cell levels in the groups, along with statistical
analysis.
Dependent on the manufacturer, the reference range for
AFP is up to 10–15 IU ml21. The post-wash levels were
significantly reduced (P,0.001) with no further reduction
seen post-filtration (P¼0.996). On average, there was a
98.7% reduction of pre-wash levels by the washing stage.
Mean heparin levels pre-wash were 1.33 IU ml21 (95%
CI 0.91–1.75 IU ml21) in Group 1 and 1.44 IU ml21
(95% CI 0.82–2.05 IU ml21) in Group 2. Levels were
reduced by 100% in both the groups (P,0.001) by the
washing stage with no heparin being detected post-wash or
post-filtration in all 34 cases.
Fetal squames cells were present in 12 out of 34 cases
(six from each group) pre-wash, present in all post-wash
samples, with a significant reduction post-filtration
(P,0.001). Squames were present in two post-filtration
samples, with two cells seen in each case. Both cases were
from Group 1. Pre-wash samples were heavily diluted with
AF and heparinized saline from surgery explaining why 22
samples were negative.
The mean percentage fetal red cells post-filtration from
all cases (both groups) was 1.51% (95% CI 0.98–2.05),
with a range of 0.13–4.35%. The first seven cases (three
from Group 1 and four from Group 2) performed by the
Kleihauer technique generated a mean 1.72% (95% CI
20.65 to 4.08), whereas the remaining cases performed by
flow cytometry resulted in mean 1.47% (95% CI 0.92–
2.01).
Discussion
This study has shown the efficiency of the washing stage
of the cell salvage machine, when used in combination
with a leucodepletion filter, in significantly reducing levels
of AF contaminants.
AFP was significantly reduced post-wash to levels well
within the normal range for the general population, con-
firming the results from previous studies.1 5 6
During the study, the amount of heparin used was higher
than with other surgical disciplines due to the hypercoagul-
able state of pregnancy. It would be expected that pre-wash
samples were heavily contaminated with heparin, and this
was confirmed during the study. It has been previously
reported that residual levels of heparin remain in salvaged
blood,4 but we have now demonstrated the complete
removal of heparin by the washing process in all 34 cases.
The role of fetal squames cells in AF embolus is still
debated. In one study,1 fetal squames cells were still
present even with the additional step of filtering the
washed blood through a leucodepletion filter, with only
Table 2 Coexisting diseases
Co-morbidity Number
Smoker 5
Diabetic 2
Asthma 2
Epilepsy 1
Protein S deficiency 1
Polyartetitisnodosa 1
Table 3 Analysis and comparison for Group 1 and Group 2. AFP, alpha-fetoprotein. Values are mean (95% CI). *We acknowledge that the observed power
results are low; this, however, is one of the largest studies to date in the obstetric setting. †Mean HCT post-filtration was 45% in Group 1 and 42% in Group 2
Group 1 Group 2 P-value Observed power*
AFP pre-wash (IU ml21) 253.72 (183.64–323.80) 381.60 (193.63–569.57) 0.19 0.26
AFP post-wash (IU ml21) 2.71 (0.80–4.62) 3.14 (1.45–4.83) 0.72 0.06
AFP post-filtration (IU ml21) 2.58 (0.54–4.62) 3.53 (1.29–5.76) 0.51 0.10
Hb pre-wash (g dl21) 2.14 (1.52–2.75) 1.83 (1.17–2.50) 0.48 0.11
Hb post-wash (g dl21) 16.95 (16.28–17.62) 16.20 (15.26–17.14) 0.18 0.27
Hb post-filtration† (g dl21) 15.77 (15.07–16.47) 14.74 (13.70–15.78) 0.17 0.27
Squames cells pre-wash (cells per slide) 1.12 (20.02 to 2.25) 0.94 (0.01–1.74) 0.80 0.06
Squames cells post-wash (cells per slide) 34.59 (10.89–58.28) 43.71 (14.42–73.00) 0.61 0.08
Squames cells post-filtration (cells per slide) 0.27 (20.11 to 0.66) 0 0.18 0.26
Fetal red blood cells (%) 1.34 (0.56–2.12) 1.76 (0.95–2.57) 0.43 0.12
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two out of 27 post-filtration cases being negative.
Advanced filters may reduce this contamination.2
Of the 27 cases in our study, only two were positive post-
filtration with two cells seen in each slide for each case.
These were found when one suction was used. However, it
is difficult to differentiate between fetal and adult squames
cells. There is no evidence to show that fetal squames cells
routinely enter the maternal circulation,7 and so the signifi-
cance of this contamination is difficult to quantify and in
fact may have no clinical significance.
Fetal red blood cells were still present in the final
product, consistent with previous studies,2 6 and so could be
significant in cases of red cell antigen incompatibilities
between the mother and fetus. Rh(D) incompatibilities,
although clinically significant, are generally avoided by
routine prophylactic anti-D treatment throughout the preg-
nancy. However, fetal hyperbilirubinaemia and anaemia in
future pregnancies can occur when antibodies have been
formed to other red cell antigen incompatibilities. Examples
of other clinically relevant antibodies that have been impli-
cated in haemolytic disease of the newborn include anti-K,
anti-c, anti-Fy(a), and anti-Jk(a).8 Nevertheless, it must be
appreciated that there is still a risk of alloimmunization of
the mother either from transfusion of allogenic blood or a
sensitizing event during pregnancy.
Current treatment of obstetric haemorrhage is with allo-
genic blood transfusion; however, there are concerns with
allogenic blood. To date, there have been four confirmed
cases of vCJD transmission via allogeneic blood, confirm-
ing that vCJD can be transmitted through blood
transfusion.9
These potential risks of transfusion and reduction in
availability of blood make it important to establish the use
of cell salvage in obstetrics. It has been shown in more
than 400 documented cases where cell salvaged blood has
been returned to mothers with no significant adverse
results.4 10 11 Several key studies have commented on the
use of cell salvage.12 – 14
This current study is one of the largest to date, with
results that add to the growing body of evidence, showing
there is little or no possibility for AF contamination to
enter the re-infusion system, when used in conjunction
with a leucodepletion filter. The role of the leucodepletion
filter in this study has confirmed that it is required to
remove AF contamination in cell salvage. WBC, platelets,
and squames cells were still present post-wash but were
significantly reduced by the filter. Whether the squames
are of fetal or maternal origin is perhaps irrelevant as the
filters have shown that they can remove both. As expected,
AFP and heparin levels were not reduced by the filter, but
heparin was completely removed in the washing process.
Regarding cell salvage in obstetrics, these results could
be used to change the guidelines and allow routine
re-transfusion of salvaged blood as opposed to overriding
guidance in extreme emergency, and therefore allowing
cell salvage to be used for elective and emergency cases.
Even though it was not our intention to re-transfuse any
salvaged blood in this study, 500 ml was transfused to
two cases. No changes in clinical state, heart rate, or
clinical complications were noted, showing that in elective
cases unexpected large blood loss can still occur and cell
salvage can have a role to play in this situation.
This initial project acted as an exploratory study, and
after the collection of these data, we have now implemented
a comprehensive programme of cell salvage within our
Trust to all women undergoing elective Caesarean sections,
and further work is ongoing.
We conclude that one suction may be used in the obste-
tric setting, and washed filtered blood from partially filled
bowls should not be re-transfused, regardless of the clini-
cal situation. To obtain maximum washing efficiency in
removing AF and fetal contaminants, only complete bowls
in the automatic mode should be accepted.
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Thus, arguments based on financial loss
are finely balanced.
‘Needlestuck’ staff become patients
too, and staff who are denied the knowl-
edge of patients’ viral status are exposed
to significant harms, as Hartle eloquently
outlined. We are aware of several such
cases in which doctors have come to
significant harm as a result of probably
unnecessary post exposure prophylaxis.
Thus, the situation is not incapacitated
patient vs professional staff member but
patient vs patient, a situation that will be
all too familiar to intensivists. The staff
member’s rights to autonomous in-
formed consent, non-maleficence and
justice are all ignored by current General
Medical Council guidance (itself based
on an untested interpretation of the
relevant case law and statute).
We argue that in such cases, weigh-
ing the competing claims of the four
principles leads to the moral conclusion
that the incapacitated patient be tested.
Burrows and Padkin have shown that
the majority of our profession would
probably draw the same conclusion.
Furthermore, we argue that a reasonable
court, be it criminal, civil or profes-
sional, would in all likelihood arrive at
the same conclusion.
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Cell salvage and leucocyte
depletion filters
We read with interest the recent edito-
rial ‘cell salvage induced hypotension
and London buses’ concerning hypo-
tension associated with the use of the
leucocyte depletion filters [1].
At the Royal Cornwall Hospital
Trust, we routinely collect blood for
cell salvage at the time of caesarean
section. We are currently recruiting
to a study involving re-infusion of
cell-salvaged-blood and following up
women post re-infusion. At the time of
caesarean section, the collected blood is
washed and processed if there is enough
in the collection bowl, or if there are
clinical signs of blood loss. We consent
women for a re-infusion of the cell-
saved blood. All women who have their
blood returned are monitored during
the re-infusion and are followed up at
three and six months postoperatively.
At follow-up, a blood sample is taken to
test for antibody formation.
We have re-infused cell-saved blood
to 70 patients. All these patients have
received the re-infusion through a
leucodepletion filter (Pall LeukoGuard
RS Filter; Pall Europe, Portsmouth,
UK), and in all cases only one suction
device was used. We have not observed
any haemodynamic changes attributable
to these re-infusions. However, we
have not pressurised the bag or syringed
the contents through the filter. We are
aware that users have pressurised blood
through the LeukoGuard RS filter
without complication, although the
manufacturer’s product instructions
state: ‘use of this filter with a pressure
cuff should comply with the recom-
mendations of cell salvage equipment
manufacturers’ instructions for use’.
We have already demonstrated alpha-
fetoprotein is significantly reduced post
wash following cell-salvage, to levels
well within the normal range for the
general population, before passing
through the filter. Heparin is also
eliminated and whilst the washing pro-
cess does not eliminate the presence of
fetal squames, their significance in the
circulation remains unknown [2].
Whilst the decision to re-infuse
salvaged blood from a particular patient
or patient group is a clinical one, the
LeukoGuard RS filter has not been
validated by the manufacturer for its
ability to remove fetal squames from
salvaged blood during re-infusion.
Consequently, one cannot rely on the
filter’s ability to remove these contam-
inants during re-infusion of salvaged
blood and the filter is not currently
endorsed for use for this purpose. The
product instructions state that the filter
is only validated and indicated for the
removal of leucocytes, fat particles and
microaggregates from intra-operative
salvaged-blood intended for re-infusion.
We found the LeukoGuard RS filter
significantly reduced the presence of
fetal squames with only two out of 34
cases testing positive after filtration [2].
Transfusion-induced hypotension is a
recognised phenomenon and has been
reported both with and without the use
of bedside leucocyte removal filters.
Although some publications have sug-
gested that this is an event secondary to
the use of leucocyte removal filters [3],
a 9-year study of adverse transfusion
reactions found an overall incidence of
anaphylactic or anaphylactoid reactions
of 1.3% (21 of 1613) and of these, nine
had associated hypotension [4]. None of
these reactions involved the use of
bedside leucocyte removal filters.
We recognise the limited flow
achievable through a filter is a limitation
when re-infusing cell-saved blood dur-
ing hypovolaemic resuscitation. In such
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cases, we estimate and provide minimal
volume resuscitation and transfusion of
peri-operative allogenic blood, and sub-
sequently commence slower re-infusion
of cell-saved blood. In patients who
decline allogenic blood, such as Jeho-
vah’s Witnesses, we would consider
removing the filter from the re-infusion.
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Fibrinogen concentrate use
during major obstetric
haemorrhage
Bell and colleagues described a series of
six cases in which fibrinogen concen-
trate was used in combination with
blood products to treat postpartum
obstetric haemorrhage [1]. Other stud-
ies have also demonstrated a reduction
in blood loss when using this blood
product [2, 3]. Hypofibrinogenaemia is
common in obstetric haemorrhage,
especially if there is a consumptive
coagulopathy [4] and we would like to
report a case where fibrinogen concen-
trate was sufficient to arrest major
antenatal vaginal bleeding after diagno-
sis of abruption and fetal death, before
other blood products were available.
A 38-year-old multiparous woman
was admitted at 34 + 2 weeks of gesta-
tion with a five-hour history of severe
abdominal pain and no fetal move-
ments. A transabdominal ultrasound
scan revealed an intrauterine death,
secondary to placental abruption, with
a large retroplacental clot. On admission
she had no vaginal bleeding, but was
tachycardic with a pulse rate of
116 beats.min)1 and a blood pressure
of 108 ⁄ 70 mmHg. We administered a
bolus of 500 ml of colloid solution and
commenced Hartmann’s solution at
125 ml.h)1, and sent blood for cross-
matching. Initial blood results (taken at
the time of admission, but available two
hours later) showed haemoglobin (Hb)
8.1 g.dl)1, platelets 258 · 109.l)1,
fibrinogen 1.9 g.l)1, activated partial
thromboplastin time (APPT) 27 s and
prothrombin time (PT) 14.5 s.
As the blood results became available,
she had a sudden vaginal blood loss of
750 ml followed by continuous bleeding
of 200–300 ml every 15 min; her blood
pressure was 89 ⁄ 56 and heart rate
114 beats.min)1. She looked pale and
peripherally shut down. We took a fur-
ther full bloodcount and coagulation test,
butbasedontheclinicaldeterioration, the
previous low fibrinogen of 1.9, the his-
tory of abruption and the likelihood of
fulminating disseminated intravascular
coagulopathy (DIC), a consultant hae-
matologist advised that 4 g fibrinogen
concentrate should immediately be given
with four units of fresh-frozen plasma.
We administered the fibrinogen con-
centrate (CSL Behring, King of Prussia,
PA, USA) within 15 min, with two units
of blood, and within 10 min her vaginal
bleeding stopped. We then administered
the fresh frozen plasma and a further two
units of blood. Her clinical picture
improved over the next 30 min; she
had artificial rupture of membranes and
labour was induced with an oxytocin
infusion at 0.06 units.h)1. The blood
results taken before and after the
blood products showed Hb 6.8 g.dl)1,
platelets 241 · 109.l)1, fibrinogen 0.9
g.dl)1, APPT 34.6 s and PT 15.8, and
Hb 6.1 g.dl)1, platelets 111 · 109.l)1,
fibrinogen 1.5 g.dl)1, APPT 36.5 s and
PT 15.7 s, respectively.
We gave her further three units of
blood and four of fresh frozen plasma, on
the basis of a third set of blood results.
There was no further bleeding, her
clinical condition stabilised and she had
a spontaneous vaginal delivery of a
dead fetus with a 2000-ml blood clot
three and-a-half hours later. At deliv-
ery, she was normotensive, her heart
rate had settled to 90 beats.min)1, she
was passing over 100 ml.h)1 of urine
and she was peripherally well perfused.
Following delivery, she received no
further blood products although her
platelets fell to 57 · 109.l)1 and she
had three 500-mg doses of tranexamic
acid on the advice of the haematolo-
gist.
We believe that this is the first report of
major antenatal obstetric haemorrhage
associated with DIC arrested by fibrino-
gen concentrate alone, which allowed
induction of labour and subsequent vag-
inal delivery. Fibrinogen concentrate was
availablemorequickly thanotherclotting
products as it is rapidly solubilised from an
ampoule in 50 ml water and given as a
bolus. To raise the plasma fibrinogen
concentration by 1 g.l)1 in a 70-kg
person, 1000 ml fresh frozen plasma (6
standard UK units), or 260 ml cryopre-
cipitate (10 standard UK units) will be
required [5]. Administration of adequate
doses of fresh frozen plasma or cryopre-
cipitate to treat hypofibrinogenaemia
during obstetric haemorrhage will there-
fore take a substantial amount of time,
even with an efficient blood bank and
portering system.This case alsohighlights
the importance of monitoring the fibrin-
ogen levels in obstetric haemorrhage and
treating hypofibrinogenaemia early and
aggressively as the APTT, PT and platelet
count were unreliable during the initial
presentation.
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OBSTETRICS
Intraoperative cell salvaged blood as part of a blood
conservation strategy in Caesarean section: is fetal red cell
contamination important?†
C. J. Ralph1*, I. Sullivan2 and J. Faulds1
1 Department of Theatres and Anaesthesia and 2 Department of Haematology, Royal Cornwall Hospital, Truro, TR1 3LJ Cornwall, UK
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Editor’s key points
† Intraoperative cell
salvage (IOCS) is
increasingly used as part
of a blood conservation
strategy.
† Its widespread use in
obstetrics has been
hindered by concerns
over amniotic fluid
embolism and fetal red
cell contamination.
† In this series of 70
patients, the incidence of
red cell contamination
resulting in antibody
formation was very low.
† IOCS reduced the
requirements for
allogeneic blood.
Background. Cell salvage is used in obstetric surgery as part of a blood conservation
strategy in our Trust. This carries a theoretical risk of amniotic fluid embolism and also a
risk of fetal red cells being present in the re-infusion, resulting in alloimmunization. In
this study, we attempted to quantify the risk of antibody formation from re-infusion of
autologous blood after Caesarean section.
Methods. Women presenting for elective Caesarean section were routinely requested to
consent for collection of blood by cell salvage, using one suction device. If an adequate
volume of blood was collected, it was processed and, if clinically appropriate, re-infused
via a leucodepletion filter. Women who received a re-infusion were followed up to test
for antibody formation.
Results. Seventy women consented for re-infusion and follow-up. The median volume re-
infused was 324 ml (range 118–1690 ml). The median fetal red cell contamination was
0.8 ml (range 0.2–12.9 ml). All re-infusions were given without adverse clinical signs. No
antibodies were detected in 48 follow-up samples. One positive anti-S antibody was detected.
Conclusions. The implementation of a blood conservation strategy which includes the use of
intraoperative cell salvage appears safe and can contribute to a reduction in the number of
blood transfusions to the obstetric population. We remain uncertain of the significance of
fetal red cell contamination.
Keywords: amniotic fluid embolism; blood transfusion; blood transfusion, autologous;
Caesarean section
Accepted for publication: 13 April 2011
Allogeneic blood transfusion carries potentially catastrophic
risks of infection and incompatibility reactions. To conserve
allogeneic blood, we revised our local transfusion guidelines,
introduced i.v. iron therapy where indicated, and established
intraoperative cell salvage (IOCS) into routine practice in our
obstetric operating theatre.
Despite the benefits of transfusing autologous blood,
there remains a perceived risk of contamination with amni-
otic fluid, a risk of alloimmunization of the mother by fetal
red blood cells (RBCs), and a belief that the introduction of
IOCS will require additional resources.
We concluded from earlier work that there was little possi-
bility for amniotic fluid contamination to enter the
re-infusion system when used with a leucodepletion filter
and that cell salvaged blood was safe.1 However, we were
unable to quantify the significance of fetal red cell
contamination or red cell antigen incompatibilities between
the mother and fetus.
The aim of this study was to quantify the fetal red cell
contamination of maternal salvaged blood and assess the
risk of this contamination. The secondary aim was to add
to the growing evidence that supports the safe use of IOCS
in obstetrics.
Methods
All women undergoing elective Caesarean section at the
Royal Cornwall Hospital Trust were asked to participate in
the study. They were informed at the Pre Assessment Clinic
of the benefits and risks of cell salvage and received a
patient information sheet, and surgical consent was
obtained for the use of cell salvage. Women having Category
†Presented in part at the Obstetric Anaesthetists’ Association meeting, Jersey, 2009.
British Journal of Anaesthesia 107 (3): 404–8 (2011)
Advance Access publication 14 June 2011 . doi:10.1093/bja/aer168
& The Author [2011]. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
2 or 3 Caesarean sections, who were able to read the patient
information sheet before the re-infusion of autologous blood,
were also asked to participate in the study. Category 1 emer-
gency sections were excluded as were all women who
received cell salvaged blood without a chance to read the
patient information leaflet. Ethical committee approval was
gained from Cornwall and Plymouth Research Ethics Com-
mittee to study the contamination of Salvaged Maternal
Blood by Fetal red Cells during Caesarean section (ref: 07/
H0203/257).1
During surgery, any blood lost (blood with amniotic fluid)
was collected with a specific wide-bore sucker into a reser-
voir in a Haemonetics Cell Saverw 5 system (Haemonetics
Corp., Braintree, MA, USA). The suction line was anticoagu-
lated (30 000 IU heparin per litre of saline), pre-prepared,
and attached to power of 150 mm Hg. Suction pressure
was increased to a maximum of 300 mm Hg in the presence
of heavy bleeding, although higher settings were avoided if
possible as these can damage red cell structure. Although
a Yankauer tip can be attached, it was not used routinely
because it can theoretically compromise red cell integrity.2
The surgeon and assistant aimed to maximize blood col-
lection via the wide-bore sucker as red cell retrieval was
more effective from aspirated blood than blood extracted
from washed swabs. However, when the swabs were
heavily soiled with blood, they were washed and blood col-
lected from the wash. Fetal blood spillage was kept to a
minimum whenever possible, with the surgeons cutting the
umbilical cord close to the clamp.
If the surgeon or anaesthetist judged the blood loss to
potentially require replacement and there was sufficient
blood aspirated into the reservoir, then the collection was
processed. The final decision to re-infuse was made jointly
by the obstetrician and anaesthetist in discussion with the
woman whenever possible, and this discussion was docu-
mented. The salvaged blood bag was labelled with a
Patient Identification Label which corresponded to the
patient’s wristband and was prescribed in the usual way on
the i.v. fluids prescription chart. Before a decision to use
the blood, the bag remained at the patient’s bedside and
was not stored in a fridge. If the blood was to be re-infused,
a patient blood sample was obtained for test of fetal red cell
contamination, before re-infusion.
Re-infusion of the salvaged blood usually took place
within 2 h of collection but had to occur within 6 h of the
start of the collection. Written informed consent was
obtained from all women who received a re-infusion. This
consent was usually obtained after delivery, but when signifi-
cant blood loss was predicted, the consent was taken before
surgery. All women received the processed washed blood
through a leucodepletion filter (Pall LeukoGuardw RS Filter,
Pall Europe, Europa House, Portsmouth, UK). Blood warmers
and pressurized bags were not used. Routine observations
were continued throughout the re-infusion.
A monitoring sheet was completed for all cases, even if
collection only (no processing or re-infusion) occurred (see
Supplementary Appendix 1).
A blood sample was obtained from the post-filtration
re-infusion bag. Initially, the protocol required no further
sampling direct from the patient; however, an amendment
to the original protocol (January 2010) included a patient
sample to be obtained before re-infusion. Samples were
sent directly for processing to test for full blood count and
using the Kleihauer–Betke technique to detect fetal red cells.
Consenting patients agreed to return for a follow-up appoint-
ment 3–6 months after surgery, at which time, a sample of
venous blood was obtained to screen for any maternal anti-
bodies. Any positive antibody screens were investigated
further, discussed with the Consultant Haematologist and Con-
sultant Obstetrician, the significance assessed, and, where
appropriate, communication with the patient was undertaken
by a consultant and the Ethics Committee informed.
Results
Seventy women were enrolled to the study, with mean age 33
yr (range 22–43 yr). All were ASA class I or II. Forty-eight of
the 70 women recruited were undergoing elective surgery
(Category 4 Caesarean section). Nineteen were having Cat-
egory 3 or 2 sections, eight of whom had some bleeding
before operation. The remaining three cases were women
who were taken to the operating theatre because of bleeding.
The mean preoperative haemoglobin (Hb) concentration
was 11.3 g dl21 [SD 1.0 (range 8.7–13.3 g dl21)]. These higher
concentrations reflect that the majority of cases were under-
going elective operations and not bleeding before surgery.
The median estimated blood loss during the procedure was
900 ml (range 400–7000 ml). Collected blood was only pro-
cessed if there was an estimated blood loss of more than 1
litre and only re-infused if a full bowl was processed.
When possible, before re-infusion, postoperative Hb con-
centrations were measured either with a HemoCue
(HemoCue AB, Angelholm, Sweden) device at the bedside or
a formal laboratory sample. The mean Hb concentration
after operation was 9.0 g dl21 [SD 1.3 (range 6.6–11.5 g dl21)].
Re-infusions were offered to all women, regardless of the
postoperative Hb concentration. With informed consent,
some women chose to have the re-infusion of autologous
blood, despite normal Hb concentrations.
The median total collected and processed volume was
2339 ml (range 1458–6723 ml). This resulted in a median
RBC re-infusion volume of 324 ml (range 118–1690 ml).
Thirteen of the 70 women who received autologous blood
also had allogeneic blood ordered and issued, and went on to
receive one or more units of blood in addition to the
re-infusion, ranging from one to 16 units. Four women
received other blood products (fresh frozen plasma, cryopre-
cipitate, and platelets) in addition. Two of the four women
who received additional blood products were bleeding
before operation and had a ruptured uterus. The other two
women were not bleeding before operation; one had an elec-
tive section for a fibroid and the other a Category 3 section
for placenta praevia/accreta.
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Twelve of the 13 women received their allogeneic blood
transfusion in the delivery suite and one in the post-natal
ward.
Samples obtained from the processed re-infusion packs
were collected into EDTA and processed on a Bayer Advia
120 Full Blood Count analyser (Bayer, Newbury, UK), providing
Hb and haematocrit (Hct). Samples were also tested to quan-
tify any fetal RBCs present, using the Kleihauer–Betke
technique.
The mean Hb concentration of the processed blood was
14.2 g dl21 [SD 2.0 (range 10.8–18.9 g dl21)] with a mean
Hct of 0.418 [0.06 (range 0.322–0.541)].
In all samples obtained from the processed re-infusion
packs, fetal RBCs were detected, with a median contami-
nation volume of 0.8 ml (range 0.2–12.9 ml). Two cases
were excluded from calculations due to being significant out-
liers with contamination of more than 25 ml. There were
potentially user errors in the sampling method, resulting in
poor quality of the Kleihauer–Betke slides.
All women consented for re-infusion consented for
follow-up and were contacted between 3 and 6 months for
a follow-up appointment. Eighteen women were uncontact-
able. Forty-eight women attended follow-up and had
samples tested for antibody formation. One positive antibody
was detected. Investigations confirmed this as anti-S. The
clinical significance of this antibody in obstetrics is
unknown. The remaining four cases are due for a follow-up
appointment in the next few months.
As part of the blood conservation programme, figures for
the consumption of blood throughout the Trust were also
compared with those used in obstetrics. Data from the pre-
vious 3 yr demonstrated a reduction in blood transfusion in
the obstetric population.
Fifty-eight patients (in 2007/08) needed an allogeneic
blood transfusion during or immediately after delivery.
Sixty-two were transfused in 2008/09 and 40 in 2009/10.
The total number of units transfused decreased from 244
(2007/08) to 241 (2008/09) to 197 (2009/10), with the per-
centage of overall transfusions used in obstetric practice
decreasing from 2.3% to 1.7%. The birth rates in each year
were similar. The use of IOCS increased during the study
period and was greatest during 2009/10, which may in part
account for the greater reduction in the figures for this
period.
Discussion
Cell salvage and autologous blood transfusion is an estab-
lished method of blood conservation for surgical procedures
that are anticipated to involve significant blood loss.
However, despite the endorsement of the AAGBI, OAA, and
NICE, its use is not established in obstetric practice.3 4 We
found that the introduction of IOCS has been associated
with a reduction in allogeneic blood transfusion in obstetric
practice over the past 3 yr. This has been demonstrated in
other units and speciality areas, and we were keen to estab-
lish cell salvage as part of our blood conservation strategy in
obstetrics, where surgical cases can cause unpredictable and
significant blood loss.5 6 The risks of allogeneic blood are sig-
nificant, leading to a review of the triggers for transfusion
and implementation of other strategies to conserve blood.7 8
For the 70 women having IOCS in this study, the availability
of autologous blood resulted in an over-estimation of the
need for allogeneic blood, with blood ordered being either
all or partly returned unused (14 and 13 women,
respectively).
One reason for the slow adoption of IOCS in obstetrics has
been the perceived risk of amniotic fluid embolism. In earlier
work, we demonstrated a-fetoprotein is significantly reduced
post-wash after cell-salvage, to concentrations well within
the normal range for the general population, before
passing through the filter. Heparin is also eliminated, and
while the washing process does not eliminate the presence
of squame cells, their significance in the circulation
remains unknown.1 Squame cells present post-wash are sig-
nificantly reduced post-filtration. It is therefore rec-
ommended to re-infuse through a leucodepletion filter
which removes any remaining fetal contaminant. As there
is little or no possibility of amniotic fluid contamination
re-entering the re-infusion system and, of the 1.1% of
reports to SHOT associated with autologous transfusion reac-
tions, there have been no reports of death or major morbidity
indicative of a sudden obstetric collapse, this risk remains
entirely theoretical.7
Other perceived barriers to implementing IOCS are costs,
manpower planning, and training. We have overcome these
issues by establishing the cell saver into routine practice. In
our unit, the set-up and use of IOCS is included into the
routine preparation of the obstetric operating theatre and
is entirely run by the normal quota of obstetric theatre
staff. This has been aided by the introduction of a compe-
tency training programme for operating department prac-
titioners (ODP) and we use one ODP to both assist the
anaesthetist and operate the cell saver machine. No
additional manpower has been required to facilitate the
use of cell salvage and it is currently used for more than
40% of all our Caesarean sections. We only use one suction
device, as the washing process is effective in removing
a-fetoprotein, and contamination is similar using one or
two suction devices; using one suction device reduces
waste and improves blood collection volumes.1 The suction
line is pre-prepared, enabling theatre personnel to
commence IOCS, even in urgent or emergency cases. Over
the last 2 yr, blood has been collected but not processed in
450 patients. Thus, costs have been minimized by processing
only those collections where significant blood loss occurs
and allogeneic transfusion is likely. All re-infusions have
been administered through a leucodepletion filter by
gravity alone. No haemodynamic changes were observed
during the re-infusions, although recent case reports have
reported hypotension after rapid re-infusions through a
leucodepletion filter.9 Transfusion-induced hypotension is a
recognized phenomenon and has been reported both with
and without the use of bedside leucocyte removal
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filters.10 11 In cases requiring rapid resuscitation, we use
volume resuscitation with little or no perioperative transfu-
sion of allogeneic blood, allowing the subsequent adminis-
tration of the slower re-infusion of cell salvaged blood. In
patients who decline allogeneic blood, such as Jehovah’s
Witnesses, we would consider removing the filter from the
re-infusion.12 13
There remains a risk of alloimmunization of the mother by
re-infusion of fetal RBCs in the final washed product. These
may be significant in cases of red cell antigen incompatibility
between the mother and fetus. However, the potential for
sensitization can occur throughout pregnancy and at deliv-
ery, as concentrations of fetal RBCs in the maternal circula-
tion increase during pregnancy. Peak transplacental
haemorrhage (TPH) occurs at delivery, with nearly 1% of
women in the third trimester having TPHs of .2.5 ml and
0.3% having .15 ml.14 We previously reported similar
amounts of contamination in parturients with a median
fetal RBC volume of 0.48 ml (range 0–4.6 ml) before delivery
and a maximum of 9 ml after delivery, although many of
these women had an obvious TPH during delivery.15 There-
fore, re-infusing a median fetal red cell volume of 0.8 ml
(range 0.2–12.9 ml) in cell salvaged blood is comparable
with that found normally in the maternal circulation after
delivery. The maximum we have re-infused has been 12.9
ml, and in two cases (excluded from the analysis), contami-
nation volumes were .25 ml. Both these re-infusions (320
and 280 ml) were to women who delivered twins. Other
reported volumes of fetal RBCs collected by cell salvage
range from 0.2 to 19 ml.16 – 18 The critical volume of contami-
nation required to provoke an antibody response or an
immune response to red cell antigens (Kell, Duffy, and Rh,
for example) is unknown.
Data from a 3 yr period show that 0.4% of obstetric
patients at our Trust have a clinically significant antibody.
Some of these antibodies resulted from pregnancy or,
fewer, after an allogeneic blood transfusion (Table 1). The for-
mation of anti-D in mothers of an Rh(D)-positive fetus,
although clinically significant, has been reduced by the use
of routine prophylactic anti-D treatment throughout the
pregnancy. Less commonly, other clinically significant anti-
bodies, such as anti-K, anti-c, anti-Fy(a), and anti-Jk(a),
have been implicated in haemolytic disease of the
newborn.19
Follow-up of 48 cases has detected one case of anti-S
antibodies. This was not detected antenatally and the clinical
significance of this is unknown. We were unable to establish
whether the anti-S was produced due to the cell salvage
re-infusion or due to contamination from multiple antenatal
bleeds suffered by this patient from 33 weeks gestation or
from the significant placental abruption requiring delivery
by Caesarean section. Estimated blood loss at the time of
operation was 2.5 litre; 400 ml autologous blood was
re-infused. We feel it was more likely that the antibody
anti-S was produced due to the multiple TPH during preg-
nancy and delivery, although we cannot exclude cell
salvage with certainty.
Owing to the low incidence of antibody formation and
relatively small numbers of patients followed up, it is imposs-
ible to speculate if the incidence of antibody formation or
alloimmunization after autologous blood transfusion is
greater, less, or the same as that which occurs in pregnancy.
Despite this, there already has been a suggestion that the
risk of alloimmunization is unlikely to be greater than that
incurred in a normal vaginal delivery.20
Large numbers of women need to be followed up to
assess the incidence of antibody formation and also to
evaluate the introduction of cell salvage into routine prac-
tice.21 We suggest that a central database is formed to
collate this information and assess the risk of
alloimmunization.
In conclusion, the introduction of cell salvage in obste-
tric surgery can reduce allogeneic blood transfusions. The
procedure is efficient, and IOCS has been introduced with
minimal manpower or resource implications. The signifi-
cance of the risk of alloimmunization by fetal RBCs is
uncertain after a re-infusion of cell salvaged blood.
Further work and collaboration is required to assess this
risk and we recommend that all women are followed up
to test for antibody formation 3–6 months after
re-infusion.
Supplementary material
Supplementary material is available at British Journal of
Anaesthesia online.
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SUMMARY
Objective: To assess if a modified thrombin clotting time test
could be used as a simple quality control (QC) method to
screen for unfractionated heparin in the product obtained from
obstetric intraoperative cell salvage cases before re-infusion.
Background: A national QC scheme has recently been piloted
to monitor the quality of autologous blood being returned
to the patient. Laboratory tests include full blood count
and microalbumin. Unfractionated heparin testing should be
performed to ensure that there is no gross contamination of
heparin in the final product; however, presently, there is no
quick cheap test available suitable for heparin detection.
Materials and Methods: Samples were collected into plain non-
anticoagulated tubes and centrifuged at 2500 × g for 5 min.
Supernatant was mixed with commercially available coagulated
normal plasma and a thrombin clotting time test performed.
Results: Calibration runs demonstrated that our system was
sensitive up to 0·14 IU mL−1 heparin, linear between 0·08 and
0·14 IU mL−1.
Conclusion: We have shown that the thrombin clotting time
test can be modified and used as a cheap and reliable marker for
heparin contamination. We have successfully incorporated this
modified test into our hospital’s obstetric QC scheme.
Key words: cell salvage, intraoperative, obstetrics, quality
control.
The use of intraoperative cell salvage (ICS) and autologous
blood transfusion has become an important method of
blood conservation, with the main aim of reducing allogenic
transfusions and its associated complications.
Correspondence: Ian J. Sullivan, Haematology and Blood Transfusion
Laboratory, Department of Blood Transfusion, Royal Cornwall
Hospital Trust, Truro, Cornwall TR1 3LJ, UK.
Tel.: 01872252500; fax: 01872252500;
e-mail: ian.sullivan@rcht.cornwall.nhs.uk
Spilled blood is aspirated from the operation site through
a double lumen suction device into a collection reservoir. The
salvaged blood is mixed with heparinised saline at the point of
suction/collection with a pre-prepared volume of heparinised
saline. The red blood cells undergo a washing and centrifugation
process and are re-suspended in normal saline ready for
re-infusion. This process is known to remove, or reduce, the
levels of free haemoglobin, clotting factors, platelets, white
blood cells and heparin (Catling & Thomas, 2006). Previous
studies have shown that heparin was still present in the product,
although not at levels to inhibit clotting (Umlas & O’Neill,
1981; Kling et al., 1988; Burman et al., 2002). We have recently
demonstrated that complete removal of heparin is possible in
34 of 34 samples (Sullivan et al., 2008).
A national quality control (QC) scheme has recently been
piloted in the UK to monitor the quality of autologous blood
being returned to the patient (Faulds, 2009). Laboratory tests
include a full blood count (haemoglobin/haematocrit) to assess
the quality of the end product and microalbumin as a marker
of the washing efficiency. It was deemed important that, if
possible, heparin testing is performed to ensure there is no gross
contamination of heparin in the final product being returned
to the patient. There have been concerns from surgeons that
heparin may still be present in final end product which could
compromise the patient’s recovery.
There is no quick cheap test available suitable to screen for
heparin contamination. The activated partial thromboplastin
time is used to monitor heparin anticoagulant therapy but
cannot reliably screen for heparin at low levels. The anti-Xa assay
is expensive and may not be available in all the laboratories.
The thrombin clotting time test was deemed as a suitable
alternative due to its sensitivity to heparin, which results in
prolongation of the test when heparin is present. Reconstituting
thrombin reagent with imidazole-buffered saline, as opposed to
calcium chloride, will also increase the sensitivity further (Carr
et al., 1986).
The aim of this investigation was to assess if the routine
laboratory thrombin clotting time test could be modified and
First published online 16 December 2011 © 2011 The Authors
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Fig. 1. Calibration curve for intraoperative cell salvage samples
processed by the modified thrombin clotting time test.
used as a simple marker to detect gross heparin contamination
in the product of ICS before re-infusion.
MATERIALS AND METHODS
A sample was collected from the re-infusion pack into plain
non-anticoagulated blood bottles and centrifuged at 2500 × g
for 5 min. Supernatant from the cell salvage sample was mixed
1 : 1 with commercially available coagulated normal plasma and
the thrombin clotting time test performed. Normal plasma was
used as a standardised source of fibrinogen.
Samples were processed on an ACL TOP analyser (Instrumen-
tation Laboratory UK Ltd, Cheshire, UK) using the pre-set test.
Eighty microlitres of supernatant from cell salvage sample was
added to 80 μL of Instrumentation Laboratory (Instrumentation
Laboratory UK Ltd) normal plasma. Instrumentation Labora-
tory thrombin reagent (concentration 3·0 UNIH mL−1) was
reconstituted with imidazole-buffered saline (pH 7·4). Hundred
microlitres of this reagent was added to the above and time to
clot was measured. Acquisition time for the test was set at 300 s.
With each batch, a ‘blank’ was run. This consisted of imidazole
buffer being substituted with the cell salvage sample supernatant,
added to normal plasma and thrombin clotting time test was
performed. This allowed clotting times to be converted to a ratio.
The thrombin reagent was adjusted to give a normal clotting
time of 15 s.
As part of initial investigations, four calibration runs were
performed on separate occasions, showing reproducibility and
consistency. Buffer samples spiked with known amounts of
heparin were tested and the calibration curve was plotted.
Ratios obtained from cell salvage samples could then be read
off the calibration curve to ascertain approximate heparin
concentration.
Allowing for reagents, rinse, cuvettes and buffer equates to
approximately £0·70 per test, compared to approximately £4·00
per test using the recognised anti-Xa assay on the analyser.
RESULTS
Figure 1 shows the calibration curve.
DISCUSSION
We have shown that the thrombin clotting time test can be
modified and used as a simple marker for heparin contamination
in obstetric cell salvage when unfractionated heparin is used as
the anticoagulant.
This modified thrombin clotting test was shown to be a
reliable and sensitive marker in measurement of heparin between
0 and 0·14 IU mL−1 heparin, and linear between 0·08 and 0·14
IU mL−1 (cv 0·002). Concentrations >0·15 IU mL−1 heparin
resulted in no measurable clot being detected on the analyser.
It has not been validated for acid citrate dextrose (ACD) and
further investigations on whether this test can be used when
ACD is the anticoagulant will be performed.
The test was designed to screen to exclude gross heparin
contamination. This technique can only detect up to 0·15
IU mL−1 heparin, which equates to a clinically insignificant
amount that could be safely re-infused. Only at levels
>0·5 IU mL−1 would heparin significantly affect in vivo
coagulation.
During a quality assurance pilot programme (Faulds, 2009),
it became apparent that no routinely available test could provide
a rapid measure of clinically significant heparin contamination.
The anti-Xa assay is expensive and not readily available. As
a pre re-infusion screen, our method is readily available and
reduces those specimens that might require a factor Xa assay in
QC of ICS.
Initial calibration and testing of cell salvage samples were
performed on obstetric cases. It was extended to include
other surgical specialities. In orthopaedic cases the assay is
unreliable, possibly owing to a haemolysed end product.
Manufacturer’s product information for the thrombin time
reagent indicate that free haemoglobin must exceed 0·5 g dL−1
before it interferes with the test. The degree and significance
of haemolysis in orthopaedic cell salvage require a separate
study.
We conclude that this modified test is a cheap (<£1 per
test), quick and reliable marker for heparin contamination in
obstetric cases where cell salvage is used. Further testing when
using cell salvage for vascular, urology and gynaecology cases is
planned. We have successfully incorporated this modified test
into our hospital’s QC scheme for ICS.
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SUMMARY
Objectives: The aim of this investigation was to explore the
potential use of the tests lactate dehydrogenase (LDH) and
Haemolysis Index as haemolysis markers in intra-operative cell
salvage (ICS) blood in comparison to plasma free haemoglobin
levels.
Background: Quality control (QC) should be seen as a
fundamental part of any ICS blood conservation programme,
however, due to lack of available knowledge, familiarity and
experience, QC is still a comparatively new subject. A QC pilot
scheme is currently being undertaken by the Royal Cornwall
Hospital in association with the UK Cell Salvage Action Group
to explore potential markers that can be used to assess the quality
of blood obtained from ICS. This test list should be available to all
ICS users and achievable within financial budgets. Currently this
proposed test list includes a full blood count, a protein marker
such as urine albumin/microalbumin and heparin monitoring.
Haemolysis testing is another key marker.
Methods/Materials: Samples were collected from ICS pro-
cessed blood and allogeneic SAGM leucodepleted red cell units
and processed for plasma free haemoglobin, LDH and Haemol-
ysis Index.
Results: There was a very strong correlation between plasma
free haemoglobin and LDH (0·960), and plasma free
haemoglobin and the Haemolysis Index (0·944).
Conclusion: We have shown that the LDH and Haemolysis
Index tests are suitable and reliable alternatives for measuring
haemolysis from samples obtained from ICS or allogeneic blood.
We have incorporated the LDH test into our Hospital’s ICS QC
package and recommend that this test is considered for all ICS
QC samples.
Correspondence: Ian J. Sullivan, Haematology and Blood Transfusion
Laboratory, Royal Cornwall Hospital Trust, Truro TR1 3LJ, Cornwall,
UK. Tel.: +44 018 72252500; fax: +44 018 72240302;
e-mail: ian.sullivan@rcht.cornwall.nhs.uk
Key words: allogeneic blood, free haemoglobin, haemolysis,
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Quality control (QC) is an integral part of laboratories though
less common in clinical anaesthesia (Kelleher et al., 2011). QC
should be seen as a fundamental part of any intra-operative cell
salvage (ICS) blood conservation programme, however, due to
lack of available knowledge, familiarity and experience QC is
still a relatively new subject. A recent report showed that ‘58%
of respondents do not currently QC ICS machines and 68% do
not QC the operators of ICS’ (Jones & Howell, 2011). What few
centres do undertake QC employ their own control measures,
with no standardised process. It is hoped that a benchmarking
process for QC can be developed allowing centres to compare
processes and performances.
A pilot scheme is currently being undertaken by the Royal
Cornwall Hospital in association with the UK Cell Salvage Action
Group to explore potential markers that can be used to assess
the quality of blood obtained from ICS. This test list should
be available to most hospital users, while achievable within
tightening financial budgets. Presently this proposed test list
includes a full blood count (haemoglobin and haematocrit),
a protein marker such as urine albumin/microalbumin,
heparin monitoring and additionally being able to quantify
haemolysis.
Haemolysis is the breakdown of red cells and results in free
haemoglobin being released into circulation. Within ICS this can
be caused by the surgical procedure as well as occurring at the
collection (aspiration method, vacuum pressures for example)
or processing stages. It has been suggested that haemolysis levels
may increase during machine use (Hansen et al., 2004).
Plasma free haemoglobin, as a measure of haemolysis,
can be quantified using spectrophotometry or enzyme-linked
immunosorbent assay (ELISA) techniques. It is recommended
that routine haematology laboratory analysers are not used to
measure plasma free haemoglobin due to the reduced sensitivity
at the lower ranges. For example, one type of full blood count
(FBC) analyser has a reported lower detection range of 0·0 g dL−1
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Fig. 1. Plasma free haemoglobin and LDH levels.
Fig. 2. LDH and plasma free haemoglobin results where plasma free haemoglobin is less than 1 g dL−1.
but has a deviation of 0·2 g dL−1 at such low values. This
would not provide valid and reproducible detection when the
average free Hb is 0·3 g dL−1. In an ideal situation QC samples
would be analysed using sensitive test methods or specifically
designed analysers, such as the HemoCue® Plasma/Low Hb
System (HemoCue, Angelholm, Sweden) which can detect
down to 0·0 g dL−1. However, difficulties with sourcing such
analysers, along with purchase costs of the unit and the cor-
responding cuvettes/reagents, and processing time constraints,
will unfortunately mean this option is not suitable for most
users of ICS.
Due to these reasons, alternative tests need to be identified
that are cheap and readily available to users. Two such tests that
are being proposed in this article are the lactate dehydrogenase
(LDH) test and the Haemolysis Index.
LDH is an enzyme widely distributed in almost all body
cells. In health only a small amount is detected, but is released
from the cells into the bloodstream when cells are damaged or
destroyed. Because of this, the LDH test can be used as a general
marker of injury to cells.
The Haemolysis Index is a simple colourimetric test involving
pre-diluting the blood sample with saline and reading the
red colour of haemolysis using colourimetry. It may be used
by laboratories as a measure of quality indices assessing
haemolysis levels in samples that may interfere with laboratory
tests.
© 2013 The Authors Transfusion Medicine, 2013, 23, 326–329
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Fig. 3. Plasma free haemoglobin levels and Haemolysis Index.
Fig. 4. Plasma free haemoglobin levels and potassium from ICS samples.
Aim
The aim of the project was to explore the potential use of
LDH and the Haemolysis Index as markers of haemolysis, on
comparison to the HemoCue Plasma/Low Hb System.
MATERIALS AND METHODS
Ethics Committee opinion was sought, but approval was not
required.
As part of ongoing QC process within the Royal Cornwall
Hospital, blood was collected from salvaged blood and allogeneic
saline, adenine, glucose, mannitol (SAGM) leucodepleted red
cell units. Samples were centrifuged at 1000 × g and the
supernatant processed on a HemoCue Plasma/Low Hb System
(HemoCue, Angelholm, Sweden) and a Hitachi Modular P800
chemistry analyser (Roche Diagnostics, West Sussex, UK) for
LDH and Haemolysis Index.
Data was collected from a total of 100 samples for plasma free
haemoglobin and LDH analysis, however, due to unexpected
analyser problems throughout this investigation data was only
available from 44 cases when assessing Haemolysis Index.
Of the 100 samples, 55 were from allogeneic red cell units
and 45 were from ICS. Mean age of allogeneic units 21 days
(SD 10), range 4–42. All ICS samples were taken in the clinical
setting from orthopaedic (primary and revision hip surgery),
Transfusion Medicine, 2013, 23, 326–329 © 2013 The Authors
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vascular and obstetric (caesarean section) cases using either
a Haemonetics Cell Saver® 5+ (Haemonetics Ltd, Watford,
UK), Haemonetics OrthoPat® (Haemonetics Ltd) or Dideco
Electa (Sorin Group UK Ltd, Gloucester, UK). ICS samples were
taken post-wash after running through an IV giving set filter
(170 microns) via a three-way tap. No needles were used in
the collection of ICS samples, as this is a potential cause of
haemolysis.
Statistical analysis
Correlation analysis was performed using Pearson’s correlation
or Spearman’s correlation.
RESULTS
There was a very strong correlation between plasma free
haemoglobin and LDH (0·960), and plasma free haemoglobin
and the Haemolysis Index (0·944). Correlation between LDH
and the Haemolysis Index was 0·996. Figure 1 demonstrates the
correlation between all LDH and plasma free Hb levels; Fig. 2
focuses on plasma free Hb levels less than 1 g dL−1, which are
levels usually obtained from allogeneic and ICS samples (RCHT
data). Figure 3 demonstrates the correlation between plasma
free Haemoglobin and Haemolysis Index.
DISCUSSION
We have shown that the LDH and Haemolysis Index tests are
suitable and reliable alternatives for measuring haemolysis from
samples obtained from ICS or allogeneic blood. There was a
very strong correlation between both tests and the plasma free
haemoglobin result obtained from the HemoCue Plasma/Low
Hb System.
The LDH test should be routinely available in all hospitals,
with costs less than £0·50 and can be processed in a relatively
quick time period. The Haemolysis Index test is even cheaper,
but may have issues which will limit its ability to be routinely
used. This test is analyser manufacturer dependent and may
only be offered by large laboratories. There are a number of
laboratories that do not measure quality indices such as the
Haemolysis Index, and with no national requirement to do so.
We suggest that if this test is to be included into a Hospital’s QC
package, discussions are held with the laboratory first to assess
availability.
Previous suggestions have been that potassium may be a
suitable test for ICS quality (Szpisjak et al. 2000; Personal
communication J. Faulds). From data within our Institute, we
identified that there was not a consistent strong correlation
between potassium and free haemoglobin levels from combined
allogeneic and ICS, with a correlation of −0·16. On breakdown
into allogeneic and ICS, the correlation was slightly higher in
blood obtained from ICS (correlation 0·69) compared to 0·4
in allogeneic blood, this being due to potassium leakage during
storage rather than increased haemolysis. Figure 4 demonstrates
the correlation of potassium with plasma free haemoglobin from
ICS samples.
In conclusion, we have incorporated the LDH test into our
Hospital’s ICS QC package and recommend that this test be
considered for all ICS QC samples. Due to potential availability
issues with the Haemolysis Index we propose that this test is
not routinely run as part of the UKCSAG QC package but may
be performed by individual hospitals to collect further data and
enhance the understanding of haemolysis in ICS blood.
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SUMMARY
Objectives/Background: Haemolysis is still a re-occurring
theme in intra-operative cell salvage (ICS) with further haemol-
ysis possibly caused by suction pressure, washing/centrifuging
process and aspiration method. Previous investigations, along
with manufacturer’s reports, state that between 75 and 95% of
free haemoglobin (Hb) is removed by the washing and centrifu-
gation process; however, if these results are above the expected
levels, excess free Hb may remain after washing.
The aim of this article was to quantify haemolysis levels
whilst employing different aspiration methods from skimmed
(orthopaedics) and pooled (obstetrics) surgery types and
comparing this to allogeneic blood.
Methods/Materials: Samples obtained from 50 allogeneic units
and 50 ICS cases (25 obstetric and 25 orthopaedic) were tested
for plasma free Hb levels.
Results: Free Hb testing as a marker of haemolysis was great-
est in orthopaedic 17·2 g L−1 (range: 1·7–57·0 g L−1), obstet-
ric 2·8 g L−1 (range: 1·0–13·5 g L−1) and allogeneic 0·95 g L−1
(range: 0·2–4·8 g L−1) cases.
Conclusion: ICS involving skimming collection techniques
(orthopaedics) had significantly more haemolysis than
pooled collections (obstetrics) (P < 0·001). Further analysis
of orthopaedic data highlighted a difference between the three
machines used with the Haemonetics OrthoPat (Haemonet-
ics Ltd., Watford, UK) significantly higher with a free Hb of
29·8 g L−1 compared with the other two machines 6·7 g L−1
(P < 0·001). On comparison of ICS blood to allogeneic blood,
free Hb levels obtained from ICS were significantly higher
(P < 0·001).
Key words: allogeneic, cell salvage, haemolysis, obstetric,
orthopaedic.
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The advantages and benefits of intra-operative cell salvage (ICS)
are well known with 2,3-diphosphoglycerate levels twice that
of allogeneic blood and normal 24 h survival rates (Burman
et al., 2002; Hansen & Seyfried, 2011). However, haemolysis
is still a re-occurring theme with further haemolysis possibly
caused by the vacuum pressure or the washing/centrifuging
process.
Similarly, the collection of salvaged blood appears to play a
crucial part in the degree of haemolysis. The spilled orthopaedic
surgical blood tends to be of a gradual loss, suctioning red
cells from bone and tissue in a ‘skimming’ fashion. This causes
mechanical trauma as they pass nonendothelial or mesothelial
surfaces, as well as coming into contact with lytic enzymes, acti-
vated coagulation factors, fat, bone and surgical contaminants
such as cement (Mortelmans et al., 1994). In obstetrics or vas-
cular surgery there is more of a pooling of spilled blood. When
collected, these red cells are not exposed to the same trauma as
seen in skimming.
The volume and rate of blood collected is an important factor
when salvaging blood. It has been suggested that lower vacuum
pressures produce less haemolysis, especially in post-operative
drains (Munoz et al., 2011), although higher vacuum rates are
sometimes requested by surgeons to clear the surgical operating
field rapidly (J. Faulds, 2014, personal communication). Within
our cell salvage training programme we actively set the vac-
uum between 100 and 150 mmHg for all cell salvage machines,
although this may be increased for short periods to support
clearing the surgical site.
Previous investigations, along with manufacturer’s reports,
state that between 75 and 95% of free haemoglobin (Hb) is
removed by the washing and centrifugation process (Levy et al.,
2001; Valbonesi et al., 2001; Hansen et al., 2008; Haemonetics
Product Brochure, 2012a,b). However, if the results are above the
levels expected, excess free Hb may remain after washing and
therefore infusing large volumes of ICS blood may compound
comorbidities due to the total load of free Hb (Sloan et al., 2009).
Free Hb as a result of haemolysis released into the circulation
is bound by haptoglobin which is then removed by the reticu-
loendothelial system, with haptoglobin being able to bind up to
First published online 3 September 2014
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1·25 g Hb per litre of plasma (Hoffbrand et al., 2001). Unbound
free Hb is filtered by the glomerulus and reabsorbed in proxi-
mal tubule cells. When in excess, or insufficient haptoglobin to
bind to the free Hb, free Hb becomes nephrotoxic resulting in
circulatory free Hb in the plasma. When levels exceed reabsorp-
tion rates in the kidneys, it presents in urine as haemoglobinuria
(Dacie & Lewis, 1992; Rother et al., 2005). Acute renal failure
could theoretically occur in severe episodes of haemoglobinuria
caused by re-infusions of haemolysed ICS blood. This however
does not seem to occur in the clinical setting possibly due to the
low volumes returned in most surgical collections.
Free Hb is a scavenger of nitric oxide (NO) irreversibly
binding to and reducing levels. NO is a regulator of smooth
muscle tone and platelet activation and acts as a vasodilator
in the microcirculation (Rother et al., 2005; Ley et al., 2012).
Reduced NO levels result in vasoconstriction, systolic and dias-
tolic blood pressure (BP) increases, reduced tissue oxygenation,
smooth muscle dystomies, gastrointestinal (GI) contractions,
endotheliac dysfunction and platelet aggregation with increased
thrombotic events (Rother et al., 2005; Sloan et al., 2009; Kelle-
her et al., 2011; Vermeulen Windsant et al., 2012). Haemolysis
also results in the release of enzymes that can affect NO synthesis
(Rother et al., 2005).
Previous investigations on the scavenging effect on NO by free
Hb demonstrated a clear correlation (P = 0·002) in patients who
received allogeneic blood transfusions such that as circulating
free Hb levels increased, NO consumption also increased. As
expected, patients transfused with more allogeneic units had
an increased free Hb level post transfusion, increasing to a
maximum after 120 min before decreasing. Patients who had
lower pre-transfusion haptoglobin levels also had higher free Hb
levels (Vermeulen Windsant et al., 2012).
As well as NO scavenging, the heme part of Hb breakdown
can increase procoagulant effects resulting in increased platelet
activation and increased release of inflammatory substances
(Rother et al., 2005; Sloan et al., 2009). Damaged cells also cause
coagulation abnormalities and other inflammatory morbidities
including acute lung injury (Kelleher et al., 2011).
It has been previously suggested that ICS can only reduce free
Hb levels to 0·3 g L−1 as further haemolysis will occur during
the processing and that levels may increase during machine use
(Hansen et al., 2004).
The aim of this investigation was to assess the quantity of
haemolysis due to different aspiration collection methods in ICS:
orthopaedics and obstetrics, and to add this data to the already
published knowledge. Data was compared with that collected
from allogeneic blood.
MATERIALS AND METHODS
Data was collected from 50 ICS cases and from 50 allogeneic
units. Ethics Committee opinion was sought, but approval was
not required. Data from this article has been presented at the
2013 Network for Advancement of Transfusion Alternatives
(NATA) symposium and the 2013 British Blood Transfusion
Society (BBTS) annual conference (Sullivan & Faulds, 2013a,
2013b).
ICS samples
Only the final product that would be re-infused to the patient
was analysed. Pre-wash samples were not analysed. All ICS
samples were taken in the clinical theatre setting, with all ICS
machines operated in the automatic mode. Partial bowls were
excluded from this investigation. Partial bowls from ICS is
a debated subject with concern on the washout efficiency of
contaminants and the quality of the final product, although the
evidence for this concern is limited. The role of partial bowls
is beyond the scope of this article and will be addressed in a
separate report.
Post-wash samples were collected into ethylenediaminete-
traacetic acid (EDTA) after running through an IV giving set
filter (170 μm) via a three-way tap. As has been previously
identified as the potential cause of haemolysis, and is therefore
recommended, no needles or excessive pressure were used in
the collection of samples or transferring of samples into the
respective tubes. Sample tube tops were removed prior to gently
running the blood down the side of the tubes.
Patients
Samples were obtained from 25 patients undergoing elec-
tive caesarean section. In 21 cases, blood was collected into
a Haemonetics Cell Saver5+ incorporating SmartSuction-
HarmonyAutoregulating Surgical Suction (Haemonetics Ltd.,
Watford, UK), whereas in the remaining four cases blood was
collected into a Dideco Electa (Sorin Group UK Ltd., Gloucester,
UK) using an integrated vacuum device.
From the 25 orthopaedic cases, the majority were primary
total hip replacement (THR) (n= 18) or revision hip surgery
(n= 5). A Haemonetics OrthoPat(Haemonetics Ltd.) using
piped wall vacuum was used in 10 primary THR and 1 revision
hip surgery, the Dideco Electa was used in 3 primary THR and
2 revision hip cases, with the Cell Saver 5+ used in 5 primary
THR and 2 revision hip surgeries. The remaining two cases
were one revision total shoulder replacement and ORIF fracture
distal femur, both using the OrthoPat.
Allogeneic samples
All units tested were leucodepleted and stored in Saline, Ade-
nine, Glucose, Mannitol (SAGM). Samples were either taken
from wasted or time expired units that were still within the cold
chain criteria, or a blood sample was taken from the unit giving
set prior to connecting to a patient’s cannula. No needles were
used. Blood was collected into EDTA. Average age of the blood
was 21 days.
In order to compare haemolysis levels from allogeneic and
ICS levels to what could be expected in the general population,
data were collected from 30 samples within our Institute and
tested for plasma-free Hb levels.
© 2014 British Blood Transfusion Society Transfusion Medicine, 2014, 24, 280–285
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Table 1. Median haemoglobin, haematocrit and free haemoglobin levels; (IQR)
Sample
size
Median Hb (IQR),
min–max
(g L−1)
Median HCT (IQR),
min–max
(L L−1)
Median free haemoglobin (IQR),
min–max
(g L−1)
ICS all 50 165 (59·5), min–max: 113–262 0·502 (0·164), min–max: 0·314–0·744 4·65 (15·4), min–max: 1·0–57·0
ICS orthopaedic 25 197 (102), min–max: 113–262 0·557 (0·263), min–max: 0·314–0·744 17·2 (28·6), min–max: 1·7–57·0
ICS obstetrics 25 156 (31), min–max: 130–209 0·460 (0·107), min–max: 0·371–0·662 2·8 (2·6), min–max: 1·0–13·5
Allogeneic blood 50 197 (23·0), min–max: 163–219 0·656 (0·061), min–max: 0·513–0·728 0·95 (1·4), min–max: 0·2–4·8
min–max, minimum–maximum.
Sample analysis
All samples were processed immediately to avoid any stor-
age changes. Samples were analysed on an Advia2120 Haema-
tology System (Siemens UK, Surrey, UK) to obtain product
Hb and haematocrit (Hct). To quantify free Hb levels, sam-
ples were centrifuged at 1000× g for 5 min and supernatant
tested on a HemoCuePlasma/Low Hb System (HemoCue Ltd.,
Derbyshire, UK).
To assess if any further haemolysis occurred in the laboratory
due to centrifuging samples for obtaining the supernatant, cen-
trifugation experiments were performed. Samples were obtained
from six ICS cases on separate occasions (two primary THR
and four from elective caesarean section) and were distributed
evenly into separate tubes and centrifuged at speeds ranging
from 110 to 1700× g, duration times between 2 and 5 min using
braked and unbraked systems. Supernatant was then analysed
for plasma-free Hb levels, using the HemoCue method stated
above.
Statistical analysis
Parametric data was analysed using the t-test sample; non-
parametric data was analysed using the Median test or the
Mann–Whitney test. P < 0·05 is considered statistically signif-
icant.
RESULTS
The initial centrifugation experiment showed no difference in
haemolysis (plasma-free Hb levels) when subjected to varying
centrifugal speeds and duration times; however, low centrifugal
speeds of 110× g were insufficient to separate the supernatant
from the red cells needed for testing.
Table 1 lists the median Hb, haematocrit and free Hb levels
along with the inter-quartile range and minimum–maximum
values from ICS and allogeneic units.
Free Hb levels were noted to be greatest in orthopaedics. On
comparison of skimmed (orthopaedics) to pooled (obstetrics)
free Hb levels were significantly higher in orthopaedic samples
(P < 0·001). Median pooled free Hb level was 2·8 g L−1 with a
median skimmed level of 17·2 g L−1.
On further analysis of the orthopaedic data there was a
difference between the three machines used, with the OrthoPat
significantly higher with a free Hb of 29·8 g L−1 compared with
the other two machines 6·7 g L−1 (P< 0·001).
On comparison of ICS blood to allogeneic blood, free
Hb levels obtained from ICS were significantly greater than
those obtained from allogeneic blood (P < 0·001), with the
range (0·2–4·8 g L−1) similar to other published ranges (Szpis-
jak et al., 2000; Burman et al., 2002; Vermeulen Windsant
et al., 2012).
As the concentration of free Hb in the final ICS post-wash
product will be affected by the total volume re-infused, it is
often more appropriate to know the final amount of free Hb that
would be re-infused to the patient. This is known as the dose and
is useful when comparing products with different haematocrits.
It can be calculated by multiplying the supernatant volume by
the free Hb concentration (Haemonectics Corporation, 2008).
Table 2 shows the total free Hb dose from ICS and allogeneic
units from this study.
Comparison of skimmed to pooled ICS collections, the total
free Hb dose was significantly higher (P < 0·001). On breakdown
of the orthopaedic data, and again consistent with the free Hb
concentration reported, the total Hb dose was greater from the
OrthoPat 1·26 g when compared with the other two machines of
0·72 g.
Free Hb levels as a representation of what could be expected
in the general population within our Institute, had a median
free Hb of median 0·3 g L−1 [interquartile range (IQR): 0·2;
minimum–maximum 0·1–0·6].
DISCUSSION
Free Hb levels obtained from our orthopaedic cases are greater
than other published data [range: 0·75–3·73 g L−1 (Roberts et al.,
Table 2. Total free Hb dose from ICS and allogeneic units from this
study
Median free Hb dose (IQR),
min–max (g)
ICS orthopaedic 0·94 (0·91), min–max: 0·09–6·20
ICS obstetrics 0·29 (0·39), min–max: 0·10–1·37
Allogeneic 0·10 (0·13), min–max: 0·02–0·44
min–max, minimum–maximum.
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1991; Mortelmans et al., 1994; Spain et al., 1997; Cuby et al.,
2001)] but a direct correlation cannot be made because of limited
case numbers and differences in the type of surgery and labora-
tory methodology.
On assessment of the higher levels obtained from the use
of the OrthoPat in our investigation, no definitive conclusions
can be made as the case numbers were limited, although this
finding is consistent with a recent report with free Hb lev-
els from the OrthoPat ranging from 4·0 to 67 g L−1 (Baxter
et al., 2012).
Data can only be found from one obstetric report with a
free Hb level of 1·6 g L−1 (Fong et al., 1999). There are however
several reported cases from ICS use in cardiac surgery with
levels ranging from 0·1 to 3·1 g L−1 (Kling et al., 1988; Spain
et al., 1997; Cuby et al., 2001; Kelleher et al., 2001; Levy et al.,
2001; Burman et al., 2002; Serrick et al., 2003). Blood lost during
cardiac surgery is more likely to pool in a manner similar to
obstetrics.
Free Hb levels that could be expected in the general popu-
lation with median 0·3 g L−1 are marginally higher than other
reports with levels up to 0·1 g L−1 (Crosby & Dameshek, 1951;
Hanks et al., 1960; Mortelmans et al., 1994; Sloan et al., 2009),
but this could be due to collection, storage or transport issues,
or the testing methodology used. However, these normal ranges
are significantly less than the reported free Hb levels in allogeneic
and ICS blood (P < 0·001).
Reviewing the published data on total free Hb doses in
the re-infused product, the only reported ICS case in obstet-
rics identified a free Hb dose of 0·103 g (Fong et al., 1999).
In the study by Spain et al. (1997), as the average re-infused
volume was highest in vascular surgery, it had the high-
est total free Hb dose of 1·15 g per patient. In their cardiac
cases, the average dose was approximately 0·60 g per patient,
and in the orthopaedic ‘skimming’ setting, with the lowest
returned volume, the total dose per patient was approximately
0·3 g.
In a recent study exploring the fragility of cell salvaged
blood, washed and unwashed post total knee arthroplasty, it was
demonstrated that there was more haemolysis and damage in the
washed group compared with the unwashed group as shown by
a higher free Hb and higher mechanical fragility index. Washed
blood, similar to methods we have used in our institution had a
total free Hb dose of 0·55 g but this was not statistically different
(P= 0·615) when compared with unwashed ones (Ley et al.,
2012).
On comparison of the data obtained from our Institute to
the available published data, free Hb concentrations and doses
from pooled collections are consistent; however, our orthopaedic
data is greater than those reported. This we feel warrants further
investigations and is part of an ongoing quality assurance work
within our Institution.
Although we have statistically demonstrated a difference,
it does not address the clinical significance of this and the
other results and at what level of re-infusing free Hb would
this become significant. This could be far more difficult to
assess, however due to variances between individuals. For
example, patients with active inflammation may have increased
haptoglobin levels and therefore have the potential to clear
the free Hb faster. In addition, certain clinical situations will
complicate the assessment of re-infusing free Hb/haemolysed
blood so any changes in the BP or renal function, for example,
will not be easily distinguished between the surgical proce-
dure and ICS blood re-infused. It has been suggested that
0·1 g L−1 free Hb significantly impairs NO metabolism, levels
greater than 0·16 g L−1 are linked to renal injury/dysfunction
and greater than 1·0 g L−1 may cause haemoglobinuria
(Widman, 1989; Reiter et al., 2002). Theoretically a patient’s
haptoglobin levels would be sufficient to cover approximately
3 g of free Hb transfused before haemoglobinuria occurs,
equivalent to 10 donor units with haemolysis levels of 0·5%
(Sowemimo-Coker, 2002).
Within orthopaedics, an alternative system is the reinfusion of
unwashed blood from post-operative drains. The quality of this
blood is debated because it is known to have higher haemolysis
levels (Munoz et al., 2004, 2011), yet there have been many cases
where blood from post-operative drains has been infused with
higher levels of haemolysis without any harm being evident
(Blevins et al., 1993; Ayers et al., 1995, Munoz et al., 2011). This
may be due to sufficient haptoglobin being present to absorb
a significant amount of free Hb. It has been suggested that
there is enough haptoglobin in the circulation to cover up to
1500 mL reinfusion of unwashed blood, whilst washing reduces
the haemolysis further (Munoz et al., 2004, 2011). Levels of
haptoglobin have not been shown to decline faster in those
receiving such unwashed blood compared with no cell salvage
(Sebastian et al., 2000). As such the importance of small amounts
of infused free Hb is uncertain.
In order to ascertain the complete clinical significance of
free Hb infusions, the dilutional effect of re-infusing into a
total blood volume and the circulatory haptoglobin levels, it
would be beneficial to measure haptoglobin and free Hb levels
in the patient pre and post re-infusion, as well as assessing the
re-infused product. There are very few case reports where this
has been performed, with Mortelmans and colleagues showing
an increase post re-infusion from 0·08 to 0·58 g L−1. The final ICS
post-wash product had a concentration of 1·77 g L−1 (Mortel-
mans et al., 1994).
On the basis of our findings and the available data, we feel we
are unable to comment completely on the significance of rein-
fusing haemolysed blood as we have analysed only post-wash
samples. There were however no complications noted in any
of the ICS re-infusions, and on review of our 50 patients’
post-operative renal function there were no new cases of renal
dysfunction noted by assessment of electrolytes, urea and crea-
tinine.
In conclusion, this report has confirmed that haemolysis of
varying degrees (at least 1 g L−1) is still present in the final
product that could be re-infused to the patient. This would agree
with previous reports in that further haemolysis will still occur
during the processing and use of ICS machines. Free Hb levels
© 2014 British Blood Transfusion Society Transfusion Medicine, 2014, 24, 280–285
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obtained from autologous and allogeneic units were higher than
those found in the normal population, with increased levels in
ICS when compared with allogeneic blood. The significance of
this is still unclear. Owing to the elevated results obtained in this
current study, we feel that free Hb levels need to be addressed
further and we will be repeating this study, including analysis
of free Hb and haptoglobin levels and renal function in patients
pre- and post-reinfusion.
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www.obstetanesthesia.comIs cell salvaged vaginal blood loss suitable for re-infusion?K.M. Teare,a I.J. Sullivan,b C.J. Ralpha
aDepartment of Anaesthesia, bBlood Transfusion Department, Royal Cornwall Hospital Trust, Truro, Cornwall,
UKABSTRACTBackground: Haemorrhage is one of the commonest causes of maternal critical care admission. Cell salvage used during caesarean
section can contribute to a reduction in allogeneic blood consumption. This study sought to provide a practical method to salvage
blood lost after vaginal delivery and a description of the constituents before and after washing.
Methods: Blood lost after vaginal delivery was collected from 50 women and washed in a cell salvage machine. No blood was re-
infused to any patient in this study. The following measurements were made pre- and post-wash: haemoglobin (haematocrit),
alpha-fetoprotein, albumin, lactate dehydrogenase, plasma free haemoglobin, heparin concentration, fetal red cells and identifica-
tion of bacterial species and colony-forming units (cfu).
Results: Median haemoglobin concentration post-wash was 15.4 g/dL. Alpha-fetoprotein, lactate dehydrogenase and albumin
concentrations were significantly reduced post-wash (<1 KU/L, 183 IU/L, 0.011 g/L, respectively; P <0.001). Median fetal red cell
level post-wash was 0.15 mL [range 0–19 mL]. Median bacterial contamination concentration post-wash was 2 cfu/mL, with a
median total count of 303 cfu.
Conclusions: Vaginal blood can be collected efficiently with little disruption to patient management. The amounts of haemolysis
and washout of non-red cell blood components are consistent with results in our cell salvage quality assurance programme for
caesarean section and non-obstetric surgery. Although bacteria are detectable in all the post-wash and post-filter samples, the med-
ian residual contamination is similar to that found with cell salvage in caesarean section, and if re-infused would result in a cir-
culating bacteraemia of <1 cfu/mL; this is similar to that seen with dental procedures (0.3–4.0 cfu/mL) and is thought to be
clinically insignificant.
c 2014 Elsevier Ltd. All rights reserved.
Keywords: Bacteria; Blood transfusion; Autologous; Obstetrics; Intra-operative cell salvage; Postpartum haemorrhageIntroduction
The Confidential Enquiry into Maternal and Child
Health reports have consistently identified haemorrhage
as an important direct cause of maternal death.1 It is one
of the commonest reasons for maternal critical care
admission, and obstetric patients are significant users
of allogeneic blood products.2 There are risks associated
with donor blood transfusion which include acute trans-
fusion reaction, lung injury and, although rare, the
possibility of death from transfusion error, and trans-
mission of infection which may have serious long-term
consequences. These risks are monitored by annual
Serious Hazards of Transfusion (SHOT) reports.3 The
morbidity from blood transfusion also includes postop-
erative infection; the risk increasing with each unit trans-
fused.4 Allogeneic blood is an increasingly scarce and
expensive resource, and in the UK a well-developedAccepted December 2014
Correspondence to: K.M. Teare, Department of Anaesthesia, Noble’s
Hospital, Douglas, Isle of Man, IM4 4RJ, UK.
E-mail address: kateteare@yahoo.co.ukblood transfusion service exists to minimise risk. In
some countries there is difficulty supplying allogeneic
blood, and in addition patients may refuse allogeneic
transfusion on religious grounds. Blood conservation
strategies, including cell salvage, aim to reduce con-
sumption of allogeneic blood.
In current obstetric practice, the use of cell salvage is
generally restricted to caesarean section. A 2012 survey
of UK obstetric units found that 47% had cell salvage
equipment, with frequency of use varying between
units.5 Cell salvage was introduced at The Royal Corn-
wall Hospital Trust (RCHT) in 2008 and is now used
routinely at caesarean section. The number of obstetric
patients who receive allogeneic blood per delivery in
our unit has reduced from 1.8% in 2008 to 0.8% in
2013, with a reduction in the mean number of units
transfused per patient from 3.3 to 1.9. In 2013, however,
81% of women who received allogeneic blood delivered
vaginally, not by caesarean section. There is currently
no evidence to support or reject the use of cell salvage
after vaginal delivery. This study aimed to test the feasi-
bility and effectiveness of a method to salvage vaginal
Suction unit
Collection 
reservoir
Fig. 2 Collection drip stand with reservoir and suction
104 Vaginal blood and cell salvageblood loss, with a description of constituents before and
after washing in a cell salvage machine.
Methods
This descriptive study assessed blood salvaged by a cell
saver after vaginal delivery in a series of 50 participants.
The study was approved by the National Research
Ethics Service Committee Southwest: Plymouth and
Cornwall [12/SW/0136]. All participants gave written
informed consent. The study was conducted at the
RCHT. No cell-salvaged blood was re-infused to any
participant.
Inclusion criteria were vaginal delivery and an
estimated blood loss of P200 mL after transfer to the
operating theatre for clinical reasons, which included
on-going blood loss, instrumental delivery, manual
removal of placenta and perineal tear repairs. Women
whose blood loss was managed entirely in delivery rooms
were excluded.
Collection was carried-out by the clinical team using
the equipment shown in Figs. 1 and 2. After delivery of
the baby, the obstetrician placed an under-buttock
drape with pouch (Steri-Drape 1084, 3M Health Care,
Bracknell, UK) to collect blood. Similar drapes are com-
monly used in UK maternity units and non-obstetric
theatres. The aspiration and anticoagulation line was
lowered into the pouch. Approximately 200 mL of hep-
arinised saline (30000 U in 1000 mL) was run rapidly
into the pouch and the rate then adjusted to a slow drip.
Once surgical treatment was complete, the blood/hepa-
rinised saline mix was aspirated into the reservoir and
processed with a Cell Saver 5+ Autologous Blood
Recovery System (Haemonetics Ltd., Coventry, UK).
Processing was performed in the automatic mode with
a wash volume of 1500 mL, double the manufacturer’s
recommended setting. This is the same setting used in
our hospital at caesarean section, and had been decided
before introduction of the obstetric cell salvage service.
In all cases a single aspiration line was used.6
Samples of salvaged blood were taken from: (1) the
collection reservoir labelled ‘pre-wash’; (2) the re-
infusion bag labelled ‘post-wash’ and (3) after passing
the full volume through a leucodepletion filter (RS1Fig. 1 Position of under buttock drapeVAE Pall Medical, Portsmouth, UK) labelled ‘post-
filter’. At all stages the blood was agitated gently before
sampling to ensure even mixing. The following measure-
ments were made at each stage:
1. Full blood count: haemoglobin concentration (Hb)
and haematocrit (Hct) were analysed on an Advia
2120 Haematology System (Siemens UK, Surrey,
UK).
2. Alpha-feto protein concentration (AFP), used as a
marker of amniotic fluid contamination, was pro-
cessed on a Hitachi Modular P800 chemistry analyser
(Roche Diagnostics, West Sussex, UK).
3. Fetal red blood cells (fetal RBCs) using the Kleihau-
er-Betke test.
4. Micro-albumin, as a marker of washing efficiency,
was processed on a Hitachi Modular P800 chemistry
analyser (Roche Diagnostics, West Sussex, UK).
Table 1 Patient characteristics
Age (years) 30 [26–35]
K.M. Teare et al. 1055. Heparin level using the anti-Xa test was processed on
an Instrumentation Laboratory TOP Coagulometer
(Instrumentation Laboratory, Warrington, UK)
6. Plasma free haemoglobin concentration (free Hb), as
a marker of haemolysis, was measured using a
HemoCue Plasma/Low Hb System (HemoCue
Ltd, Derbyshire, UK). To aid assessment of haemol-
ysis, lactate dehydrogenase (LDH) was also mea-
sured. It has been shown to be a reliable indicator
of haemolysis in cell salvage, allowing comparison
with haemolysis concentrations from other cell sal-
vage techniques.7
7. Bacterial contamination: aerobic and anaerobic
enriched blood cultures were inoculated with 5 mL
each, collected into standard aerobic (BacT/ALERT
SA) and anaerobic (BacT/ALERT SN) bottles and
processed using the Blood culture BacT/ALERT
Microbial Detection System (bioMérieux Ltd.,
Hampshire, UK). A separate 1 mL sample was
spread on an agar plate and incubated for 12 h, after
which a colony count was performed according to
standard procedures.
The percentage of red cells available to re-infuse was
calculated only for those 31 women who had a drape
placed immediately after delivery (i.e. those who had
an instrumental delivery in theatre, rather than gave
birth in a delivery room and subsequently moved to the-
atre). The calculation was:
1. Maternal venous preoperative Hct multiplied by esti-
mated blood loss. Clinicians used graduated mark-
ings on the collection reservoir and pictures of
blood soaked swabs and receivers to estimate blood
loss.
2. Post-wash salvaged blood Hct multiplied by its
volume.
Washout efficacy of the cell salvage machine was
calculated for LDH, AFP, albumin and heparin as
pre-wash minus post-wash divided be pre-wash
expressed as a percentage. The last maternal venous
blood sample taken before delivery was tested for
Hb/Hct along with fetal red cell levels using the
Kleihauer-Betke test.
Bacterial contamination (species and quantity) of cell
salvage blood was also measured in 20 patients undergo-
ing emergency caesarean section. Post-wash salvaged
blood was sampled from the re-infusion bag and tested
using the same methods.Parity 1 [1–1]
Body mass index at booking (kg/m2) 25.5 [22.5–29.5]
Gestation (weeks) 40 [40–41]
Estimated blood loss (mL) 700 [500–1500]
Pre-delivery haemoglobin (g/dL) 12.3 [11.3–13.0]
Post-delivery haemoglobin* (g/dL) 9.3 [8.4–10.3]
Data are median [IQR]. *Values following transfusion, when required.Statistical analysis
Non-parametric data are presented as median and
range or interquartile range (IQR). Non-parametric
data analysis was performed using Wilcoxon Signed
Ranks Test.Results
Fifty-seven women were recruited. The first seven collec-
tions were processed in a 70 mL bowl with poor and
unexpected washout rates; those results were excluded
from further analysis. The 125 mL bowl was used for
the remainder of the study.
A series of 50 participants is presented (Table 1). The
50 participants were delivered by instrumental or nor-
mal vaginal delivery; 48 had singleton births and two
delivered twins. Nine women received an allogeneic
blood transfusion (median 1 unit; range 1–3 units). In
48 cases the wash volume was 1500 mL. In two cases
the machine automatically increased the wash volume
to 1815 mL and 2500 mL respectively, as the sensors
detected inadequate washing. From the 50 cases, 34
were from complete bowls, the remaining 16 were from
partial bowls, defined as a centrifuge bowl that was not
completely filled with the cell salvage machine in
automatic mode. Laboratory Data from all 50 cases
are presented (Table 2). Table 3 shows median [IQR]
values from the full bowls only.
Median pre-wash volume was 800 mL [IQR
700–1200 mL]. Median post-wash volume was 133 mL
[IQR 118–204 mL].
In 31 women, the drape was placed immediately after
delivery; in the others there was delay whilst transferring
to theatre. For those 31 women a median of 28% [IQR
21-35%] of red cells lost were available to re-infuse.
The washout efficiency of the cell salvage machine is
shown by a median washout reduction rate of 95% for
LDH and 99% for AFP, albumin and heparin (Table 2).
Albumin was significantly reduced post-wash (P <0.01)
with no further significant reduction post-filter
(P=0.77). Albumin levels post-wash were similar to
levels collected from caesarean section patients with a
maximum of 0.13 g/L detected post-wash, equivalent
to a 99.9% wash-out rate.
Alpha-fetoprotein, used as a marker of amniotic
fluid, was significantly reduced post-wash (P <0.01),
consistent with previous investigations.6,8 The maximum
level detected post-wash was 8 KU/L, and this was due
to the pre-wash sample having a very high concentration
of AFP initially; this still represented 99.9% wash-out
efficiency. There was no further significant reduction
Table 2 Constituents of salvaged blood
Pre-wash Post-wash Post-filter
Haemoglobin (g/dL) 3 [1.9–4.4] 15.4 [15.3–17.9] 11.2 [6.0–15.3]
Haematocrit 0.087 [0.054–0.1] 0.461 [0.314–0.5] 0.333 [0.167–0.5]
AFP (KU/L) 62 [23–294] <1 [1–3] <1 [1–1]
LDH (IU/L) 374 [239–762] 183 [125–350] 87 [47–192]
Albumin* (g/L) 11 [6–13] 0.011 [0.005–0.030] 0.013 [0.005–0.021]
Heparin (IU/mL) 6.3 [5.9–6.5] 0 [0–0] 0 [0–0]
Free haemoglobin (g/dL) 0.13 [0.07–0.3] 0.1 [0.04–0.25] 0.11 [0.03–0.38]
Fetal RBCs (mL) 0.28 [0.02–1.4] 0.15 [0.04–1.99] 0.08 [0.002–0.77]
Data are median [IQR]. *Albumin derived from micro-albumin test; AFP: alpha-fetoprotein; LDH: lactate dehydrogenase; RBC: red blood cells.
Table 3 Constituents of salvaged blood from full bowls
only
Pre-wash Post-wash Post-filter
Haemoglobin (g/dL) 3.3 16.4 14.5
Haematocrit 0.102 0.490 0.439
AFP (KU/L) 78 <1 <1
LDH (IU/L) 526 259 142
Albumin* (g/L) 11 0.011 0.013
Heparin (IU/mL) 6.3 0 0
Free haemoglobin (g/dL) 0.14 0.13 0.13
Fetal RBCs (mL) 0.26 0.61 0.15
Data are median and derived from 34/50 full bowls. *Albumin derived
from micro-albumin test; AFP: alpha fetoprotein; LDH: lactate
dehydrogenase; RBC: red blood cells.
106 Vaginal blood and cell salvagepost-filter (P=0.82). Lactate dehydrogenase was signifi-
cantly reduced post-wash (P <0.01) and post-filter (P
<0.01). The reason for the reduction in LDH post-filter
while other contaminants were not reduced is unclear.
Plasma free Hb levels were reduced post-wash but the
reduction was not statistically significant (P=0.40),
and there was no further reduction post-filter
(P=0.61). Heparin was significantly reduced post-wash
(P <0.01). It was detected in 4/50 samples post-wash.
Three of the four positive results were from partial
bowls, and contained a median of 0.14 IU/mL which
equated to a total dose of 16 IU. If re-infused this would
be clinically insignificant. There was no further signifi-
cant reduction of heparin post-filter (P=0.90).
Fetal red cells were detected in all except three cases.
The median volume of fetal red cells post-wash was
0.15 mL [range 0–19 mL] (Fig. 3). Maternal peripheral
blood samples, taken between two hours and two days
before delivery, showed fetal red cells were already pres-
ent in 13 cases (26%): median level 0 mL; [IQR
0–0.48 mL], with a maximum fetal red blood cell volume
of 3.4 mL.
Post-wash bacteria counts were significantly reduced
(P <0.001) (Table 4). Bacteria were detected in all the
post-wash and post-filter samples (median residual con-
tamination 2 cfu/mL). The predominant bacteria identi-
fied in this study were Escherichia coli, Enterococcus sp.
and coagulase-negative staphylococci which were likelyto be part of the genital or skin flora (Table 5). At emer-
gency caesarean section, post-wash cell salvaged blood
had detectable bacteria in all 20 samples (Table 4).
Discussion
The study has shown that blood lost vaginally can be
collected in an efficient manner with minimal impact
or disruption to the clinical team or patient manage-
ment. The drapes did not dislodge, and there were no
episodes of blood running outside the pouch. The collec-
tion system was simple and quick to set up. A dedicated
member of staff is not required to operate the collection
system, although a trained member of staff must be part
of the team.
Blood collections were confined to theatre in order
to limit training requirements to a small team. Collec-
tion in delivery rooms is possible after training mid-
wives, although most women with ongoing bleeding
are transferred to the operating theatre for further
management. Midwives could collect blood using a
drape included routinely in all delivery packs: in our
hospital this would cost an additional £1.50 per pack.
Heparinised saline can be poured into the drape by a
midwife as soon as excessive bleeding is recognised.
Aspiration of blood to the cell salvage machine reser-
voir does not need to be immediate and can be
performed when a trained person arrives. In our
institution this would be an operating department prac-
titioner or theatre nurse. The costs of disposable items
for the cell salvage machine (approximately £90) are
only incurred when excessive and on-going bleeding
occurs, and these costs are recovered if transfusion of
only one unit of blood is avoided.
Results from this study are consistent with those
obtained from caesarean section and vascular cases
using intra-operative cell salvage at the RCHT.6 Unpub-
lished data from caesarean section with full bowls post-
wash have median values of Hb 15.3 g/dL; Hct 0.455;
LDH 236 IU/L; albumin 0.0064 g/L; and fetal RBC
0.6 mL. The 16 cases from partial bowls had a lower
and variable post-wash Hb [IQR 5.9–10.3] and Hct
[IQR 0.170–0.312]. Median post-wash volume of the
partial bowls was 118 mL [IQR 115–122 mL]. This is
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Fig. 3 Fetal red cell volumes detected in post-wash samples
Table 5 Species of bacteria detected from partial and full bowls.
Vaginal delivery Caesarean section
Pre-wash
(n=50)
Post-wash
(n=50)
Post-wash
(n=20)
Escherichia coli* 34 39 1
Enterococcus spp.* 33 36 3
Enterobacter cloacae 0 0 1
Coagulase-negative staphylococcus 14 11 16
Staphylococcus saprophyticus 2 0 0
Staphylcoccus aureus 0 0 1
Lactobacillus spp. 5 3 0
Mixed anaerobes 4 3 0
Coliforms 2 1 0
Alpha haemolytic streptococci 2 1 2
Group B streptococci* 2 1 0
Haemolytic streptococci mixed (Non-A, B, C) 1 2 0
Diptheroids 2 0 1
Proteus* 1 1 1
Data are numbers. *Organisms found in the three vaginal samples with the highest bacterial counts.
Table 4 Bacterial counts from vaginal delivery and caesarean section
Vaginal delivery* Caesarean section
Pre-wash Post-wash Post-filter Post-wash
Bacterial concentration (cfu/mL) 8 [1–84] 2 [1–25] 3 [1–14] 1 [1–1]§
Total bacterial count (cfu) 3400 [1278–52200] 303 [188–1245] 438 [98–2115]
Data are median [range]. *Data from 32 patients. P <0.001 compared to pre-wash.; §Maximum value 30 cfu/mL.; Median post-wash volume
165 mL.
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machine tops-up the bowl with saline. The role of partialbowls from cell salvage in caesarean section is currently
unclear.
108 Vaginal blood and cell salvageAs this is the first study to attempt collection of vag-
inal blood loss, only women who bled 200 mL or more
were studied. This volume of blood loss was chosen as
the amount likely to be sufficient to fill a 125 mL centri-
fuge bowl. However, 200 mL may not be sufficient for
processing in all cases because it is dependent on the
maternal Hct, degree of haemolysis and the amount of
blood lost on swabs.
Red cell haemolysis occurs during suction and centri-
fugation in the cell salvage process and produces free Hb
which was not removed by washing. Samples taken
post-wash revealed less haemolysis than that seen at
the same stage in caesarean section and far less than that
in orthopaedic surgery. Levels were similar to that
found in allogeneic blood.
Fetal red cell contamination was expected. Both the
quantity and range of data, including higher outlying
values (19 mL in this study), are consistent with previ-
ous reports involving caesarean sections.6,9–11 The rea-
son for the outlying value is not known. The presence
of fetal red cells in the maternal circulation is an
important consideration for red cell antigen incompat-
ibilities between mother and fetus. Rhesus incompati-
bilities have been significantly reduced by routine
prophylactic anti-D treatment throughout pregnancy,12
but other antibodies to red cell antigens can result in
fetal hyperbilirubinaemia and anaemia in future preg-
nancies. Clinically relevant antibodies that have been
implicated in haemolytic disease of the newborn
include anti-K, anti-c, anti-Fy(a), and anti-Jk(a).13
However, there is also a risk of alloimmunisation of
the mother either from allogeneic blood or a sensitising
event during pregnancy. A total of 26% of women in
this study had fetal red cells present in venous samples
at some time before delivery. Fetal red cells are known
to be present in the maternal circulation before deliv-
ery, with approximately 50–78% of samples being posi-
tive in the third trimester.14,15 During delivery further
contamination of the maternal circulation is likely.
Contreas et al. found 50% of maternal blood samples
had detectable fetal red cells after delivery.16 We do
not know if transplacental exposure to fetal red cells
occurred in all participants because postnatal maternal
samples were not tested. In the absence of transplacen-
tal exposure, re-infusion of salvaged blood could pres-
ent a risk of alloimmunisation.
Our previously published study from 26 participants
undergoing caesarean section reported the fetal cell
count as a percentage.6 Reviewing those data and calcu-
lating the fetal red cell contamination in mL, the median
value was 0.57 mL [IQR 0.34–0.82] with a minimum of
0.05 mL and maximum of 5.57 mL. There was poor cor-
relation between fetal cell contamination and post-wash
blood volume (correlation=0.368).6 These are similar to
findings in the current study. We continue to investigate
alloimmunisation rates following re-infusions ofsalvaged blood during caesarean section and fetal red
cell contamination levels present in the maternal
circulation.
Although bacteria are detectable in all the
post-wash and post-filter samples, the median post-wash
residual contamination (2 cfu/mL) was similar to that
in cell salvage in caesarean delivery (1–1.3 cfu/mL).10
The median dose that would be re-infused would be
303 cfu (cfu mL x post-wash volume) which, when
diluted by the maternal circulation, would result in a
circulating bacteraemia of <1 cfu/mL. This is similar
to that seen in asymptomatic bacteraemia during den-
tal procedures (0.3–4.8 cfu/mL)17 and is likely to be
clinically insignificant.
Waters et al. assessed bacterial contamination in cae-
sarean section patients and detected a median post-wash
concentration of 1.3 cfu/mL [IQR 0–4 cfu/mL]. Samples
from the maternal iliac vein were found to contain the
same species of bacteria.10 Of the organisms identified
by Waters 93% were staphylococci. Median concentra-
tions of bacteria identified in the current investigations
(post-wash) were similar, although the range of concen-
tration was larger. The current study found that blood
salvaged at caesarean section also contained bacteria.
The median quantity was similar to that in vaginal cases,
although the upper range was higher in vaginal cases.
Species were the same as found in vaginally salvaged
blood but with a predominance of skin organisms.
Women who receive salvaged blood after emergency
caesarean delivery have similar rates of postoperative
infection to those who do not.18 Cell salvage washing
can reduce bacterial load in contaminated blood. In
one in-vitro study, expired allogeneic blood was inocu-
lated with known quantities of bacteria and colony
counts performed after washing. A mean reduction of
99% was found for E. coli.19 Studies of blood salvaged
from apparently sterile surgical sites have found bacte-
rial contamination rates of 12.7–33.3%. In penetrating
abdominal trauma, 91.7% were contaminated.20 Studies
of between 18 and 152 patients have examined the rela-
tionship between re-infusion of contaminated blood and
postoperative infection. Recipients included liver trans-
plant and penetrating abdominal trauma patients.20
No association with postoperative infection has been
found.20 All studies involved surgery where broad spec-
trum antibiotics are given routinely.
In this study the leucodepletion filter added no benefit,
and bacterial concentration appeared to increase with
the use of a filter. This may be an artefact of passing
small volumes through a filter that retains some red cells.
Median Hb post-wash (pre-filter) was 15.4 g/dL, which
reduced to 11.2 g/dL post filter. Our series includes low
volume blood loss that many clinicians would be unlikely
to consider re-infusing. The volume of washed blood was
further reduced by removing samples for testing before
using the filter. The effect of the filter retaining some
K.M. Teare et al. 109red cells would effectively increase the concentration of
all other components including bacteria. This may not
be an issue with higher volume bleeds where the fixed
volume of the filter becomes less significant.
Most women in the study did not experience a post-
partum haemorrhage, but were included to make the
study possible. As our unit has 4700 deliveries per year,
to include only major vaginal haemorrhages
(P2000 mL) would require prolonged recruitment.
Having completed this study we now know that it is pos-
sible to collect vaginal blood loss without impeding sur-
gical management, but this was not known at the outset.
We failed to demonstrate a relationship between fetal
red cell contamination and volume of salvaged blood.
We believe smaller bleeds can be valid proxies for severe
haemorrhage as we would not expect total quantities of
amniotic fluid contamination, fetal red blood cells and
bacteria to increase as the volume of maternal blood loss
increases.
This is the first study to assess the practicality of sal-
vaging vaginal blood, and efforts were not made to max-
imise the red cell volume collected. There was no
training period for staff to practise collection, and cases
where collection had been sub-optimal were included.
There were two cases in which the heparinised saline
was not switched on until some minutes into collection,
and swabs were not washed. Appropriate training and
washing swabs are likely to increase red cell recovery.
Blood lost in delivery rooms was not included; 19
women who delivered out of theatre lost blood before
starting the collection in theatre. The delay between col-
lection and washing of salvaged blood was due to a
researcher being called to complete processing of the
collection. This delay was an issue unique to the study
and does not occur in clinical use at caesarean section.
In practice the washing and processing of the collection
would start, and usually be completed, during the oper-
ative procedure.
Quantitative bacterial analysis was obtained from
only 32 out of 50 cases and limited in sensitivity from
1–100 cfu/mL. When 10 mL blood samples were tested
in enriched cultures, bacteria were present in all cases;
samples reported as <1 cfu/mL were analysed as 1
cfu/mL. Three post-wash samples were reported as
>100 cfu/mL, and have been rounded to 100 cfu/mL
for analysis although the true upper limit of bacterial
contamination was not established.
In conclusion, blood lost vaginally can be salvaged.
Following washing in the cell saver, blood composition
is similar to that re-infused after caesarean section for
Hb, haemolysis, efficiency of washout of amniotic fluid
and heparin. Fetal red cells are present in volumes no
greater than in blood from caesarean section. Bacteria
are present in blood to be re-infused, although the quan-
tity is low and unlikely to increase the risk of infection.
The actual risk of post-reinfusion infection has not beenestablished. Re-infusing salvaged vaginal blood loss is a
treatment option the authors would consider in life-
threatening haemorrhage in women who cannot have
allogeneic transfusion. A trial of cell salvaged blood
re-infusion versus allogeneic blood transfusion after
vaginal birth is needed.
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SUMMARY
Background: The significance of fetal red blood cell (RBC)
contamination in obstetric intra-operative cell salvage is not
fully known. It is unclear if we re-infuse a larger volume of
fetal RBCs into the maternal circulation than the amount that
occurs secondary to transplacental haemorrhages is unclear. We
also do not know if there is a critical volume required to cause
alloimmunisation or if larger volumes increase the risk.
Objectives: The aim of this study is to provide data on the level
of fetal RBC contamination in the maternal circulation prior
to delivery and immediately post-partum and to compare these
levels to those found in processed cell-salvaged blood.
Methods: In the first part of this study, we quantified the levels of
fetal RBCs circulating in women immediately prior to delivery.
This was then repeated with a separate group measuring the
levels of fetal RBCs pre- and post-delivery.
Results: We found that 37% of women had fetal cells detected in
their circulation, median 0·00 mL (IQR 0–0·24; average 0·3 mL,
maximum 4·56 mL). Fetal RBCs were present pre-delivery
(maximum 0·66 mL) in 16% of women, increasing to 53%
post-delivery (median 0·66 mL; IQR 0·22–2·20, maximum
21·20 mL).
Conclusions: We have shown that fetal RBCs are present in
the maternal circulation throughout pregnancy and that the
volumes are comparable to that obtained from intra-operative
salvage, with contamination amounts of up to 19 mL. At the
Royal Cornwall Hospital, our experience and evidence supports
offering intra-operative salvage to all women, and we have not
noted an increase in antibody formation, compared to allogeneic
transfusion.
Key words: alloimmunisation, cell salvage, fetal RBCs,
obstetric.
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Fetal red blood cells (RBCs) are known to be present in the
maternal circulation throughout the ante-natal and peri-natal
periods. However, the available published data to define the
range of circulating fetal RBCs are limited to small case numbers
and are outdated (Klein & Anstee, 2014).
Our previous projects on the use of cell salvage in obstet-
rics, both in caesarean sections and vaginal deliveries, showed
that fetal RBCs are collected during the cell salvage process
(Sullivan et al., 2008; Teare et al., 2015). Due to the similarities
between fetal and adult RBCs, in size and density, the cell salvage
machines cannot differentiate between them, and therefore, any
fetal RBCs aspirated will be washed, filtered and returned to the
woman together with her own RBCs.
The significance of this contamination is not known and
has not been systematically investigated. It is unclear, e.g. what
follows if we re-infuse a larger volume of fetal cells into the
maternal circulation than the amount that occurs secondary
to transplacental haemorrhages in normal pregnancy. It is also
unclear, at least in this setting, if there is a critical volume of
fetal RBCs required to cause alloimmunisation or if progressively
larger volumes of fetal RBCs increase the risk of alloimmunisa-
tion. Furthermore, there is no evidence to show how these rates
of alloimmunisation compare to those following an allogeneic
blood transfusion.
The formation of anti-D in a woman with an RhD-positive
baby, although clinically significant, has been reduced by the use
of routine prophylactic anti-D treatment throughout pregnancy.
However, fetal hyperbilirubinaemia and anaemia in future preg-
nancies can still occur when antibodies have been formed to
other mismatched red cell antigens, e.g. following the formation
of anti-K, anti-c, anti-Fy(a) and anti-Jk(a) (Murphy et al., 2013).
When using obstetric cell salvage (ICS) during a caesarean
section, there is a need to be aware of the risk of formation of
antibodies other than anti-D. This fact is not widely appreci-
ated, and many investigators involved in obstetric ICS are still
only concerned with the risk of anti-D. If ICS is to be routinely
employed in obstetrics, the formation of other clinically signif-
icant antibodies that could impact future pregnancies must be
considered, and potential risk must be addressed by multidisci-
plinary teams.
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At the Royal Cornwall Hospital (RCH), we have now
re-infused ICS blood to more than 900 women undergoing a
caesarean section with no significant clinical complications.
We have shown that it is a cost-effective and feasible procedure
and has reduced the rate of allogeneic transfusion in what is a
young and healthy population (Ralph et al., 2009; Ralph et al.,
2011). We have also shown that it is feasible to collect blood for
re-infusion from vaginal deliveries (Teare et al., 2015).
The pathophysiology of an amniotic fluid embolus (AFE) and
its association with obstetric ICS is uncertain but remains a the-
oretical risk. The clinical diagnosis of AFE is usually one of
elimination and is now considered to be a type of anaphylactic
reaction rather than an embolic disease. Furthermore, the wash-
ing and filter processes used in cell salvage have now been shown
to effectively remove amniotic fluid contaminants, fetal squames
and other debris (Catling et al., 1999; Waters et al., 2000; Sullivan
et al., 2008). We feel that fetal RBC contamination is perhaps the
only barrier to what could be a valuable routine service offered
to all parturients.
The aim of this study was to measure the level of fetal RBC
contamination in the maternal circulation prior to delivery and
during the delivery process and to compare these levels to those
found in processed, cell-salvaged blood.
MATERIALS AND METHODS
We quantified the levels of fetal cells in 100 women imme-
diately prior to delivery using a visual microscopic counting
method based on differences of solubility properties in acid
conditions of fetal haemoglobin (HbF) and adult haemoglobin
(Kleihauer-Betke Technique). To improve the accuracy and pre-
cision of these measurements, we repeated this experiment in a
further 100 women pre- and post-delivery, measuring the RhD
antigen by indirect immunofluorescence and flow cytometry.
Estimation of fetal RBC in maternal circulation
pre-delivery
A total of 100 women attending the Delivery Suite at RCH
were randomly selected for fetal RBC estimation. As the fetal
blood group was unknown, counts had to be performed using
the Kleihauer–Betke method, which was performed follow-
ing British Society for Haematology (BCSH) guidelines (Austin
et al., 2009). Testing was performed on the pre-delivery blood
sample taken as part of the routine admission to the Delivery
Suite. As no additional samples were required and all data were
anonymised, Ethics Committee opinion was sought, but spe-
cific approval was not required. No women receiving ICS were
included.
Estimation of fetal RBC in maternal circulation pre-
and post-delivery
A further 100 RhD-negative women who gave birth to an
RhD-positive baby were tested using a BRAD-3-FITC mon-
oclonal anti-D (Source: IBGRL, NHSBT Filton, UK) by flow
cytometry, counting 500 000 cells on a FACSCanto flow cytome-
ter (BD Biosciences, Oxford, UK). Women were not excluded
based on their ABO status. No women receiving ICS were
included. Post-partum samples were taken approximately
30-45 min post-delivery, as per BCSH guidelines (Austin et al.,
2009).
Data were also collected on previous pregnancies, gestation,
estimated blood loss and the maternal and fetal blood groups.
The strength of an antibody screen pre-delivery due to pro-
phylactic anti-D [negative – no prophylactic anti-D detected
pre-delivery, weak (<2+ grading) or strong (>2+ grading)] was
also assessed for any correlation between fetal RBC levels and
antibody strength. The grading criteria were based on the results
obtained from the pre-delivery group sample and screen sam-
ple when tested on an Immucor NEO Blood Grouping Analyser
(Norcross, GA, USA) in combination with the grading scores
used by UK NEQAS Blood Transfusion (West Hertfordshire
Hospitals NHS Trust, UK).
Statistical analysis
Parametric data are presented as mean and standard devia-
tion (sd). Non-parametric data are presented as median (IQR
and/or range). Data were analysed using the Mann–Whitney
test, Kruskal–Wallis test and Spearman’s rank test as appropriate.
RESULTS
Estimation of fetal RBC in maternal circulation
pre-delivery
From the 100 samples analysed pre-delivery, the average gesta-
tion was 39 weeks (sd 1·8), with the majority of women between
at 37 and 40 weeks gestation (IQR 38–40). Six women delivered
between 32 and 36 weeks, and nine women exceeded term.
The average estimate of fetal RBC in the maternal circulation
was 0·3 mL (IQR 0·0–0·24; median 0·0 mL). Of the 100 cases,
37 (37%) had fetal cells detected, with a maximum of 4·56 mL
detected. The remaining 63 cases had no fetal cells detected
when counting 25 low-power fields (as per guidelines); however,
when examining the slide outside this area, eight were positive,
with an occasional cell seen. This would be equivalent to a fetal
contamination of less than 0·24 mL. From the 37 positive cases,
32 were less than 2 mL. The remaining cases were 2·16, 2·64, 2·86,
3·36 and 4·56 mL.
Estimation of fetal RBC in maternal circulation pre-
and post-delivery
A further 100 samples were analysed. These samples were taken
from RhD-negative women who gave birth to an RhD-positive
baby. The median gestation of pregnancy was 40 weeks (range
34–42 weeks). Seven samples were taken from women who had
exceeded term. The median parity was one (range 1–6), and
median estimated blood loss was 400 mL (range 100–2300 mL).
© 2018 British Blood Transfusion Society Transfusion Medicine, 2018, 28, 298–303
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Table 1. Reported fetal red blood cell contamination levels in obstetric ICS blood
Investigation Number of cases Findings
Blood salvage during caesarean section (Rainaldi et al., 1998) 15 Three of 15 cases positive, 1·8–2% fetal RBC contamination
level.
Estimated maximum of 3 mL.
Cell salvage in obstetrics: an evaluation of the ability of cell salvage
combined with leucocyte depletion filtration to remove amniotic
fluid from operative blood loss at caesarean section (Catling et al.,
1999)
27 Average 9·6% fetal RBCRBC contamination level (range
2–19%)1
Clearance of fetal products and subsequent immunoreactivity of blood
salvaged at caesarean delivery (Fong et al., 1999)
10 All positive, mean 0·4% fetal RBC contamination level2
Amniotic fluid removal during cell salvage in the caesarean section
patient (Waters et al., 2000)
14 1·7% fetal RBC contamination level2
Contamination of salvaged maternal blood by amniotic fluid and fetal
red cells during elective Caesarean section (Sullivan et al., 2008)
26 Median 0·57 mL (range 0·05–5·57 mL)
The development and implementation of an obstetric cell salvage
service (McDonnell et al., 2010)
3 280–1600 cells in 50 low-powered fields
Is cell-salvaged vaginal blood loss suitable for re-infusion? (Teare et al.,
2015)
50 Median 0·15 mL (range 0–19 mL)
Royal Cornwall Hospitals Trust Quality Control Quality Control
programme (our unpublished observations)
56 Median 0·39 mL (range 0–12·8 mL)
1The authors in this study reported fetal red cell contamination as a percentage; however, they commented that, based on average ICS volume of 100 mL,
this would equate to 9·6 mL (range 2–19 mL). However, it appears that the haematocrit of the product may not have been taken into consideration, and
the fetal contamination would be lower than this.
2These two investigations also reported fetal red cell levels as a percentage and therefore cannot be translated into straightforward volume contamination
as the haematocrit and ICS blood volume need to be taken into consideration.
From the women for whom samples were taken pre- and
post-delivery, there was no correlation between post-delivery
fetal red cell contamination levels, number of previous pregnan-
cies, gestational age or estimated blood loss (correlation −0·218,
0·076 and 0·170, respectively).
From these 100 samples, 72 women had vaginal deliveries
and 28 delivered by caesarean section. We were unable to match
the ABO groups due to the routine use of ICS for over 95%
of our caesarean section patients. Many women received ICS
re-infusions following a caesarean section, and this would have
resulted in an increased rate of false positives, with positive cases
post-delivery due to ICS and not the delivery process. This is
discussed further below.
Of the 100 cases, 16 (16%) were positive pre-delivery (max-
imum 0·66 mL), with 53 cases (53%) positive post-delivery. Of
the 53 positive samples tested post-delivery, the median fetal red
cell level was 0·66 mL (IQR 0·22–2·20; maximum 21·20 mL).
Of the 72 women who had a vaginal delivery, 12 sam-
ples (17%) were positive pre-delivery and 38 (53%) were pos-
itive post-delivery. The median fetal cell level post-delivery in
these 50 positive cases was 0·44 mL (IQR 0·22–1·42; range
0·22–12·96 mL). Of the 28 women who had a caesarean section
delivery, four samples (14%) were positive pre-delivery, and
15 (54%) were positive post-delivery. Median fetal cell level
post-delivery of the 15 positive cases that had a caesarean section
was 1·32 mL (IQR 0·33–6·37; range 0·22–21·20 mL). There
was no statistical difference between post-delivery fetal RBC
contamination levels and whether delivery was by vaginal or cae-
sarean section (P = 0·377).
From the 100 cases tested pre- and post-delivery, 81% were
ABO compatible (i.e. no maternal ABO antibodies directed
against fetal red cells). Post-delivery results were statistically
higher in ABO-compatible deliveries (P < 0·001) (median
0·22 mL, mean 1·52 mL, range 0–21·20 mL in ABO compatible;
median 0·00 mL, mean 0·92 mL, range 0–1·54 mL in ABO
incompatible). This would suggest that fetal red cells are cleared
faster from the maternal circulation in ABO-incompatible
deliveries, confirming previous work summarised by Klein &
Anstee, 2014.
Following the finding regarding ABO compatibility and fetal
RBC levels, there was interest in whether the strength of pro-
phylactic anti-D detected in the pre-delivery sample had any
impact on fetal RBC levels post-delivery in maternal circulation.
As such, the strength of the antibody screen and post-delivery
contamination levels were examined. Unlike ABO incompati-
bilities, there was no statistical link between antibody strength
of prophylactic anti-D detected in the pre-delivery sample and
the level of fetal RBC contamination in the post-delivery sample
(P = 0·566).
DISCUSSION
The current study has confirmed previous reports that fetal
RBCs are present in the maternal circulation, with up to 37% of
Transfusion Medicine, 2018, 28, 298–303 © 2018 British Blood Transfusion Society
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woman having fetal cells present in their circulation pre-delivery,
increasing to 53% post-delivery.
As for other published levels, Gordon & Bhoyroo, 1966,
reviewed 42 cases and identified fetal RBCs present in the mater-
nal circulation during the antenatal period from 8 weeks gesta-
tion through to labour, with levels increasing as the pregnancy
progressed, with the highest volume in the third trimester; 18·8%
of the cases were positive in the first trimester, increasing to
78% in the third trimester. This was attributed to the reducing
efficiency of the ageing placenta towards the end of pregnancy
(Gordon & Bhoyroo, 1966; Urbaniak, 1998). In addition, dur-
ing the third trimester, the fetoplacental blood volume is the
highest: 150 mL at 31 weeks gestation compared to 25 mL at
19 weeks gestation (Urbaniak, 1998). It has been concluded that
the biggest risk of alloimmunisation would therefore occur after
28 weeks gestation (Urbaniak, 1998). The current study (testing
from 34 weeks’ gestation) and those of Mehta et al., 1979 and
de Wit et al., 2011, (testing from 26 weeks) showed no correla-
tion between fetal RBC volume and gestational age (correlation
0·165).
The report by Clayton, 1966 detected fetal cells in the mater-
nal circulation in 40–50% of cases, with a later report by
Bowman et al., 1986, who studied 33 healthy patients and
detected fetal RBCs of up to 0·06 mL prior to delivery, in the
first and second trimester, increasing to a maximum of 5·15 mL
in the third trimester. A total of 63·6% of their cases were
positive post-delivery, range 0·05–26·6 mL. Only three cases
post-delivery had fetal levels of greater than 1 mL. They con-
cluded that up to 75% of the patients were exposed to fetal RBCs
at some time during pregnancy, at labour or after delivery and
also confirmed that the volume of bleed increased as pregnancy
progressed.
A further investigation by Chhabra et al., 2011, examined
bleeding in the third trimester; 40% were positive pre-delivery,
and of these cases, half had levels of less than 0·25 mL, 27·5%,
0·25–1 mL and 22·5% greater than 1 mL. Post-delivery, 56%
were positive. However, these results cannot be compared
directly to ours as they only studied bleeding cases due to
ante-partum haemorrhages, placental abruption or unclassified
haemorrhage.
From our recent investigation into the feasibility of using
ICS from vaginal blood loss, all 50 patients included had a
Kleihauer performed pre-delivery with 13 cases (26%) being
positive (range 0–3·4 mL) (Teare et al., 2015); this is consistent
with the data collected from the current study.
Transplacental haemorrhage (TPH) is known to occur
ante-natally outside known sensitising events, e.g. trauma. Peak
TPH has been identified during delivery, again as a result of
placental separation, resulting in the highest chance for fetal
RBCs entering the maternal circulation. This has been con-
firmed by several reports, with one report commenting that
0·94% of patients at 30–39 weeks gestation have TPHs greater
than 2·5 mL, and 50% have detectable fetal RBCs post-delivery.
Of this 50%, 1% had a TPH greater than 3 mL and 0·3% 10 mL
or more (Contreras, 1998). Another report stated that during
the labour process 1% of women will have a TPH greater than
4 mL and 0·3% greater than 15 mL (Austin et al., 2009).
From our results and the other studies listed above, there
is evidence that 16–78% of women are exposed to fetal RBCs
ante-natally, with levels of up to 5·15 mL, and more than half of
all mothers are exposed to fetal RBCs post–delivery, with levels
of up to 26·6 mL. But how does this compare to what is found
in ICS?
Table 1 lists the fetal RBC contamination levels in obstetric
ICS from published reports. The data need to be treated with
caution as the number of reports and the sample size populations
are low and the standards of testing and measurement vary. In
some case reports, ICS was only used in large traumatic blood
losses, and this is perhaps not a representative population of
routine deliveries, therefore making it hard to justify any final
comments. It does, however, demonstrate that fetal RBCs are
present in the final re-infused ICS product in volumes of up to
19 mL, with no investigations finding values of fetal RBC higher
than 19 mL in the maternal circulation pre- or post-delivery.
On reviewing the initial data from our previous study involv-
ing 26 cases undergoing caesarean sections (Sullivan et al.,
2008), we originally reported fetal red cell contamination in sam-
ples taken from the ICS reinfusion pack as a percentage. Revis-
iting this data and calculating the fetal red cell contamination
volume, the median was 0·57 mL (IQR 0·34–0·82), with a mini-
mum of 0·05 mL and maximum of 5·57 mL. There was no signif-
icant difference between the use of one suction and two suction
devices (P = 0·5334). There was no correlation between fetal cell
contamination and returned ICS volume (correlation= 0·368),
and from our report on using ICS in vaginal blood loss, median
fetal red cell contamination was 0·15 mL (range 0–19 mL) (Teare
et al., 2015).
Current ongoing QC data (unpublished observations) within
our institution of ICS blood obtained in caesarean section cases
indicate that we have a median fetal red cell contamination of
0·39 mL (IQR 0·20–1·15; max 12·8 mL) of fetal RBC in the ICS
re-infusion volume.
It is not known what volume is needed to provoke an anti-
body response. Will 1 mL do the same as 19 mL? Gunson et al.,
1970, calculated that 0·5 mL would be enough to initiate an
anti-D response in healthy male volunteers, with another report
stating that even 0·1 mL RBC may initiate an anti-D response
(Jakobowicz et al., 1972) The volume needed to provoke an
immune response to other red cell antigens (e.g. K, Fy, Rh) is not
known and would perhaps have to be greater than that needed
for RhD due to the fact that RhD is the most immunogenic
red cell antigen. The true volume required for sensitisation is
unlikely to be quantified due to the complications involved in
replicating a full human immune system in vitro. From the data
we have collected at RCH, we have calculated the current risk
of producing an antibody due to allogeneic blood transfusion is
0·35%. To rule out an increased rate of producing an antibody
from receiving ICS blood with 95% certainty – that the upper
95% confidence interval is less than 0·45% – would require
a total study size of 15 236 patients; the total sample is split
© 2018 British Blood Transfusion Society Transfusion Medicine, 2018, 28, 298–303
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randomly, 7618 patients to receive allogeneic blood compared
to 7618 receiving ICS blood, making this study not feasible.
Since 2012, RCH has established a 24/7 routine use of ICS
in the obstetric operating theatre, using it in >95% cases and
re-infusing most women who have a processed volume of blood.
All those women who receive a re-infusion are followed up 3–4
months post-re-infusion to have a sample taken for antibody
screening. To date, we have had two cases develop an antibody
post-ICS (with no allogeneic transfusion). Both cases had a com-
plicated obstetric history, one with repeated ante-natal bleeds
and admissions from the beginning of the third trimester and
the second with a twin vaginal delivery requiring urgent surgical
intervention due to complications and bleeding (first baby was
delivered vaginally with the second by caesarean section an hour
later). As such, no definitive answers can be drawn, although it
would suggest that ICS-processed blood does not put women
at any more of a risk of antibody formation than women who
receive an allogeneic transfusion. We strongly recommend that
other institutions using ICS in obstetrics adopt this method of
following up women 3–4 months post-re-infusion in order to
collect data on alloimmunisation rates.
We also recommend, when possible, that to assist with data
collection and assessment of fetal red cell contamination, sam-
ples should be taken post-delivery pre-ICS re-infusion for fetal
red cell calculation (Kleihauer). However, it must be stressed that
if a decision is made to undertake this testing, laboratories must
be involved in initial discussions, and samples must be clearly
marked as research only and not to be confused with post-natal
samples from RhD-negative mothers for anti-D dosage (which
must be taken post-re-infusion, as per guidelines). So far 6 of 16
samples (38%) that have been taken immediately post-delivery
but before re-infusion of ICS blood have shown to be positive
for fetal cells (range 0·24–6·2 mL).
In conclusion, we have shown that fetal cells are present
in the maternal circulation ante-natally in 37% women and
post-natally in 53% of women. Using this evidence, we offer
ICS to all woman undergoing caesarean sections and re-infuse
processed blood if available regardless of post-operative Hb
estimation. We have not noted an increase in antibody formation
in those women who have received a re-infusion of ICS blood but
suggest continuing surveillance of antibody formation in these
cases to determine the true rate of alloimmunisation after the
use of ICS.
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Summary 
 
The use of cell salvage in obstetrics has been increasing steadily. There are now some concerns 
relating to cost and there remains a perceived risk of amniotic fluid embolus and of fetal red cell 
sensitisation. We present observational data of intra-operative cell salvage in obstetrics, 
alloimmunisation rates, quality of cell salvaged blood and consider the use of partial first bowls. 
Some of this data has been previously presented at meetings and published in abstract form. 
 
From 2008 to the end of 2017, 1170 women have had a re-infusion of cell salvaged blood with no 
clinical safety concerns. Median returned volume 231ml (interquartile range 154-306ml), minimum 
80ml, maximum 1690ml. Cell salvage was set up for collection for all category of caesarean sections 
in greater than 95% of cases. 
 
Of the 1170 re-infused, 647 (55%) women have provided a follow-up sample for alloimmunisation 
testing, with two positive cases. We have not seen an increase in the dose of prophylactic anti-D 
being administered post-delivery. 
 
This large data set demonstrates using cell salvage routinely as part of our obstetric patient blood 
management strategy has resulted in an overall reduction in the number of women transfused 
allogeneic blood and the amount of blood transfused. The quality of blood processed from partial 
first bowls is no worse than that from full bowls. We have not used the leucodepletion filter since 
2015 and have not noted any adverse clinical events to date, either with or without the 
leucodepletion filter. 
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INTRODUCTION 
 
The most recent Confidential Enquiries into Maternal Deaths (MBRRACE-UK) report covering the 
period 2013-15 has shown that obstetric haemorrhage is still a leading cause of maternal death, with 
no improvement in numbers over the last 20 years [1]. The Royal College of Obstetrics and 
Gynaecologists ‘Green-top’ guidance estimates that each year in the UK there are greater than 4000 
cases of severe obstetric haemorrhage, with the majority receiving an allogeneic transfusion [2]. The 
most recent NHS Maternity Statistics report [3] for the period 2016-17 in England showed 27.8% of 
deliveries were by caesarean section and that rates increased with age and accounted for 44.1% of 
deliveries to women aged 40 and over. Of these women, 23.5% were having elective caesarean 
sections and 20.1% were emergencies. Women aged 40 and over also have the highest BMI at 
booking. All these are risk factors for bleeding and can result in increased allogeneic transfusion 
rates. 
 
For operations such as caesarean section that are predicted to have a blood loss of more than 500 
ml, the use of cell salvage is encouraged as an alternative to allogeneic blood [4]. However the 
recently updated Association of Anaesthetists of Great Britain and Ireland guidelines on cell salvage 
(July 2018) [4], no longer advocate routine use of cell salvage in obstetrics following the results of 
the largest multicentre randomised controlled study (SALVO) [5]. The availability of cell salvage in 
obstetric practice had been steadily increasing and a survey conducted in 2017 showed cell salvage 
was available in 84% of obstetric units, although only 50% of units had 24-h access and used it 
routinely [6]. There is still a perceived risk of amniotic fluid embolus despite there being no reported 
cases, and an unquantified risk of fetal red cell sensitisation resulting from the potential 
contamination of the aspiration and salvaged processed blood with fetal red blood cells. There are 
also concerns with issues relating to resources, staffing, training and resulting costs.  
 
Multiple studies have found autologous blood (cell salvaged blood) to be a safer alternative to 
allogeneic blood; with adverse effects from cell salvaged blood quoted as 0.027% compared to 
0.14% with allogeneic blood [7]. There are also increased risks of infections, morbidity and five-year 
mortality with allogeneic blood [8-14]. Recipients may be exposed to unknown pathogens in 
donated blood of which we are currently unaware, but in the future may be significant. 
Complications of allogeneic blood transfusion can increase length of stay rates by 1.3% per unit 
transfused [15]. Women who delivered at our hospital who have had an allogeneic transfusion are 
more likely to have a higher estimated blood loss and infections treated post-operatively, when 
compared to those who have had a re-infusion of cell salvaged blood, or no transfusions [15]. 
Women receiving cell salvaged blood are at lower risk of receiving an allogeneic blood transfusion 
and developing post-partum anaemia [16-17]. Our priority is to reduce exposure of women to 
allogeneic blood and consider alternatives when appropriate.  
 
We present our practice and large observational database to demonstrate the routine use of 
intraoperative cell salvage and re-infusion of cell salvaged blood has provided a safe alternative to 
allogeneic blood, to over 1000 women. It is an important component of our obstetric blood 
conservation strategy which shows re-infusing cell salvaged blood has resulted in not only a reduced 
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risk of exposure to allogeneic blood, but also a reduction in the number of units of allogeneic blood 
transfused. We include data on follow-up alloimmunisation rates and quality of cell salvaged blood. 
 
 
METHODS 
 
We have performed a retrospective cohort study using data collected on our hospital databases. All 
of these are approved by the Caldicott Guardian. Ethics Committee and Research & Development 
approval was sought where required.  
 
We use cell salvage routinely in our maternity operating theatre for all women having caesarean 
section, as well as women having major surgery such as post-partum laparotomy. We use a Cell 
Saver® 5+ System (Haemonetics Corporation, Braintree, MA, USA) which is dedicated to this location. 
The machine is set up and operated by an operating department practitioner (ODP), whose other 
duties are to assisting the anaesthetist. All ODPs are trained in cell salvage following a 
comprehensive competency-based training programme, including theoretical and practical based 
skills assessment.  
 
The machine is initially set up for collection only. Since 2008 we have used a single specific wide-
bore sucker without a Yankauer tip to collect blood into the reservoir [18], which is anticoagulated 
with a pre-prepared solution of saline containing 30,000 IU heparin.l-1. The suction pressure is 
normally set at 150 mmHg but is increased to a maximum of 300mmHg in the presence of heavy 
bleeding. We routinely wash the swabs in saline to increase red cell return [19].  
 
If the operating team judge that the patient has lost enough blood to require replacement and there 
is sufficient blood collected in the reservoir, then the blood processing system is opened, set up and 
the collection is processed with a double wash of 1500 ml saline for a 125 ml bowl. If, after 
processing in the automatic setting, the bowl is not filled to capacity with red cells, this is called a 
partial first bowl. Due to concerns with the washing efficiency of incomplete bowls, these partial first 
bowls of less than 125 ml red blood cells are not usually re-infused but discarded. Subsequent partial 
bowls can be topped up to 125mls, from processed red blood cells and are not discarded. With 
experience, the ODP becomes better able to assess which collections, when processed, will fill a 125 
ml bowl. 
 
The final decision to re-infuse the cell salvaged blood is made jointly by the obstetrician and 
anaesthetist, in discussion with the woman whenever possible. Re-infusions are offered to all 
women, regardless of the postoperative haemoglobin concentration. These are usually given in the 
operating theatre or immediately postoperatively in recovery. The blood is never removed from the 
patient’s bedside, and it is discarded if not re-infused within six hours of the start of the collection. 
Routine observations are continued throughout the re-infusion as for allogeneic blood and per Trust 
protocol. 
 
Blood warmers and pressurised bags are not used for re-infusion, which is administered by gravity 
alone. Re-infusions were all administered through a leucodepletion filter (Pall LeukoGuard® RS Filter; 
Pall Europe, Portsmouth, UK) until 2012.  The use of filters was gradually reduced until 2015 when 
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they were removed, and blood was given through a standard blood giving set. Throughout the data 
collection period, this has been the only change to our cell salvage practice. 
 
Data are collected for all cases where cell salvage is used, including pre-operative haemoglobin 
concentration, estimated blood loss, start time of collection, volume collected, volume of re-
infusion, expiry time and patient and staff details. If processed cell salvaged blood is not re-infused, 
the reasons for this are documented. These are recorded on a monitoring sheet intra-operatively 
and then transferred to an electronic database. Any technical problems with cell salvage are noted 
on the Trust cell salvage monitoring forms and reported to the Blood Conservation Team, and 
manufacturer if applicable. Any adverse events relating to cell salvage are reported in accordance 
with the Trust Incident Reporting Policy, and where appropriate to relevant external bodies (Serious 
Hazards of Transfusion (SHOT) haemovigilance scheme; Medicine and Healthcare Products 
Regulatory Agency (MHRA)). 
 
Transfusion practice throughout the data collection period has been restrictive, with a transfusion 
trigger of haemoglobin concentration < 70 g.l-1, and review after each unit transfused.  
 
Our Trust guidelines on management of major obstetric haemorrhage, in use throughout the period 
of data collection, have not changed with regards to the use of tranexamic acid. 
 
 
Other blood conservation strategies such as ante-natal and post-natal treatment of anaemia have 
been implemented since the start of the data collection period. In 2012 the treatment of iron 
deficiency anaemia was changed from Venofer (Vifor International; Glattbrug, Switzerland) to a 
single total dose intravenous preparation (Ferrinject, Vifor International; Glattbrug, Switzerland). 
The number of women receiving ante-natal total dose intravenous iron has always been less than 
five women per year. Post-natally women with a haemoglobin value ≤ 80 g.l-1 are offered total dose 
intravenous iron, or ≤ 95 g.l-1 if symptomatic. Women with haemoglobin values above the threshold 
for total dose intravenous iron will be discharged home on oral iron.   
 
To assess the risk of alloimmunisation due to fetal red cell contamination, consenting patients are 
invited to send a repeat blood sample three to four months after surgery to screen for any maternal 
antibodies. 
 
Throughout the reported time period we performed quality control sampling on an ad hoc basis. 
Samples for quality control were taken from the re-infusion pack (post-wash, pre-giving set filter) to 
check the quality of blood being returned (haemoglobin and haematocrit), the amount of haemolysis 
(lactate dehydrogenase and plasma free haemoglobin tests), protein levels (microalbumin and 
potassium tests), heparin contamination and fetal red cell levels. Samples are collected after running 
through an IV giving set filter (170microns) via a three-way tap and not obtained using a syringe and 
needle which can cause haemolysis [20]. Sample tube tops are removed prior to gently running the 
blood down the side of the sample tube.  
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RESULTS 
 
From April 2008 to the end of 2017, 1170 women have had a re-infusion of cell salvaged blood 
(figure one). All cell salvaged blood was collected in the operating theatre in all cases. Cell salvage 
was set up for collection for all caesarean sections (emergency and elective, category one to four) 
and post-partum laparotomies, being used in more than 95% of cases from 2012. Although each 
year the percentage of processed collections which are reinfused increases (from 53% in 2012 to 
70% in 2017), the number of actual caesarean section cases reinfused blood is just over 30% of the 
cases (table one).  
 
All re-infusions have been administered without clinically significant adverse events, with no cases of 
maternal collapse or hypotension seen either with or without the leucodepletion filter. The median 
(IQR [range]) volume of cell salvaged blood that was returned was 231 (154-306 [80-1690]) ml.  
 
The rate of allogeneic transfusions to the whole obstetric population has fallen to 0.6% (0.4% of 
intra-partum women), and for women who have had a caesarean section it is 0.2%. In 2017, 71% of 
Obstetric allogeneic blood transfusions were given to women following a vaginal delivery, with 89% 
in 2016 and 95% in 2015. Table two lists the transfusion data from the last ten years. 
 
Of the 1170 re-infused cases, 44 women also received an allogeneic red blood cell transfusion using 
84 red cells in total. Twelve cases received FFP (49 units in total), two cases received a unit of 
platelet each and three cases received cryoprecipitate, each case having two units. One of these 
cases was a Jehovah’s Witness who received two units of cryoprecipitate only. 
 
Of the 1170 women re-infused, 509 (44%) have provided a sample, and on further checking of 
women who did not provide a sample, a further 138 had a group and screen taken at a later date 
(“incidental follow ups”) for other reasons such as subsequent pregnancy, other hospital 
attendances, surgical/medical procedures, taking the total to 647 (55%). Two cases have returned a 
positive antibody screen. 
 
Table three describes the cell salvage blood quality data. Data is also included from ‘partial’ first 
bowls from inadequate collection volumes, and allogeneic red blood cell units for comparison. As 
expected the haemoglobin and haematocrit were lower in partial bowls, but the plasma free 
haemoglobin, lactate dehydrogenase and potassium levels from full bowls were found to be higher 
(p=0.000, p=0.000, p=0.000 respectively), with albumin levels similar with no significant difference 
between full and partial bowls (p 0.861). Plasma free haemoglobin and lactate dehydrogenase levels 
from partial bowls were found to be similar to that of allogeneic blood, however levels from full 
bowls were higher than allogeneic, although free haemoglobin levels were not statistically significant 
(p=0.826, p=0.000 respectively). We have previously identified that there is more haemolysis in cell 
salvaged blood compared to allogeneic blood [20]. The pH of cell salvage blood is higher than that of 
allogeneic blood (mean from full bowls 7.55 (SD 0.09); partial bowls 7.39 (0.22); allogeneic units 6.85 
(0.17). 
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Fetal red blood cells were present in nearly all cell salvaged samples tested. Median level from full 
bowls (n=104) was 0.59ml (0.17-1.48 [0.00-19.00]). Median levels from partial bowls (n=32) was 
0.21ml (0.04-0.54 [0.00-3.83]). The difference between partial and full bowls was statistically 
significant (p=0.001).  
 
 
 
DISCUSSION 
 
We have presented data which demonstrates the routine use of cell salvage, which is integral to our 
obstetric patient blood management strategy, has resulted in an overall reduction in the number of 
women transfused allogeneic blood and the amount of blood transfused (figure one and table two).  
 Compliance with our restrictive blood transfusion practice has been audited annually and presented 
locally and regionally to inform best practice [21-22]. As such the small increase in allogeneic blood 
use in 2014 was audited and presented locally to re-establish the principles of using blood wisely 
[21].  
 
Our biggest group of obstetric patients requiring allogeneic transfusion are those who deliver 
vaginally, without the option for cell salvaged blood, with a smaller group of women who have a 
caesarean section requiring   post-natal ‘top-up’ transfusions, despite a restrictive transfusion 
trigger. Not only has the percentage of women needing an allogeneic blood transfusion dropped to 
far lower than the suggested 5% standard [23], but as important, is the reduction of the number of 
units of blood transfused, which has reduced from a median of two units (IQR 2-3) in 2008 to less 
than two units after 2012 when the service was fully established (median 1, IQR 1-2) (table two).  
 
Since 2016, the allogeneic transfusion rate has plateaued, mainly due to the women who bleed 
following a vaginal delivery who then require a blood transfusion. We have undertaken a feasibility 
study which shows it is possible to collect blood from vaginal blood loss, salvage it and potentially re-
infuse. No patients were reinfused during this study, but the evidence supports the safe use of 
vaginal cell salvage in certain clinical situations [24]. The authors are supporting a further trial 
repeating this study [6].  
 
Few women received tranexamic acid and it was not used routinely throughout the study period, 
however this has not been documented formally and use of tranexamic acid may have increased in 
2017 following publication of the WOMAN study [25].  
 
There are a number of perceived risks and barriers to implementing a routine cell salvage service in 
obstetrics, which include the potential for an increased risk of alloimmunisation secondary to the re-
infusion of fetal red blood cells in the final processed cell salvaged blood. If cell salvage is routinely 
employed in obstetrics, formation of other clinically significant antibodies other than anti-D, that 
could impact on future pregnancies, must be considered. We have attempted to assess this risk by 
following up all women who have had a re-infusion of cell salvaged blood, three to four months 
post-delivery and checking their blood for antibody formation [26]. 
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Of the 647 (55%) women who have received cell salvaged blood that have been tested for antibody 
formation, there have been two cases with a positive antibody screen. Both were anti-E. The first 
case was an abruption with an estimated blood loss of 600ml, receiving 237ml of cell salvaged blood 
and one-unit allogeneic transfusion (unit was E antigen negative). The second case was a twin 
vaginal delivery requiring urgent surgical intervention due to complications and bleeding, with the 
second baby being born by caesarean section an hour later than the first baby. 400ml of cell 
salvaged blood was reinfused avoiding the need for any allogeneic blood transfusion. The techniques 
used within our laboratory have a similar detection profile to enzyme methods for Rh antibodies, 
and as such these antibodies may be ‘naturally occurring’ (i.e. not as a result of red cell stimulus), 
but this cannot be proven with confidence. 
 
Prior to the dataset reported in this paper, there was one other case with an antibody identified 
(anti-S) that was not detected antenatally. We were unable to establish whether the anti-S was 
produced due to contamination from the fetal red blood cells in the cell salvage re-infusion or before 
this, due to the multiple transplacental haemorrhages, antenatal bleeds and final abruption resulting 
in emergency delivery by caesarean section at 33 weeks gestation. 
 
 
The SALVO randomised controlled trial [5] suggested that fetomaternal haemorrhage was higher in 
those women who had cell salvage than those who did not. However, data was only compared for 
cases where fetomaternal haemorrhage was greater or equal to 2 ml, and a RhD positive baby was 
born to a RhD negative mother using 30 cases: 21 in the cell salvage intervention group and nine in 
the control (non-cell salvage) group. Based on such low numbers we support the authors in stating 
that associating the alloimmunisation risk from these fetomaternal haemorrhage results should be 
treated with caution and no conclusion about alloimmunisation risk can be drawn from the results in 
SALVO. 
 
Other recommendations suggest considering an increased dose of prophylactic anti-D required for 
RhD negative women post cell salvage reinfusions. From our data, over the last three years looking 
at all RhD negative women re-infused cell salvaged blood who delivered a RhD positive baby (N=60), 
we have not seen an increase in the dose of prophylactic anti-D being administered. Our hospital 
issues 1500 IU doses, sufficient to cover up to a 12ml bleed/contamination. 
 
 
 
Other perceived barriers to implementing cell salvage in obstetrics include concerns about costs, 
manpower planning, and training. When cell salvage was first introduced to the maternity operating 
theatre it was only set up for elective caesarean sections. The ODPs, assisting the anaesthetist, gain 
their initial competencies in cell salvage in an elective setting before they progress to managing 
emergency cases. We have a dedicated cell salvage trainer who ensures all ODPs who are rostered 
to work in maternity theatre complete a competency-based training package which includes both 
theory and practical elements of training. Following publication of our data showing cell salvage was 
an important element of our blood conservation strategy [27], we have achieved a 24-hour, seven-
day availability without any additional staffing, using the ODP who routinely assists the anaesthetist 
to manage all elements of the cell salvage operation. 
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At the time of the invitation to participate in the SALVO study, in 2012, our data had confirmed 
benefit of cell salvage in obstetric practice and we did not have equipoise to participate, already 
using it in 98% of cases and seeing an associated reduction in transfusion. Retrospective review of 
our data indicates many women who receive cell salvaged blood are women who have no pre-
operative predictors for blood loss. By trying to predict, and only collect for those women at risk of 
bleeding, many women who bleed will be missed, and limiting the use of cell salvage to high-risk 
cases may result in reduced opportunities for training and maintenance of skills [28]. Data collected 
from 300 cases (2010-2013) showed the median estimated blood loss was 800ml (600-1000 [300-
5500]). There was no correlation between the urgency of the caesarean section and re-infused 
volume, estimated blood loss, and Para gravida (correlation 0.253, -0.228, 0.014, respectively). This 
early data set confirmed the perception that those women at risk of bleeding cannot be predicted 
and built the case for using cell salvage routinely. There was weak correlation between estimated 
blood loss and length of stay (0.334), and moderate correlation between estimated blood loss and 
cell salvaged blood re-infused volume (0.535), which would be expected. 
 
We have not performed a detailed cost analysis but feel recent estimates of cost [5] are considerably 
greater than the costs of the service we provide. Besides incurring no additional manpower costs, 
we have only ever used one suction device [5]. This saves on cost of a second suction and also 
results in more efficient blood collection, reducing waste. More UK hospitals are adopting the one 
suction approach with 58.1% of hospitals using one suction compared to 41.9% using two suction 
devices [5]. Further cost reductions are achieved when the ODPs do not open the cell salvage 
processing kit for all collection cases. They estimate blood loss and blood in the collection reservoir, 
only opening the processing kit when enough blood has been collected, which on processing is likely 
to fill a full bowl. Our data has shown that more than 60% of cases will be collection only and will not 
incur the additional expense of the processing kit which has been used in the calculation of costs in 
the SALVO study. Some of the collections when processed will be of insufficient volumes to fill the 
125ml bowl in the automatic setting of the Haemonetics cell salvage machine. These processed 
collections are classed as partial first bowls and are therefore not always re-infused. Some of these 
women may require a transfusion one to two days later. The role of partial bowls has not been 
addressed in Obstetrics, but it is likely that re-infusing partial bowls will reduce the number of 
women having a top-up transfusion post-operatively.  
 
 
 
 
The current recommendation to use a leucodepletion filter when re-infusing obstetric cell salvaged 
blood is supported with little to no evidence. Before 2000, this filter was not available, and many 
centres have abandoned their use or never used the filter, safely re-infusing cell salvaged blood 
without a problem. When blood loss is rapid, the flow rate through the filter may not be sufficient to 
give back large volumes of blood quickly. The use of a pressure cuff or syringing cell salvaged blood 
to increase rapidity of re-infusion is not advised due to the risk of air embolus and the unknown 
impact of pressure within the filter. Adverse events related to re-infusions given through a 
leucodepletion filter continue to be reported [5]. Reports to SHOT from 2010-2017 have identified 
20 hypotensive episodes associated with using the leucodepletion filter [29] and in the most recently 
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published SHOT report (for the year 2017) [30] there were eight obstetric cell salvage cases 
reported, with three of these cases linked to the filter; two resulted in hypotension, and the third 
resulted in a reduced infusion rate resulting in time expired blood.   
 
 
To maximise further use of cell salvage, and to reduce allogeneic rates, we are considering the use of 
partial first bowls for re-infusion.  Although evidence for concern is limited and could just be 
theoretical, Haemonetics™ product literature now states FDA clearance to wash and reinfuse a 
partially-filled bowl to maximise red blood cell re-infusion [31], although information available to 
support this is limited. In earlier work, we have demonstrated that processing and washing of blood 
during cell salvage significantly reduced concentrations of α-fetoprotein to well within the normal 
range for the general population. Heparin is also eliminated, and while the washing process does not 
eliminate the presence of squames cells, their significance in the circulation remains unknown. [18, 
24]. Currently quality control testing is performed monthly on an ad-hoc basis, however setting up a 
standardised quality control programme for cell salvage blood throughout the UK is something the 
authors support and are aware is undergoing consideration [personal communication Catherine 
Ralph, UKCSAG; 32]. We are investigating the quality of blood obtained from partial bowls compared 
to blood obtained from full bowls and allogeneic units (table three). 
 
Another consideration to address when comparing allogeneic to autologous cell-salvaged blood 
transfusion is that 1 ml cell-salvaged blood is not similar in vivo to 1 ml of allogeneic blood. There is 
no data comparing cell-salvaged blood with allogeneic blood although our observational data 
suggest cell-salvaged blood behaves more like whole blood with women who receive large volumes 
of cell-salvaged blood maintaining normal coagulation and requiring little to no additional clotting 
factors. This can be seen in the low volumes of other blood component support needed, as seen in 
table two. Research into this in vivo observation is currently in progress at our hospital (IRAS: 
225799; REC ref 17/NW/0586). 
 
 
 
In concluding, we have shown it is possible to safely and economically employ intra-operative cell 
salvage routinely within an obstetric unit with no additional staffing costs so long as it is set up as 
collection only and used routinely for all cases. The risk of amniotic fluid embolus remains 
theoretical and fetal red cell contamination should not be barriers to implementing a cell salvage 
service. Despite the limited follow-up data of test for antibody formation, data so far suggests that 
receiving a re-infusion of cell salvaged blood does not put women at any more risk of antibody 
formation compared to women who receive an allogeneic transfusion. However, without more 
complete follow-up, rates may be deceptive, and as we have previously recommended, all 
Institutions using intra-operative cell salvage in obstetrics should adopt this method of following up 
women post re-infusion in order to collect alloimmunisation rates. Recording this data on a central 
database will allow sufficient data to be collected and to finally quantify the risk of alloimmunisation 
in obstetric cell salvage [26]. 
 
Based on the reported observational data collected over ten years, we recommend that 
leucodepletion filters are no longer used in obstetrics, although we would support further work to 
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evidence base this recommendation. The quality of blood processed from partial first bowls is no 
worse than that of full bowls (apart from haemoglobin/haematocrit), and that partial first bowls 
should be considered in obstetrics for re-infusion. 
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Table 1 Intra-operative cell salvage collection and processing during caesarean section. Values are 
number (proportion). 
 
Year Caesarean 
sections  
Collection Processed  Proportion of 
caesarean 
sections with 
blood 
processed 
Proportion of 
processed 
cases with 
reinfusion 
2012 845 
 
806 (95.4%) 228 (28.3) 27.0 53.1 
2013 840 
 
805 (95.8) 230 (28.6) 27.4 63.5 
2014 869 
 
853 (98.2) 258 (30.1) 29.7 55.0 
2015 951 
 
930 (97.8) 288 (31.0) 30.3 63.4 
2016 826 
 
814 (98.5) 264 (32.4) 32.0 66.7 
2017 868 
 
861 (99.1) 337 (39.1) 38.8 70.0 
 
* Collection only (‘stand-by’) where lost blood is collected into the collection reservoir. Processing 
kits have not been opened yet. 
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Table 2 Royal Cornwall Hospital obstetric transfusion data from last ten years  
 
 
 Total 
women 
delivered 
Number 
of 
caesarean 
sections 
Total 
number of 
women 
transfused 
allogeneic 
blood * 
Total 
number of 
intra-
partum 
women 
transfused 
allogeneic 
blood * 
Percentage 
of intra-
partum 
woman 
transfused 
Number of 
caesarean 
section 
cases 
transfused 
Total units 
transfused 
Median 
number of 
units 
transfused 
(IQR 
[range]) 
 
Number 
of women 
who 
received 
cell 
salvaged 
blood 
Number of 
women 
who 
received 
cell 
salvage 
and 
allogeneic 
blood 
Number 
of 
women 
requiring 
fresh 
frozen 
plasma 
(FFP) 
Number of 
women 
requiring 
cryoprecipitate 
Number 
of 
women 
requiring 
platelets 
2008 
 
3278 585  79 58 1.3 * 15 259 2 (2-3 [1-
20]) 
 
20 2 9 1 6 
2009 
 
4354 764 64 43 1.0 22 192 2 (2-3 [1-
16]) 
 
25 2 6 3 5 
2010 
 
4492 801 59 44 1.0 20 155 2 (1-2 [1-
13]) 
 
34 8 7 3 4 
2011 
 
4769 876 58 40 0.8 5 167 2 (1-3 [1-
27]) 
 
87 5 7 2 2 
2012 
 
4628 845 48 35 0.8 12 100 2 (1-3 [1-5]) 
 
121 6 9 0 0 
2013 
 
4612 840 39 31 0.7 8 75 2 (1-2 [1-6]) 
 
146 4 5 1 0 
2014 
 
4388 869 54 39 0.9 17 112 2 (1-2 [1-
10]) 
 
142 10 8 2 2 
2015 
 
4316 951 21 9 0.2 1 31 1 (1-2 [1-3]) 
 
183 1 2 0 0 
2016 
 
4338 826 27 18 0.4 3 57 2 (1-2 [1-
11]) 
 
176 3 2 1 2 
2017 
 
4089 868 24 16 0.4 7 39 1 (1-2 [1-4]) 
 
236 3 2 1 1 
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*Total number of women transfused allogeneic blood include ante-natal, peri-natal and post-natal women, whereas Intrapartum women are those who 
were transfused on the Delivery Suite or immediately post theatre. 
 
 Due to change in computer system, not all data is available from 2008. Data reported is from nine months (April-December) 
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Table 3 Quality of blood obtained from cell salvage blood full bowls, compared with partial bowls and allogeneic red cells. Values are median (IQR [range])  
 
 Full bowls (N=77) Partial bowls (N=40) Allogeneic * (N=60) 
 
Cell salvage volume (ml) 
 
152 (127-229 [106-732]) 122 (118-126 [95-132]) X 
Haemoglobin (g.l-1) 
 
156 (140-171 [110-215]) 101 (78-115 [24-135]) 197 (183-205 [163-219]) 
Haematocrit (l.l-1) 
 
0.461 (0.412-0.495 [0.348-0.662]) 0.295 (0.241-0.331 [0.075-0.423]) 0.659 (0.626-0.690 [0.513-0.728]) 
Albumin  (mg.l-1) 
 
6.4 (4.2-16.6 [0.1-941.0]) 7.5 (4.4-11.0 [1.3-113.4]) >500 
Heparin (iu.ml-1) 
 
0.00 (0.00-0.00 [0.00-0.55]) 0.00 (0.00–0.00 [0.00–0.08]) X 
Potassium (mmol.l-1) 
 
1.6 (1.2-2.1 [0.6-10.2]) 0.9 (0.6-1.2 [0.4-2.9]) 38.5 (30.0-49.0 [17.0-71.0]) ‡ 
Lactate dehydrogenase (iu.l-1) 
 
243 (171-336 [67-1709]) 140 (111-200 [42-763]) 127 (79-196 [38-596]) 
Plasma free haemoglobin § (g.l-1) 
 
1.20 (0.22-2.50 [0.02-13.50]) 0.26 (0.03-0.90 [0.00-5.60]) 0.90 (0.58-1.80 [0.20-4.80]) 
 
 
* Allogeneic units were leucodepleted and stored in SAGM. Samples were either taken from wasted or time expired units that were still within the cold 
chain criteria, or from the unit giving set prior to connecting to a patient’s cannula. Again, no needles were used. Blood was collected into EDTA. Average 
age of the blood was 21 days. 
 
 Albumin results obtained from Microalbumin test. 
 
‡ Data only available from 36 samples 
 
§ Plasma free haemoglobin levels tested on a HemoCue Plasma/Low Haemoglobin System (HemoCue Ltd, Derbyshire, UK). 
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Figure 1 Number of intra-partum woman transfused cell salvaged blood on the Delivery Suite or 
immediately post theatre (square) and allogeneic blood (triangle) 
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